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ABSTRACT

The “diploid” genome of retroviruses consists of two strands of RNA that
are non-covalently linked as a “dimer” at their 5’ ends. The ubiquitous presence
of a dimeric genome among retroviruses suggests that dimerization plays a crucial
role in gRNA packaging during viral life-cycle. For almost all retroviruses,
determinants of gRNA dimerization and packaging, which are for the most part
physically and genetically indistinguishable, reside at the 5’ end of the gRNAs
and have been shown to assume higher order structures.
Employing a combination of genetic and structural prediction
approaches, we have earlier shown that Mason-Pfizer monkey virus (MPMV)
and mouse mammary tumor virus (MMTV) packaging determinants comprise
sequences at the 5’ end of the genome, starting from R and extending into the
beginning of Gag. Sequences encompassing these regions were predicted to
fold into stable RNA secondary structures comprising several structural motifs.
In an attempt to establish structure-function relationship of the higher order
features of MPMV and MMTV packaging signal RNAs, we first validated their
predicted structures employing a novel chemo-enzymatic probing strategy,
selective 2’hydroxyl acylation primer extension (SHAPE). The SHAPEanalyzed structures of MPMV and MMTV packaging signal RNAs validated
the major structural motifs, including U5/Gag long range interactions (LRIs), a
stretch of single-stranded purine (ssPurine)-rich region, and a distinctive GCrich palindromic (pal) helix loop. Minimum free-energy structure predictions,
phylogenetic, and in silico analyses of different MPMV and MMTV strains
further suggested the existence of these major structural motifs.
vii

To test the importance of the pal sequences in MPMV and MMTV
gRNA dimerization and packaging, we introduced a series of mutations in the
pal helix loops. Tests of these mutations employing in vitro and in vivo
complementary approaches, phylogenetic, and structure prediction analyses
revealed pal helix loops (5’ CGGCCG 3’ in MPMV and 5’ CGGCCG 3’ in
MMTV ) containing a canonical “GC” dyad functioning as dimerization
initiation sites (DISs) controlling MMTV and MPMV gRNA dimerization and
packaging. Furthermore, in MMTV, a second pal within the primer binding site
(PBS) was also observed that was found to be involved in gRNA dimerization.
Concomitant mutational analysis of pal II and PBS pal suggests that both pals
are required for efficient RNA dimerization, packaging and propagation of
MMTV gRNA.
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اﻟﻤﻠﺨص اﻟﻌرﺒﻲ
ﻳﺘﻜﻮﻥ ﺍﻟﻤﺤﺘﻮﻯ ﺍﻟﺠﻴﻨﻲ ﻟﻞ  retrovirusesﻣﻦ ﻧﻮﻋﻴﻦ ﻣﻦ ﺍﻟﺤﻤﺾ ﺍﻟﻨﻮﻭﻱ ﺍﻟﺮﻳﺒﻲ ﺍﻟﺘﻲ ﺗﺮﺗﺒﻂ ﺑﺒﻌﻀﻬﺎ ﻋﻦ
ﻁﺮﻳﻖ ﺭﻭﺍﺑﻂ ﻏﻴﺮ ﺗﺴﺎﻫﻤﻴﺔ ﻋﻠﻰ ﺷﻜﻞ  Dimerﻓﻲ ﺍﻟﻨﻬﺎﻳﺎﺕ ﺍﻟﺨﺎﺻﺔ ﺑﻬﺎ. .ﻭﺟﻮﺩ ﻓﻲ ﻫﺬﺍ ﺍﻟﻤﺤﺘﻮﻯ ﺍﻟﺠﻴﻨﻲ
ﺍﻟﻤﺘﺮﺍﺑﻂ ﺑﻬﺬﺍ ﺍﻟﺸﻜﻞ ﺑﻴﻦ retrovirusesﻳﺸﻴﺮ ﺇﻟﻰ ﺃﻥ  dimerizationﻳﻠﻌﺐ ﺩﻭﺭﺍ ﺣﺎﺳﻤﺎ ﻓﻲ ﺗﺠﻤﻴﻊ
gRNAﺧﻼﻝ ﺩﻭﺭﺓ ﺍﻟﺤﻴﺎﺓ ﺍﻟﻔﻴﺮﻭﺳﻴﺔ .ﻏﺎﻟﺒﺎ ﻭﻓﻲ ﻣﻌﻈﻢ ﺍﻝ  retrovirusesﻓﺄﻥ ﻣﺤﺪﺩﺍﺕ gRNA
dimerizationﻭﺗﻌﺒﺌﺘﻬﺎ ،ﻭﺍﻟﺘﻲ ﻫﻲ ﺑﺎﻟﻨﺴﺒﺔ ﻟﻠﺠﺰء ﺍﻷﻛﺒﺮ ،ﻻ ﻳﻤﻜﻦ ﺍﻟﺘﻤﻴﻴﺰ ﺑﻴﻨﻬﺎ ،ﺗﻘﻊ ﻓﻲ ﺍﻟﻨﻬﺎﻳﺔ )‘ (5ﻟﻞ
 gRNAsﻭﺍﻟﺘﻲ ﺛﺒﺖ ﺍﻧﻬﺎ ﺗﻜﻮﻥ ﻫﻴﺎﻛﻞ ﺛﺎﻧﻮﻳﺔ.

ﺑﺘﻄﺒﻴﻖ ﻣﺠﻤﻮﻋﺔ ﻣﻦ ﺍﻟﻤﻨﺎﻫﺞ ﻟﻠﺘﻨﺒﺆ ﺍﻟﻮﺭﺍﺛﻲ ﻭﺍﻟﺒﻨﻴﻮﻱ ،ﻟﻘﺪ ﺃﻅﻬﺮﻧﺎ ﻓﻲ ﻭﻗﺖ ﺳﺎﺑﻖ ﺑﺄﻥ ﻣﺤﺪﺩﺍﺕ ﺍﻟﺘﺠﻤﻴﻊ
ﻟﻔﻴﺮﻭﺳﻲ  MPMVﻭ  MMTVﻣﺘﻮﺍﺟﺪﺓ ﻓﻲ ﺍﻟﻨﻬﺎﻳﺔ'  5ﻣﻦ ﺍﻟﻤﺤﺘﻮﻯ ﺍﻟﺠﻴﻨﻲ ،ﺑﺪءﺍ ﻣﻦ  Rﻭﺗﻤﺘﺪ ﺇﻟﻰ ﺑﺪﺍﻳﺔ
ﺍﻝ  . Gagﻭﺟﺪ ﺍﻥ ﺍﻟﺘﺘﺎﺑﻌﺎﺕ ﺍﻟﻤﻤﺜﻠﺔ ﻟﻬﺬﻩ ﺍﻟﻤﻨﺎﻁﻘﺘﻜﻮﻥ ﻫﻴﺎﻛﻞ ﺛﺎﻧﻮﻳﺔ ﻣﺴﺘﻘﺮﺓ ﺗﻀﻢ ﺍﻟﻌﺪﻳﺪ ﻣﻦ ﺍﻟﺰﺧﺎﺭﻑ
ﺍﻟﻬﻴﻜﻠﻴﺔ  .ﻓﻲ ﻣﺤﺎﻭﻟﺔ ﻻﻗﺎﻣﺔ ﻋﻼﻗﺔ ﺑﻴﻦ ﺍﻟﻬﻴﻜﻞ ﻭﺍﻟﻮﻅﻴﻔﺔ ﻟﻠﻬﻴﺎﻛﻞ ﺍﻟﺜﺎﻧﻮﻳﺔ ﻟﻤﺤﺤﺪﺍﺕ ﺍﻟﺘﺠﻤﻴﻊ ﻟﻔﻴﺮﻭﺳﻲ
MPMVﻭ  , MMTVﻟﻘﺪ ﻗﻤﻨﺎ ﺍﻭﻻ ﺑﺎﻟﺘﺤﻘﻖ ﻣﻦ ﺻﺤﺔ ﺍﻟﻬﻴﺎﻛﻞ ﺍﻟﻤﺘﻮﻗﻌﺔ ﻣﺴﺒﻘﺎ ﻭﺫﻟﻚ ﻋﻦ ﻁﺮﻳﻖ
ﺍﺳﺘﺮﺍﺗﻴﺠﻴﺔ chemo-enzymatic probing strategy, selective 2’hydroxyl acylation primer
extension (SHAPE).
ﺗﺤﻠﻴﻞ ﻣﺤﺪﺩﺍﺕ ﺍﻟﺘﺠﻤﻴﻊ ﻟﻔﻴﺮﻭﺳﻲ  MPMVﻭ  MMTVﺑﻮﺍﺳﻄﺔ  SHAPEﺍﺛﺒﺘﺖ ﻭﺟﻮﺩ ﺻﺤﺔ ﺍﻟﻬﻴﺎﻛﻞ
ﺍﻟﺮﺋﻴﺴﻴﺔ ،ﺑﻤﺎ ﻓﻲ ﺫﻟﻚ

ﺍﻟﺘﻔﺎﻋﻼﺕ ﻁﻮﻳﻠﺔ ﺍﻟﻤﺪﻯ ) ، U5/Gag (LRIsﺍﻣﺘﺪﺍﺩ ﺍﻟﻤﻨﻄﻘﺔ ﺍﻟﻐﻨﻴﺔ ﺑﺎﻟﺒﻴﻮﺭﻳﻨﺎﺕ

) ،(ssPurineﻭﻣﻨﻄﻘﺔ ﻏﻨﻴﺔ ﺑﺎﻝ -GCﺍﻟﻤﺘﻨﺎﻭﺏ ) . (palﺑﺎﺳﺘﺨﺪﺍﻡ ﺗﻘﻨﻴﺎﺕ ﺍﻝ Minimum free-
 energy structure predictions, phylogenetic, in silico analysesﻟﺴﻼﻻﺕ ﻣﺨﺘﻠﻔﺔ ﻣﻦ
ﻓﻴﺮﻭﺳﺎﺕ ﺍﻝ  MPMVﻭ  MMTVﺗﺆﻛﺪ ﻭﺟﻮﺩ ﻫﺬﻩ ﺍﻟﻬﻴﺎﻛﻞ ﺍﻟﻜﺒﺮﻯ.

ﻻﺧﺘﺒﺎﺭ ﺃﻫﻤﻴﺔ ﺗﺴﻠﺴﻞ  palﻓﻲ ﻣﺤﺪﺩﺍﺕ ﺍﻟﺘﺠﻤﻴﻊ ﻭﺍﻝ  gRNA dimerizationﻟﻔﻴﺮﻭﺳﻲ  MPMVﻭ
 ،MMTVﻗﻤﻨﺎ ﺑﺎﺩﺧﺎﻝ ﺳﻠﺴﻠﺔ ﻣﻦ ﺍﻟﻄﻔﺮﺍﺕ ﻓﻲ ﺣﻠﻘﺎﺕ  palﺍﻟﺤﻠﺰﻭﻧﻴﺔ .ﺩﺭﻟﺴﺔ ﻫﺬﻩ ﺍﻟﻄﻔﺮﺍﺕ ﺑﺎﺳﺘﺨﺪﺍﻡ
ﻣﻨﺎﻫﺞ ﻣﺨﺘﻠﻔﺔ ﻣﺜﻞ in vitro and in vivo complementary approaches, phylogenetic, and

ix

 structure prediction analysesﻛﺸﻔﺖ ﻭﺟﻮﺩ ﺗﺘﺎﺑﻌﺎﺕ  palﺍﻟﺤﻠﺰﻭﻧﻴﺔ (5’ CGGCCG 3’ in
)  MPMV and 5’ CGGCCG 3’ in MMTVﻭﺍﻟﺘﻲ ﺗﺤﺘﻮﻱ ﻋﻠﻰ " "GCﺻﺒﻐﻲ ﻣﺰﺩﻭﺝ ﻳﻌﻤﻞ
ﻛﻨﻘﻄﺔ ﻟﺒﺪء ﺍﻝ  dimerizationﺗﺘﺤﻜﻢ ﻓﻲ ﺗﺠﻤﻴﻊ ﺍﻟﻤﺤﺘﻮﻯ ﺍﻟﻮﺭﺍﺛﻲ ﻟﻔﻴﺮﻭﺳﻲ MPMV, MMTV
 . gRNA dimerizationﻋﻼﻭﺓ ﻋﻠﻰ ﺫﻟﻚ ،ﻓﻲ ، MMTVﻟﻮﺣﻆ ﻭﺟﻮﺩ  pal IIﺩﺍﺧﻞ ) (PBSﻭﺍﻟﺬﻱ
ﻳﺸﺎﺭﻙ ﺍﻳﻀﺎ ﻓﻲ ﻋﻤﻠﻴﺔ  .gRNA dimerizationﺗﺤﻠﻴﻞ ﺍﻟﻄﻔﺮﺍﺕ ﻟﻞ  pal IIﻭ PBSﻳﻮﺣﻲ ﺃﻥ ﻛﻼ ﻣﻨﻬﻤﺎ
ﺍﺳﺎﺳﻲ ﻓﻲ ﻋﻤﻠﻴﺔdimerization, packaging and propagation of MMTV gRNA.
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CHAPTER 1
Introduction
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1.1. Introduction
1.1.1. Retroviruses
Retroviruses are enveloped (+) sense ssRNA viruses which are members
of the retroviridae family and have been intensely studied because of their
association with cancers, leukemias, and a variety of immune system disorders
(Coffin, 1992, 1996). Retroviruses have the unique property to replicate by
“reverse transcribing” their single stranded RNA genome into a double stranded
DNA in the host cell using the virally-encoded polymerase, reverse transcriptase
(RT), which is then integrated into the host genome (Baltimore, 1970; Temin &
Mizutani, 1970).
1.1.2. Classification of Retrovirus
Using their taxonomic relatedness, retroviruses have been classified in
different genuses based on morphogenic features (Goff, 2001) as outlined below:
Genus
Alpharetrovirus, α

Features
C-type
Simple

Betaretrovirus, β

B-, D-type

Gammaretrovirus, γ

C-type
Simple

Deltaretrovirus, δ

Complex,
Oncogenic

Epsilonretrovirus, ε

Lentivirus

Complex,
Oncogenic

Complex

Examples
Avian leukosis virus (ALV)
Rous sarcoma virus (RSV)
Mouse mammary tumor virus (MMTV)
Mason-Pfizer monkey virus (MPMV)
Jaagsiekte sheep retrovirus (JSRV)
Murine leukemia viruses (MuLV)
Feline leukemia virus (FeLV)
Gibbon ape leukemia virus (GaLV)
Reticuloendotheliosis virus (REV)
Human T-lymphotropic virus
(HTLV)-1, -2
Bovine leukemia virus (BLV)
Simian T-lymphotropic virus types 1-3
(STLV-1, -2, -3)
Walleye dermal sarcoma virus
Walleye epidermal hyperplasia virus 1
Human immunodeficiency virus type 1
and 2
(HIV-1 and -2)
Simian immunodeficiency virus (SIV)
Feline immunodeficiency virus (FIV)
Equine infectious anemia virus (EIAV)
2

Spumavirus

Caprine arthritis encephalitis virus
(CAEV)
Visna/maedi virus
Human foamy virus (HFV)
Simian foamy virus (SFV)

Complex

1.1.3. Genome Organization and Characteristic Features
Retroviral virions range in size between 80-100 nm containing two copies
of 7-12 kilo bases (kb) long single stranded RNA molecules as their genome
which are non-covalently linked as a “dimer” at their 5’ end (Fig. 1.1; reviewed in
Pedersen & Duch, 2006). Following reverse transcription and integration, the
two RNA copies lead to only one provirus in cells infected with one virus.
Therefore, retroviruses are “pseudodiploid”. The flanking ends of a typical
retroviral RNA genome (which is capped and polyadenylated) contain cis-acting
non-coding controlling sequences needed for virus replication. Between the cisacting controlling sequences are present the trans-acting sequences responsible for
coding the viral structural and enzymatic proteins. In the retroviral RNA genome,
“R” (a repeat sequence) is present at both the 5’ as well as the 3’ ends whereas
“U5” (unique sequence at the 5’end) and “U3” (unique sequence at the 3’end) are
present at the 5’ and 3’ ends, respectively. During the course of reverse
transcription, the “U3” sequences are copied at the 5’ end and the “U5” sequences
are copied at the 3’ end, resulting in the formation of a complete long terminal
repeat (LTR) consisting of U3-R-U5 sequences at both ends of the viral genome
(Fig. 1.1). In close vicinity of cis-acting control sequences of the RNA genome,
there are short non-coding sequences known as 5’ and 3’ untranslated leader
region (UTR) which includes a primer binding site (PBS) and polypurine tract
(PPT) playing vital roles during reverse transcription (Fig. 1.1). Sequences in the
UTR have been shown to be involved in regulation of many essential steps of
3

4

transcribe this RNA genome (B) into the DNA (C) that is integrated into the host chromosome to become proviral DNA.

retroviral particle (A) contains two copies of full length unspliced viral RNA as its genome. Retroviruses have the unique property to reverse

FIGURE 1.1. Schematic representation of the viral RNA genome and the viral DNA along with its important cis-acting elements. A typical
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Reverse
Transcription

Coding sequences
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viral replication cycle, including genomic RNA (gRNA) dimerization and
packaging, splicing, and translation (reviewed in Kuzembayeva et al., 2014).
A classical retrovirus containing three canonical genes or open reading
frames (ORFs): gag, pol and env is called a “simple” retrovirus (Fig. 1.2; Coffin,
1992; Murphy et al., 1994). For example, in Mason-Pfizer monkey virus
(MPMV), the gag gene encodes for group specific antigen (Gag) precursor
structural polyprotein which is cleaved by viral protease during maturation into
the matrix (MA), capsid (CA) and nucleocapsid (NC) proteins (Fig. 1.3). The MA
protein (forming the inner shell) is involved in mediating a stable association of
Env glycoproteins to the viral particles, whereas NC interacts with the full length
unspliced gRNA to selectively encapsidate itself into the assembling viral
particles (reviewed in Kuzembayeva et al., 2014 and references within). The CA
proteins form the viral core. The pol gene encodes for the RT and integrase (IN)
enzymes. The RT has retroviral-specific reverse transcriptase activity
(polymerase and RNase H) to convert the RNA genome into DNA which is then
integrated into the host chromosome, a process that is facilitated by the IN
enzyme. In addition, a small open reading frame, pro , encodes for viral protease,
which carries out auto cleavage and processing of the viral polyproteins, and is
located either at the 3’ end of the gag gene, the 5’ end of the pol ORF or as an
ORF between gag and pol, depending on the virus type (Fig.1.3; reviewed in
Pedersen & Duch, 2006). The CA, RNA + protein (RNP) and the viral enzymes
(RT, RNase, and IN) form the inner core of the viral particle (Fig.1.3). The env
gene encodes for the envelope (Env) precursor protein which is cleaved into the
transmembrane (TM) and surface (SU) glycoproteins by cellular proteases for
their incorporation into viral phospholipid bilayer membrane (Fig. 1.3). For
6
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sag, superantigen gene.

only three accessory genes (dut, sag and rem) and therefore has recently been proposed to be re-classified as a murine complex retrovirus.

after interacting with cellular or viral factors, facilitate the nuclear export of unspliced genomic RNA. Compared to HIV-1, MMTV contains

contain cis-acting sequences (CTE, constitutive transport element; RRE, rev responsive element, and RmRE-Rem-responsive element) that,

such as HIV-1 contain 6 additional accessory genes, which play important roles in the completion of their life cycle. Complex retroviruses

retroviruses contain long terminal repeats (LTRs) and 3-4 canonical genes (gag, pol pro, and env). Apart from these, complex retroviruses

human immunodeficiency virus type-1 (HIV-1; complex), and (C) mouse mammary tumor virus (MMTV; complex?) retroviruses. All

FIGURE 1.2. Schematic representation of simple and complex retroviral genomes. (A) Mason-Pfizer monkey virus (MPMV; simple), (B)
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http://cronodon.com/BioTech/Virus_Tech_3.html.

genome, resulting in the generation of the proviral DNA. Figure and legends adapted from website:

reverse transcriptase (RT) and integrase (In) which are responsible for reverse transcribing and integrating the viral genome into the host

envelope contains glycoprotein spikes made up of gp120 and gp41 in the case of HIV-1. The inner core also contains viral enzymes such as

inside a protein matrix shell (inner shell; green) that is enclosed in a phospholipid bilayer membrane (blue) containing envelope. The

genome (red spirals) along with the packaging proteins form the ribonucleoprotein (RNP) inside the inner core (yellow). The core is present

FIGURE 1.3. Schematic representation of a typical retroviral particle depicting major gene products. The two copies of the viral RNA
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example, in human immunodeficiency virus type 1 (HIV-1), transmembrane
glycoprotein gp41 is responsible for the fusion between viral and cell membranes
(Allan et al., 1985; Kowalski et al., 1987; Veronese et al., 1985; Willey et al.,
1988) and surface glycoprotein gp120 mediates the binding of HIV virions to CD4
receptor (McDougal et al., 1986). The glycoprotein spike formed by gp120 and
gp41 enables the virus to attach to and fuse with target cells to initiate infection.
Complex retroviruses such as HIV-1 (Fig. 1.2) have been shown to code
for additional accessory and regulatory proteins that are derived from multiply
spliced messages (Fig. 1.4). In the case of HIV-1, apart from the canonical gag,
pol and env genes, HIV-1 contains two regulatory (tat, rev) and four accessory
(vif, vpr, vpu and nef) genes (reviewed in Balvay et al., 2007; Cullen & Greene,
1990; Pavlakis & Felber, 1990). These viral proteins in complex retroviruses play
an important role in viral replication. For example, tat encodes for transcriptional
activator (Tat) protein by binding to a structured region in the RNA called
transactive responsive element (TAR) that is important for replication by
mediating transactivation of transcription and regulation of gene expression
(Dayton et al., 1986; Fisher et al., 1986; Garcia et al., 1989; Jakobovits et al.,
1988). The rev gene encodes Rev protein (regulator of viral gene expression)
which regulates nuclear export of viral RNA into the cytoplasm (Meyer & Malim,
1994). Accessory genes vif, vpr, vpu, and nef encode for Vif (viral infectivity
factor), Vpr (viral protein R), Vpu (viral protein U) and Nef (negative effector)
proteins which perform important functions during viral replication (Frankel &
Young, 1998). For example, Vif is crucial for inhibiting the antiviral activity of a
host factor, APOBEC3 (Mehle et al., 2004; Strebel et al., 1987). Nef and Vpu
proteins are involved in the degradation of CD4 cells (Mangasarian & Trono,
11
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(2012).

Gag-Pol, Gag-polymerase; PIC, pre-integration complex; RTC, reverse transcription complex. Figure and legends adapted from Stoye

to continue its life cycle. The virion particles undergo maturation after budding. Env, envelope protein; Gag, group-specific-antigen protein;

gRNA also functions as the substrate for packaging/encapsidation into the assembling virion particles at the cell membrane (or into exocyte)

translated into Gag/Pol proteins (shown in blue circles), whereas the envelope proteins are expressed from spliced mRNA. Furthermore, the

mRNA and envelope spliced mRNA, which are then exported to the cytoplasm. In the cytoplasm, full length (unspliced) genomic mRNA is

(green) forming a provirus. (B) The integrated provirus is transcribed classically into two types of RNAs, full length (unspliced) genomic

reverse transcribed DNA is transported through the cytoplasm and imported into nucleus where it is integrated into the host chromosome

which viral RNA genome (blue) is reverse transcribed by reverse transcriptase (RT; orange circle) into a double stranded DNA (blue). The

undergoes membrane fusion (at the cell surface or endosome). The viral core is then released which undergoes partial uncoating during

FIGURE 1.4. Schematic representation of retroviral life cycle. (A) The virus binds to a specific receptor on the cell membrane and
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A
Entry
B
Exit

1997; Tiganos et al., 1997; Willey et al., 1992) during the infection process.
Recently, due to the presence of a number of accessory genes (Fig. 1.2), it has
been suggested that mouse mammary tumor virus (MMTV) be re-classified as a
complex murine retrovirus (Mertz et al., 2005).

For example, MMTV codes for

the superantigen protein (Sag; Choi et al., 1991; Frankel et al., 1991; Woodland et
al., 1991) which mediates the infection of mammary glands in mice. Rem gene
expresses the rem protein which has been shown to interact with a structural
element called Rem-responsive element (RmRE) on the MMTV gRNA to
facilitate its nuclear export (Fig. 1.2; Indik et al., 2005; Mertz et al., 2005, 2009a,
2009b; Müllner et al., 2008).
1.1.4. Retroviral life cycle
Following entry into the host cell, various events that take place in the life
cycle of a typical retrovirus leading to the production of progeny virions are
explained in figure 1.4 (reviewed in Stoye, 2012). The life cycle of a retrovirus
can be divided into entry and exit phases. The viral Env proteins interact and bind
to a specific receptor on the host cell surface to mediate entry into the cell either at
the plasma membrane or from endosomes via membrane fusion. The viral core is
then released into the cytoplasm which then undergoes partial uncoating. Reverse
transcription of the viral RNA genome into DNA by RT takes place in the
cytoplasm and the pre integration complex (PIC) is imported into the nucleus
(nuclear entry), resulting in integration into cellular DNA- a process that is
mediated by virally encoded IN. The integrated retroviral DNA is now called a
“provirus”. In the exit phase of the viral life cycle, cellular RNA polymerase II
(RNAPII) transcribes viral RNA from the proviral DNA. In the case of simple
retroviruses like MPMV, two classes of RNAs are generated: full length unspliced
14

gRNA and spliced envelope RNA (Fig.1.5). These RNAs are exported from the
nucleus to the cytoplasm for translation into viral proteins (Fig.1.4). In sharp
contrast to cellular unspliced RNAs (which are not exported out of the nucleus),
retroviruses have evolved several different mechanisms involving both viral and
cellular factors for ensuring that sufficient levels of unspliced gRNA are
transported to the cytoplasm (Fig. 1.6).
In the cytoplasm, while the spliced RNA is responsible for expressing
envelope precursor proteins, the unspliced gRNA plays a dual function: i) It act
as a template for both the translation of Gag/Pol polyproteins and ii) works as a
substrate for packaging into the assembling virus particles to continue viral life
cycle (Fig. 1.4). In many retroviruses, ribosomal frameshifting plays an important
role in expressing Gag/Pol polyproteins. Ribosomal frameshifting is a process in
which ribosomes move to a different reading frame and continue translation in
that reading frame. The ribosomal frameshift signal (RFS) that makes a ribosome
shift comprises two elements: a “slippery sequence” where the ribosome switches
the reading frame, and an adjacent stimulatory signal, usually a specific RNA
secondary structure called “pseudoknot” (Fig. 1.7) downstream of the RFS
(reviewed in Brierley & Dos Ramos, 2006). The slippery sequence has been
shown to be shifty on its own in vitro, up to 2%, but is strongly stimulated, up to
40-fold, by the presence of a hairpin pseudoknot located downstream of the
slippery sequence (Fig. 1.7). This mRNA secondary structure causes ribosomes
translating the message to pause at the position of the slippery sequence, slowing
or pausing the ribosome during translation and increasing the frequency at which
frame shifting occurs. This boosts the relative amounts of proteins encoded by the
downstream reading frames (Fig. 1.7). The NC domain of the Gag precursor
15
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Mertz et al. (2005).

either a promoter in the 5’ LTR or the env promoter for its transcription. sag, superantigen gene. MMTV part of the figure is adapted from

envelope protein. MMTV genome is transcribed into gag/pol, env, sag, and rem mRNAs by different splicing mechanisms. Sag gene uses

MPMV transcribe a full length (unspliced) gRNA which also translates into Gag/Pol polyprotein, and a spliced mRNA which codes for

FIGURE 1.5. Schematic representation of MPMV and MMTV genomes and their respective RNA transcripts. Simple retroviruses like

17

MMTV

MPMV

U3

Ψ

PBS

R U5

gag
pol

env
CTE

U3

R U5

18

export of the gRNA. Figure and legends adapted from Jaballah (2010).

responsive element (RmRE) at the 3’ of the MMTV gRNA interacts with the virally encoded trans proteins, Rem, facilitating the nuclear

of MPMV (a simple retrovirus) interacts with cellular proteins to mediate the nuclear export of the gRNA. (C) The cis-acting Rem-

efficient transport of unspliced RNAs from the nucleus to the cytoplasm. (B) The cis-acting constitutive transport element (CTE) in the case

acting Rev protein (in the case of complex retrovirus HIV-1) binds to the cis-acting structural Rev responsive element (RRE) to facilitate the

translation of structural and enzymatic proteins as well as for packaging into the assembling virion particles. (A) Virally encoded trans-

gRNAs. Diverse retroviruses have evolved different mechanisms for successfully transporting unspliced gRNA for use as a template for

FIGURE 1.6. Schematic representation of different pathways employed by retroviruses during nucleocytoplasmic transport of unspliced
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proteins encoded by the downstream reading frame. Figure adapted from Alberts et al., Molecular Biology of the Cell. 4th Edition, 2002.

translation, which in turn results in increased frequency of ribosomal frameshifting. Frameshifting enables a higher translation rate of

located just downstream of the slippery sequence. This stem loop causes ribosomes to pause at the position of the slippery sequence during

by a process known as ribosomal frameshifting. Briefly, the mRNA folds into a RNA secondary structure containing a stem loop which is

proteins. Retroviral gRNAs contain a slippery sequence that allows ribosomes to move to a different reading frame and continue translation

FIGURE 1.7. Schematic representation of ribosomal frameshifting phenomenon in retroviruses to express relative amounts of Gag and Pol
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protein interacts with the RNA dimer and packages it into budding virions at the
cell membrane or exocyte (as in the case of MMTV). Retroviral particles
assembly can occur at any of two subcellular locations based on the retroviral
classification. For example, type C retroviruses (e.g. MLV) assemble at the cell
membrane, while types B and D retroviruses (e.g., MMTV and MPMV)
preassemble at a perinuclear location forming the so called type “A” particle that
are subsequently translocated to the cell membrane for budding (reviewed in Goff,
2001). These budding particles acquire the Env glycoproteins at this step since
they are incorporated into the lipid bilayer of the host earlier after synthesis. The
virion is then released from the cell surface and undergoes maturation to become
infectious by further proteolytic cleavages and genomic RNA dimer stabilization
(Bender et al., 1978; Fu & Rein, 1993; Murti et al., 1981).
Understanding the various steps involved in the viral life cycle has also
helped us to learn about a number of cellularly-encoded genes that have been
shown to inhibit retrovirus infection by blocking the virus life cycle at different
stages (Fig. 1.8; reviewed in Goff, 2004; Pedersen & Duch, 2006; Santa-Marta et
al., 2013). These anti-retroviral defense mechanisms have been observed in
virally-infected producer and/or target cell of the virus. Cytidine deamination of
viral single stranded DNA during reverse transcription can hinder retrovirus
replication by the APOBEC family of proteins (Apolipoprotein B-editing
Catalytic Polypeptide 3 Proteins; APOBEC3; A3; Fig. 1.8). These proteins have
been shown to be packaged by HIV-1 and MPMV in the virus particles (Yu et al.,
2004; Zhang et al., 2003). It has also been reported that retroviruses may develop
resistance to such anti-retroviral host defense mechanisms. For example, HIV1Vif protein can account for the resistance to APOBEC due to possible
22
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Santa-Marta et al. (2013).

mechanism is shown by broken arrows. Unknown mechanisms are represented by question marks (?). Figure and legends adapted from

factors to overcome the host factors. The course of viral replication and actions are shown by the black arrows, while the course of inhibition

the name of the responsible host gene or gene product. Red ovals represent cellular restriction factors whereas gray hexagons represent viral

virus. (B) Target cell for infection. The symbols and the associated text represent the point of restrictions during the retroviral life cycle and

FIGURE 1.8. Role of host restriction factors and their action during retroviral (e.g. HIV-1) replication. (A) Producer cell infected with

24

interactions between the two proteins (Yu et al., 2003). Some of the other
intracellular restriction factors include TRIM and SAMHD1. Several TRIM
family members have been identified as HIV-1 restriction factor acting at different
steps in the HIV-1 life cycle (reviewed in Santa-Marta et al., 2013). The TRIM5
proteins have been shown to block HIV-1 infection by binding to the HIV-1 CA
and inducing its premature disassembly before reverse transcription can occur.
Vectors that combine anti-CCR5 chemokine receptors short hairpin RNA with
TRIM5a therapeutic targets are being tested to maximize HIV-1 replication
blockage. The sterile alpha motif (SAM) and histidine-aspartate (HD) domaincontaining protein 1 (SAMHD1; reviewed in Santa-Marta et al., 2013) have been
shown to reduce the intracellular dNTP pool below levels that support HIV-1
reverse transcription thus blocking viral replication.
Host microRNAs have also been shown to be responsible to restrict
viruses such as spumavirus, primate foamy virus type 1 (PFV-1), as part of the
RNA interference machinery in human cells (Lecellier et al., 2005). The complete
mechanism(s) of some of these factors involved in restricting the retrovirus life
cycle is yet to be fully understood. For example, in a number of retroviruses such
as HIV-1, SIV and MuLV, a ZAP protein in addition to TRIM5α have been
observed to block infection (Gao et al., 2002; Yap et al., 2004; Ylinen et al.,
2005). These restriction systems provide understandings that can be utilized into
the design of novel anti-retrovirals and unravel the yet to be identified steps of the
virus life cycle (reviewed in Goff, 2004).
1.1.5. Retroviral gRNA packaging
For a retrovirus to continue its life cycle and spread infection, it requires
packaging/encapsidation of its gRNA into the assembling viral proteins before it
25

leaves a host cell by budding (Fig. 1.4). Therefore, the efficient and specific
packaging of retroviral gRNA by the assembling virion particles is considered as
one of the hallmarks of retroviral life cycle (Fig. 1.4). During this process, fulllength, unspliced gRNA is preferentially packaged, whereas spliced viral and
cellular RNAs are generally excluded from nascent virus particles despite the fact
that retroviral genomic RNAs constitute 1% or less of the total cellular mRNAs
(Coffin et al., 1997). The specificity towards RNA packaging is conferred by the
recognition of specific cis-acting sequences, the packaging signal (Ψ), present at
the 5’ end of the viral genome, which interacts with the NC domain of the Gag
precursor protein (Fig. 1.9; reviewed in D'Souza & Summers, 2005; Johnson &
Telesnitsky, 2010; Lever, 2007; Lu et al., 2011a; Miyazaki et al., 2011).
Specifically, NC contains zinc knuckles with one or two conserved CCHC arrays
(C-X2-C-X4-H-X4-C; C = Cys, H = His, X = variable amino acid) that are
required for high affinity NC-RNA interactions in vitro (Fig.1.10; Green and
Berg, 1989; Henderson et al.,1981; Jouvenet et al., 2011; Summers et al., 1992).
The interaction between NC and the packaging signal results in the incorporation
of the gRNAs into the virus particles. Furthermore, it has been shown that
packaging can occur when the NC domains and the packaging signals are
incorporated into heterologous retroviral Gag and RNA constructs, respectively.
For example, chimeric HIV-1 virions that contain the Moloney murine leukemia
virus (MoMuLV) NC domain preferentially package MoMuLV RNA and vice
versa (Berkowitz et al., 1995; Zhang & Barklis, 1995). The sites of initial
interaction between gRNA and NC domain can occur in the cytoplasm, resulting
in the formation of subassemblies with Gag (Fig. 1.11D, top) or they can directly
associate at the plasma membrane (Fig. 1.11D, bottom) after gRNA is actively
26
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excluded from nascent viral particles.

the ψ is preferentially packaged, whereas spliced viral RNA (in which ψ is excised out during splicing) and cellular RNAs are generally

order structure and is depicted as a cartoon. (B) During retroviral life cycle, full-length, unspliced genomic RNA by virtue of the presence of

virus (MPMV) genome showing the location of packaging sequences (ψ) at the 5’ end of the genome which has been shown to assume higher

FIGURE 1.9. Schematic representation of the prevailing model of retroviral gRNA packaging/encapsidation. (A) Mason-Pfizer monkey
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domain to bind and anneal to nucleic acid. Figure and legends adapted from Jouvenet et al. (2011).

(in red) are represented with the central zinc atom (Zn). MLV contain one ZF domain, while HIV-1 contains two. The ZF enables the NC

packaging by binding to the packaging sequences (ψ) at the 5’ end of gRNA. The zinc fingers (ZFs) with the C-C-H-C consensus sequence

immunodeficiency virus type-1 (HIV-1). The C-terminus of the Gag polyprotein contains the NC domain that selectively recruits gRNA for

FIGURE 1.10. Amino acid sequences of the nucleocapsid (NC) proteins of (A) murine leukemia virus (MLV) and (B) human
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from Johnson and Telesnitsky (2010).

On the other hand, packaging of a heterodimer (virion at the center) promotes genetic recombination and genetic diversity. Figure and legends adapted

out after retroviral gRNA packaging. Packaging of two gRNAs as homodimer helps the virus in maintaining packaging specificity and genomic integrity.

Gag can be found in the cytoplasm (shown at top) or at the plasma membrane (shown at bottom) after separate active transport. (E) The viral particle buds

been shown to undergo kissing interaction in the cytoplasm which can result in homodimers and/or heterodimers. (D) The site of gRNA recruitment by

interact near the transcription sites in the nucleus which can result in favoring of homodimer formation over heterodimer formation. HIV-1 gRNAs have

of gRNA for packaging. (C) The cellular site of dimerization initiation is different for different retroviruses. For example, MLV gRNA dimers first

gRNA structure. Such a conformational change facilitates the binding of NC domain of Gag polyproteins to the NC binding site, allowing the recruitment

result in the formation of a dimer linkage structure that has exposed NC binding sites (shown in yellow) which were hidden (protected) in a monomeric

sequences, resulting in initiation of dimerization and changes in structural conformation due to base pairing between the two RNA strands. This further

core and bound by nucleocapsid (NC; shown as green dots). (B) Two copies of gRNA interact (kissing interactions) via stem loops containing palindromic

Retroviral particles containing two plus sense gRNAs joined by dimer linkage within the capsid core infect the host cell. The gRNAs are condensed in the

retroviruses such as human immunodeficiency virus type 1 (HIV-1) and murine leukemia virus (MLV; shown in red at top and green at the bottom). (A)

FIGURE 1.11. A model depicting possible mechanism(s) employed during retroviral RNA dimerization and packaging in a cell co-infected with C-type
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transported separately from all or most Gag (reviewed in Johnson & Telesnitsky,
2010; Jouvenet et al., 2011).
The sequences that are responsible for gRNA packaging in retroviruses
have been shown to be present in the form of a continuous region or could be in
the form of a discontinuous region (multipartite sequence) residing at the 5’ end of
the genome (Fig. 1.12; reviewed in Jaballah et al., 2010; Mustafa et al., 2005,
2012). Over the years, we have learned that retroviral packaging sequences are
usually located downstream of the major spliced donor (mSD). Such a unique
position of the packaging sequences facilitates the discrimination between spliced
and unspliced viral RNAs in most of the retroviruses with the exception of Rous
sarcoma and avian leukosis viruses. A classic example of such discrimination
between spliced and unspliced viral transcripts is observed in the case of HIV-1
during RNA packaging. The stem loop 2 (SL2), a major packaging determinant
containing the major splice donor (mSD) has been shown to binds with high
affinity to NC. However, because of the presence of mSD during splicing, the
SL2 undergoes conformational changes resulting in the destabilization and
absence of SL2 in the spliced RNA thereby limiting its packaging potential
(reviewed in D’Souza & Summers, 2005). On the other hand, in the case of HIV2, since the major packaging determinants are present upstream of the mSD,
therefore both spliced and unspliced transcripts contain packaging sequences
making the discrimination between spliced and unspliced transcripts difficult
during packaging. HIV-2 has overcome this disparity by by using a unique
sorting mechanism during which only those transcripts capable of translating gag
in cis can be packaged into the virus particle (Balvay et al., 2007; Griffin et al.,
2001; Kay & Lever 1999). In HIV-1, in vivo and in vitro studies have shown that
33
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et al. (2012).

references and other details of the gRNA packaging determinants are provided in the table below. Figure and legends adapted from Mustafa

beginning of gag that have been shown to be required for optimal packaging of retroviral gRNA are compared as per published data. The

shown to assume higher order structure schematically represented in the right panel. Sequences starting from nucleotide +1 in R to the

FIGURE 1.12. Schematic representation of the packaging determinants of different retroviruses (left panel), which have been universally
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Length of
5’ UTR

128 bp

270 bp

160 bp

152 bp

231 bp

MPMV (Type D)

FIV (Type C)

MMTV (Type B)

HIV-1 (Type C)

SIV (Type C)

Entire UTR (231 nts)

Entire UTR (152 nts)

Entire UTR (160 nts)

∆gag

Entire UTR

Entire UTR

Entire UTR

First 150 bp

First 50 bp + last 23 bp

5’ UTR Required

~100 nts gag

?

~100 nts gag

?

~120 nts of gag

~100 nts of gag

Last 23 nts of UTR + ~100 nts of gag

Dispensable

Dispensable

Virus

SIV
Lenti/Type C

HIV-1
Lenti/Type C

MMTV
Type B

150 nts of 270 nts UTR
FIV
Lenti/Type C

MPMV
Type D

5’ UTR

50 nts of 128 nts UTR

R U5

5’ LTR

U3

?

?

~120 bp

~ 100 bp

~ 100 bp

Gag Required

Rizvi & Panganiban, 1993; Guan et al., 2000, 2001; Patel et al.,
2003; Strappe et al., 2003; Whitney & Wainberg; 2006

Berkowitz et al., 1995; McBride & Panganiban, 1997; Clever
&Parslow, 1997; Houzet et al., 2007; Heng et al., 2012

Rizvi et al., 2009

Browning et al., 2003a, 2003b; Mustafa et al., 2005a; Kenyon
et al., 2008; Rizvi et al., 2010; Kenyon et al., 2011

Schmidt et al., 2003; Jaballah et al., 2010

References

translation and packaging takes place in competition, driving the gRNA to
translate proteins following which the transcripts undergo changes in their
structural conformation, facilitating packaging (Anderson & Lever, 2006; Butsch
& Boris-Lawrie, 2000; Dorman & Lever, 2000).
Although RNA packaging is a ubiquitous process in all retroviruses and
the packaging signal always involves sequences at the 5’ end of the retroviral
gRNA, no sequence conservation between the packaging signals of different
retroviruses has been found. Invariably, it has been shown that the packaging
sequences of all known retroviruses assume a higher order structure comprising
different structural motifs (Fig. 1.13; D'Souza & Summers, 2005; Johnson &
Telesnitsky, 2010; Lever, 2007; Lu et al., 2011a; Miyazaki et al., 2011;).
Therefore, the involvement of such structural RNA motifs on the retroviral
genomic transcripts (at times regardless of the primary sequence) have been
strongly associated with retroviral RNA encapsidation and could explain the
phenomenon of RNA cross-packaging among diverse retroviruses (Al Dhaheri et
al., 2009; Al Shamsi et al., 2011; Moore et al, 2007; Parveen et al., 2004; Rizvi &
Panganiban, 1993; White et al., 1999; Yin & Hu, 1997). This has further been
substantiated by the fact that heterodimers involving RNAs from two divergent
retroviruses can also be co-packaged (Moore et al., 2009; Motomura et al., 2008;
reviewed in Johnson & Telenitsky, 2010). RNA secondary structures predicted by
various approaches, including free energy predictions, phylogenetic analyses, and
biochemical probing, and their subsequent validation by biological assays, have
further confirmed the function of RNA structural elements in the gRNA
packaging for a number of both simple and complex retroviruses (Fig. 1.13;
Jouvenet et al., 2011). In addition to the conventional packaging sequences, a
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Interaction between nucleocapsid (NC) domain of Gag and the highly structured packaging determinants located in the 5’ untranslated

packaging determinant. SD, major splice-donor site. Figure and legends adapted from Jouvenet et al. (2011).

dimerization, while SLs C and D form the core encapsidation signal. In the case of HIV-1, DIS containing SL1 and SL3 form the major

viral RNAs. The higher order structure of the MLV packaging signal contains four stem loops (SLs A-D). The A and B SLs promote gRNA

region (5’ UTR) of gRNA results in its specific selection from a cytoplasmic pool that contains a substantial excess of non-viral and spliced

ψ).

FIGURE 1.13. Schematic representation of MLV (A) and HIV-1 (B) genomes and the secondary structure of their packaging signals (Psi;
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Human immunodeficiency virus type 1 (HIV-1)

B

Murine leukemia virus (MLV)

A

recent study has shown that HIV-1 gRNA encapsidation is also dependent on a
cis-acting RNA element, genomic RNA packaging enhancer (GRPE) located
within the gag open reading frame overlapping the Gag/Pol RFS (Fig. 1.7;
Chamanian et al., 2013). However, further experiments are warranted to establish
the precise role of GRPE in HIV-1 gRNA packaging since another recent study
has suggested that the deletion of the wild-type RFS does not impede the
packaging of the full length HIV-1 RNA (Nikolaitchik & Hu, 2014).
1.1.6. Retroviral gRNA dimerization
Another hallmark of retroviral life cycle is the packaging of two copies of
viral gRNA in the form of a non-covalently linked RNA dimer. The conservation
of this unique genomic structure among retroviruses strongly advocates that a
dimerized genome plays a critical role in the viral life cycle (reviewed in D'Souza
& Summers, 2005; Johnson & Telesnitsky, 2010; Lever, 2007). In retroviral
replication, the process of RNA dimerization is thought to be closely linked with
RNA packaging, and in some, the former depends on the latter (Hibbert et al.,
2004, reviewed in D'Souza & Summers, 2005; Johnson & Telesnitsky, 2010;
Lever, 2007; Miyazaki et al., 2011; Moore et al., 2009; Paillart et al., 2004).
Therefore, it is not surprising that for almost all retroviruses without any sequence
conservation, determinants of gRNA packaging and dimerization map to the same
~100 to 400 nucleotides (nt) at the 5’ end of the gRNA (Fig. 1.12; reviewed in
D'Souza & Summers, 2005; Johnson & Telesnitsky, 2010; Lever, 2007). These
gRNA packaging and dimerization sequences are, for the most part, physically
and genetically inseparable and their structural context, almost invariably,
contributes to these processes (D'Souza & Summers, 2005; Johnson &
Telesnitsky, 2010; Lever, 2007). Consistent with this, studies have shown that
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mutations affecting dimerization generally also affect packaging (Baig et al.,
2007; Berkhout, 1996; Lanchy et al., 2003; Lanchy & Lodmell, 2007; Laughrea et
al., 1997; McBride & Panganiban, 1997; Paillart et al., 1996). The fact that
packaged RNA remains dimeric, even in cases when RNA packaging was
reduced, suggests that the dimerization of the two genomic RNAs may be a
prerequisite for packaging (Hibbert et al., 2004; Housset et al., 1993; Levin et al.,
1974). Furthermore, single HIV-1 viral RNA molecules containing two copies of
5’ UTR (containing packaging/dimerization sequences) are packaged as
monomers, highlighting the importance of the interaction between the 5’ ends of
two RNAs as a precondition for RNA packaging (Sakuragi et al., 2001, 2002). In
addition, high affinity NC binding residues in the gRNA of MoMuLV, for
example, are sequestered between the stem loops of the monomeric structure, and
are exposed by the formation of an intermolecular duplex possibly promoted by
the chaperone activity of the NC domain of Gag (Darlix et al., 1990, 1995).
Figure 1.11 represents the prevailing model of dimerization-dependent packaging
of gRNAs.
Palindromic (pal) and semi-palindromic sequences forming helix loop
structural motifs have been strongly implicated in the initiation of the dimerization
process between two copies of retroviral gRNAs (reviewed in Greatorex, 2004;
Johnson & Telesnitsky, 2010 Moore & Hu, 2009). It has been shown that the
dimerization is initiated by a pal sequence in its structural context (pal helix-loop)
which is called the dimerization initiation site (DIS; reviewed in D’Souza &
Summers, 2005; Johnson & Telesnitsky, 2010; Lu et al., 2011a; Lever, 2007;
Moore & Hu, 2009; Paillart et al., 1996b, 2004; Russell et al., 2004;). The pal of
different retroviruses has been shown to contain a canonical “GC” dyad (reviewed
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in Hussein et al., 2010). The autocomplementary property of palindromic
sequences allows base pairing between two gRNAs in an antiparallel direction to
initiate “kissing loop” interactions (Clever et al., 1996; Haddrick et al., 1996;
Lodmell et al., 2000, 2001; Paillart et al., 1994, 1996a, 1997) that ultimately leads
to a stable dimer linkage formation exposing the otherwise hidden NC binding
sites on the gRNA for interaction with the NC domain of Gag polyprotein (Fig.
1.11; reviewed in Johnson & Telesnitsky, 2010). The site of gRNA dimerization
initiation has been shown to be different for different retroviruses (Fig. 1.9C;
reviewed in Johnson & Telesnitsky, 2010; Jouvenet et al., 2011). For example,
RSV and MLV gRNA dimers are formed in the nucleus near transcription sites
which support homodimer formation, whereas in the case of FIV and HIV-1,
gRNA dimer formation takes place in the cytoplasm resulting in generation of
either homodimers and/or heterodimers (Fig. 1.11C; reviewed in Johnson &
Telesnitsky, 2010; Jouvenet et al., 2011).
Employing a combination of genetic and structural prediction analyses, we
have recently shown that MPMV and MMTV packaging determinants needed for
optimal packaging and propagation of their gRNAs are spread out between R and
the first 120 bp of the gag (Fig. 1.12; reviewed in Jaballah et al., 2010; Mustafa et
al., 2012). To expand these studies further, MPMV and MMTV gRNA packaging
sequences were folded using minimum free energy algorithm programs like Mfold
(Mathews et al., 1999; Zuker, 2003). The folding predictions of these sequences
revealed a higher order structure comprising several structural motifs, which could
be involved in augmenting gRNA dimerization and packaging of these viruses
(Jaballah et al., 2010). Therefore, in this thesis, we have developed structurefunction relationship of various structural motifs during gRNA dimerization and
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packaging processes of these viruses. Delineating the underlying molecular
mechanisms in retroviral RNA packaging is important for enhanced understanding
of retroviral life cycle.
1.2. Objectives
The advent of recombinant DNA technology has made possible the use of
gene therapy to treat, prevent, and even control human diseases such as cardiovascular
and pulmonary disorders, diabetes and different kinds of cancers (Herzog et al., 2010;
Hu et al., 2011; Ly et al., 2007, 2008; Song et al., 2004; Tian et al., 2004). Until
2012, 1155 clinical trials had been performed for various cancers, accounting for
approximately 65% of all human gene therapy trials (Wiley, 2012; Woo et al., 2006).
Retroviruses are distinct since they carry the special RT enzyme that converts the
RNA genome into a DNA molecule, which is then integrated into the host genome,
making it “permanent” (reviewed in Telesnitsky & Goff, 1997). Therefore, modified
retroviruses known as “retroviral vectors” are ideal candidates for delivering the
therapeutic genes in human gene therapy trials due to their ability to: i) integrate into
the host genome, ensuring its stable long-term expression, ii) have large coding
capacities, thereby allowing the expression of most genes of interest, and iii)
transduce only the therapeutic gene and not the viral genes, thus avoiding host
humoral/cellular responses to viral antigens that potentially can eliminate the
transduced cells. Consequently, it is not surprising that of all gene therapy trials for
human diseases; more than 20% have used retroviral based vectors (Hu et al., 2011;
Wiley, 2012).
Among retroviruses, currently HIV-1 based vectors are being exploited;
however, their use in humans raises critical safety concerns such as the generation of
replication competent virus through recombination with human endogenous
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retroviruses. Therefore, vectors from phylogenetically distant non-human retroviruses
such as MPMV and MMTV may circumvent such safety concerns. The use of
MPMV-based vectors are also being considered ideal since the therapeutic genes to be
used may require nuclear export signals like MPMV constitutive transport element
(CTE; Bray et al., 1994) for their efficient expression in the target cells. Along the
same lines, MMTV has distinguished itself from most other retroviruses in that it
contains multiple promoters and its promoters in the LTR are inducible by steroid
hormones, making them not only “switchable” but also “tissue-specific” since they
would turn on (transcribe RNA) only in cells/tissues with receptors for steroid
hormones (reviewed in Ham et al., 1988; Klein et al., 2008; Mustafa et al., 2000).
This aspect alone (“targeted” and “inducible” gene expression) has prompted the use
of MMTV promoters for “conditional” gene expression in many in vitro systems,
especially of those genes whose constitutive expression could be toxic to cells. These
unique features have led to increasing interest in developing MPMV and MMTV
vectors for human gene therapy. However, before MPMV and MMTV based vectors
can be used for human gene therapy, it is crucial that the molecular mechanisms of the
pertinent aspects of their life cycle such as dimerization and packaging are fully
delineated.
Very little is known about the molecular intricacies involved in the
recognition of MPMV and MMTV gRNA that facilitate their dimerization and
packaging into the virus particle. The overall goal of this thesis project was to
gain a better understanding of MPMV and MMTV gRNA dimerization and
packaging mechanisms by establishing structure-function relationship(s) of the
sequences involved in these processes. Specifically, this thesis project was
undertaken to validate the higher order features of the MPMV and MMTV
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packaging signal RNAs required in cis during gRNA dimerization and packaging,
employing a newly developed SHAPE (selective 2' hydroxyl acylation analyzed
by primer extension) methodology. After having validated the RNA secondary
structure by SHAPE, in silico phylogenetic analyses, in vitro RNA dimerization
and biologically relevant in vivo RNA packaging and propagation assay were
employed to determine the role of pal sequences as potential DIS. To accomplish
these, both MPMV and MMTV were studied at the molecular and structural levels
with the results of MPMV presented in Chapter 2 and those of MMTV presented
in Chapter 3.
The specific objectives that were addressed during the course of the study
for both viruses were as follows:
A. To validate the predicted higher order features of the 5’ end of the MPMV
and MMTV sequences required for gRNA packaging by SHAPE.
B. To identify gRNA dimerization initiation site (DIS) and establish
structure-function relationship during gRNA dimerization and packaging.
C. To perform phylogenetic analyses to determine the level of conservation of
different structural motifs in MPMV and MMTV packaging signal RNA.
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CHAPTER 2

SHAPE Analysis of the 5’ end of the Mason-Pfizer Monkey
Virus (MPMV) genomic RNA Reveals Structural Elements
Required for Genome Dimerization

This chapter is a modified version of the manuscript published in the RNA Journal
in December 2013. (Aktar, S. J., et al., RNA, 19:1648-1658, 2013).
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2.1. Abstract
Earlier genetic and structural prediction analyses revealed that the
packaging determinants of Mason Pfizer Monkey Virus (MPMV) include two
discontinuous core regions at the 5’ end of its genomic RNA. RNA secondary
structure predictions suggested that these packaging determinants fold into several
stem loops (SLs). To experimentally validate this structural model, we employed
selective 2’ hydroxyl acylation analyzed by primer extension (SHAPE), which
examines the flexibility of the RNA backbone at each nucleotide position. Our
SHAPE data validated several predicted structural motifs, including U5/Gag longrange interactions (LRIs), a stretch of single stranded purine (ssPurine) rich region,
and a distinctive G-C rich palindromic (pal) SL. Minimum free-energy structure
predictions, phylogenetic, and in silico modeling analyses of different MPMV
strains revealed that the U5 and Gag sequences involved in the LRIs differ
minimally within strains and maintain a very high degree of complementarity.
Since the pal SL forms a helix loop containing a canonical “GC” dyad, it may act
as a RNA dimerization initiation site (DIS), enabling the virus to package two
copies of its genome. Analyses of wild type and pal mutant RNAs revealed that
disruption of pal sequence strongly affected RNA dimerization. However, when
in vitro transcribed trans complementary pal mutants were incubated together
showed RNA dimerization was restored authenticating that the pal loop (5’
CGGCCG 3’) functions as DIS.
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2.2. Introduction
The “diploid” genome of retroviruses consists of two (usually
indistinguishable) strands of RNA that are non-covalently linked as a “dimer”
close to their 5' end (reviewed in D’Souza & Summers, 2005; Johnson &
Telesnitsky, 2010;Lever, 2007; Lu et al., 2011a; Moore & Hu, 2009; Paillart et al.,
1996b; Paillart et al., 2004). The ubiquitous presence of such a unique dimeric
genome among retroviruses suggests that dimerization plays a crucial role in the
packaging of the genomic RNA (gRNA), as well as in the subsequent steps of the
viral life-cycle (reviewed in Moore & Hu, 2009; Paillart et al., 2004; Russell et al.,
2004).
Over the years, we have learnt that for almost all retroviruses,
determinants of gRNA dimerization and packaging map to ~100 to 400
nucleotides (nt) at the 5’ end of the gRNAs, which have been shown to assume
stable secondary structures (reviewed in Johnson & Telesnitsky, 2010; Paillart et
al., 1996b). The gRNA dimerization and packaging sequences are, for the most
part, physically and genetically indistinguishable, and consistently, it has been
suggested that the retroviral gRNA packaging and dimerization processes are
interlinked (reviewed in D’Souza & Summers, 2005; Johnson & Telesnitsky, 2010;
Lever, 2007; Lu et al., 2011a; Paillart et al., 2004).
It is becoming increasingly clear that palindromic (pal) sequences play a
crucial role in gRNA dimerization: for human immunodeficiency type 1 and type
2 viruses (HIV-1 and HIV-2), feline immunodeficiency virus (FIV), Moloney
murine leukemia virus (MoMuLV) and murine sarcoma gamma retroviruses
(MuSV). it has been shown that the dimerization process is initiated by a pal
sequence in its structural context (pal stem-loop) which is called the dimerization
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initiation site (DIS; reviewed in D’Souza & Summers, 2005; Johnson &
Telesnitsky, 2010; Lever, 2007; Lu et al., 2011a; Moore & Hu, 2009; Paillart et al.,
1996b, 2004; Russell et al., 2004). The pal of different retroviruses has been
shown to contain a canonical “GC” dyad (reviewed in Hussein et al., 2010). The
pal in the DIS loop of one gRNA has been shown to interact with the
complementary sequence in the DIS loop on the second gRNA, resulting in the
“kissing loop” interaction (Clever et al., 1996; Haddrick et al., 1996; Lodmell et
al., 2000, 2001; Paillart et al., 1994, 1996a, 1997). Due to its central role in
gRNA dimerization process that has been shown to be important for gRNA
packaging and the continuity of viral life cycle, DIS has been an attractive target
for antiretroviral drugs specifically aminoglycosides (Ennifar et al., 2003, 2006).
The formation of “kissing loop” complex is likely to be further stabilized by the
long-range interactions (LRIs) between the 5’ end (R/U5) and 3’ end (Gag)
sequences of the retroviral packaging signal RNA (reviewed in Paillart et al.,
1996b). In addition, it has also been proposed that in some retroviruses “kissing
loop” interactions and dimer linkage maturation process lead to conformational
changes exposing single-stranded nucleocapsid (NC) binding motifs, facilitating
Gag binding during recruitment of the gRNA for packaging (reviewed in D’Souza
& Summers, 2005; Johnson & Telesnitsky, 2010). Along the same lines, a recent
study has shown that in addition to the conventional dimerization/packaging
sequences, HIV-1 gRNA packaging is enhanced by a cis-acting RNA element (the
genomic RNA packaging enhancer or GRPE) overlapping the Gag/Pol ribosomal
frameshift signal (Chamanian et al., 2013).
Despite the fact that gRNA dimerization and packaging processes are
universally present in all retroviruses, there is no sequence conservation between
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the dimerization and packaging determinants among different retroviruses. Over
the years, it is becoming increasingly clear that retroviral gRNA dimerization and
packaging are reliant on highly ordered RNA structural motifs of the 5’ end RNA
region (reviewed in D’Souza & Summers, 2005; Johnson & Telesnitsky, 2010;
Lever, 2007; Lu et al., 2011a). Therefore, it is not surprising that a number of
recent cross- and co-packaging studies have elucidated that the specificity of
retroviral gRNA packaging can be manipulated by substituting dimerization and
packaging sequences at the 5’ end of genome from genetically distinct
retroviruses (Al Dhaheri et al., 2009; Al Shamsi et al., 2011). This has further
been substantiated by the fact that heterodimers involving RNAs from two
divergent retroviruses can also be packaged (Moore & Hu, 2009; Motomura et al.,
2008; reviewed in Johnson & Telesnitsky 2010).
A stretch of 5’ end sequences of the prototype betaretrovirus Mason-Pfizer
monkey virus (MPMV), which causes an immunodeficiency disease in newborn
rhesus monkey, has been shown to be involved in RNA packaging (Guesdon et al.,
2001; Harrison et al., 1995; Vile et al., 1992). Employing a combination of
genetic and structural prediction analyses, we have recently shown that MPMV
packaging determinants comprise two discontinuous core regions (“A” and “B”)
within the 5’ untranslated region (UTR; Jaballah et al., 2010; Schmidt et al., 2003).
In addition to these two regions in the UTR, stretch of ~120 nt of gag has also
been shown to be needed for optimal MPMV RNA packaging (Jaballah et al.,
2010; Schmidt et al., 2003). Based on these mutational studies and structural
prediction analyses, a minimal free energy RNA secondary structure model has
been proposed for the 5’ end (388 nt starting from R) of MPMV gRNA (Jaballah
et al., 2010; Fig. 2.1A). This model suggested that the packaging determinants
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model of MPMV packaging signal. Nucleotides are color annotated as per the SHAPE reactivities key. SD, splice donor.

Boxed areas in purple show the predicted LRIs between U5 and Gag. (B) SHAPE-constrained RNAstructure (Reuter & Mathews, 2010)

binding site (PBS), regions “A” and “B” (that have been shown to be important in gRNA packaging), and pal sequences, respectively.

(Jaballah et al.,, 2010) using Mfold (Mathews et al., 1999; Zuker, 2003). Sequences in orange, green, red, and blue represent the primer

Mfold and SHAPE included sequences from R up to 120 nt of gag. (A) MPMV packaging signal RNA secondary structure predicted earlier

FIGURE 2.1. Minimal free-energy and SHAPE-validated models of the MPMV packaging signal RNA. The region used for analysis by
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fold into several stable stem loop (SL) structures and also revealed a 14 nt GCrich pal sequence (5’ UCGCCGGCCGGCGA 3’) that folds into a hairpin with a
canonical “GC” dyad in the loop, a 16 nt stretch of single stranded purine
(ssPurine) rich region (8 nt of this ssPurine-rich region is duplicated as a basepaired sequence in an adjacent region), and LRIs between U5 and Gag sequences
(Jaballah et al., 2010). The 14 nt pal has been proposed to play a role in the
initiation of gRNA dimerization (Jaballah et al., 2010). The ssPurine-rich region
(or its repeat in region “B” when predicted to refold as the ssPurine-rich region)
has been shown to be essential for RNA packaging, possibly functioning as a
potential nucleocapsid (NC) binding site. Two long range interactions between
U5 and Gag sequences could potentially play a role in MPMV RNA packaging by
maintaining the overall RNA secondary structure as has recently been shown in
the case of FIV (Kenyon et al., 2008, 2011; Rizvi et al., 2010). Even though the
deletion analysis of 5’ end of MPMV gRNA provides a plausible explanation for
the discontinuous nature of MPMV packaging signals, the existence of the
different structural motifs of the predicted RNA secondary structure of this region
has not been validated experimentally.
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2.3. Materials and Methods
2.3.1. MPMV RNA secondary structure analyses in silico
MPMV RNA (388 nt and 550 nt) secondary structure was predicted using
the Mfold server (Mathews et al., 1999; Zuker, 2003) and validated by applying
SHAPE reactivity data in the RNAstructure software (version 5.3, Reuter &
Mathews, 2010). The predicted RNA secondary structures were redrawn with
XRNA software. Sequences from different strains of MPMV corresponding to
packaging signal RNA were employed to predict the RNA secondary structures of
the region using Mfold (Mathews et al., 1999; Zuker, 2003). A sequence
alignment of the same region for these MPMV isolates was also generated using
ClustalW to look for the conservation of sequences in different structural motifs.
MPMV nucleotide positions refer to GenBank accession number M12349 (Sonigo
et al., 1986).
2.3.2. Plasmids used for in vitro transcription (wild type and pal mutants)
In order to in vitro transcribe the wild type MPMV genomic sequences for
SHAPE analysis, SJ2 subgenomic transfer vector (described previously in
Jaballah et al., 2010) containing the cis-acting sequences needed for genome
replication was used as a template for generating the clone RCR001 by PCR.
Primers used for PCR amplification included sense (S) primer OTR1004 (5’ CCC
AAG CTT AAT ACG ACT CAC TAT AGG G CCA CCA TTA AAT GAG ACT
TGA TC 3’) containing the HindIII restriction site and the T7 RNA polymerase
promoter sequence (HindIII site is shown in italics whereas the T7 promoter
sequence is underlined) and the anti-sense (AS) primer OTR 1005 (5' AAA CCC
GGG TTC TTT CTT ATC TAT CAA TTC 3') containing XmaI/SmaI site (shown
in italics). The resulting PCR product was cleaved at the HindIII and XmaI sites
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(artificially created on either ends of the MPMV sequence) and ligated to a PUC
based cloning vector (pIC19R; Marsh et al., 1984), which was previously cleaved
with the same restriction enzymes generating wild type plasmid pRCR001.
pRCR001 contains nucleotides +1 to 550 (+1 corresponds to the first nucleotide of
the R region of the genomic RNA) under the control of a T7 promoter for in vitro
transcription of the RNA.
To study the effects of the pal sequence (5’ TCGC CGGCCG GCGA 3’)
on in vitro dimerization, a series of mutations were introduced in the pal sequence.
Briefly, these mutations were incorporated through splice overlap extension (SOE)
PCR as described previously (Gibbs et al., 1994, Jaballah et al., 2010; Rizvi et al.,
2010), using MPMV sub-genomic vector SJ2 as the template requiring two
separate amplifications in round one PCR. In brief, both S and AS primers that
were used in two separate reactions of round one PCRs were designed in a fashion
that the resulting products from the two reactions have overlapping
complementary sequences. The overlapping complementary sequences allowed
the two products to anneal during the second round of amplification with the outer
S and AS primers, resulting in a final product containing the desired deletion
mutation. The mutations introduced included deletion of the complete 14 nt pal
stem-loop sequence (5’ TCG CCG GCC GGCGA 3’) using S primer OTR 897 (5’
CAC TTT TAA ACG CGT CGT CTT CCT CAC G 3’) and AS primer OTR
898A (5' CGC GTT TAA AAG TGA AAG TAA ACT CTC TTG 3') resulting in
RCR002 (Fig. 2.2A). Substitution of the 4 nt pal loop 5’ GGCC 3’ with GTAA to
generate a stable tetra loop was created using S primer OTR 996 (5' GTA AGG
CGA TTA AAA GTG AAA GTA AAC TC 3') and AS primer OTR 997 (5' CAC
TTT TAA TAG CCT TAC GGC GAA CGC GTC GTC 3') generating mutant
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FIGURE 2.2. Sequences in pal SL augments MPMV gRNA dimerization by
functioning as DIS. (A) Table showing the 6 nt wild type pal sequence (in red)
and the different mutations introduced (in blue). (B) Gel shift assays of the
MPMV WT and pal mutants. The upper panel shows native 1% TBM (50 mM
Tris base, 45 mM boric acid, 0.1mM MgCl2) gel run at 4 °C and the lower
panel shows semi-native 1% TB (50 mM Tris base, 45 mM boric acid) gel run
at room temperature. M: monomer lane or monomer conformer; D: dimer lane
or dimer conformer for each sample. (C) Relative dimerization of the MPMV
wild type and pal mutants RNAs. Following the gel shift assays, dimerization
abilities of the RNAs in each lane were calculated and the dimerization data
was then represented as relative to the wild type dimerization.
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A
Clone
Name

Description of the Mutations

Sequence of the pal Mutants

RCR001

Wild type pal sequence

5’ TCGC CGGCCG GCGA 3’

RCR002

Deletion of 14 nt wild type pal
sequence

5’ -- -- -- -- -- -- -- -- -- -- -- -- 3’

RCR003

Substitution of 4 nt of the central
wild type pal sequence with
stable tetra loop

5’ TCGC CGTAAG GCGA 3’

RCR004

Substitution of 6 nt of the wild
type pal sequence with HIV-1 pal

5’ TCGC GCGCGC GCGA 3’

B

RCR001
M

D

RCR002
M

D

RCR003
M

D

RCR004
M

D
D

1% TBM gel

M

D
1% TB gel
1.20

Relative Dimerization

C

M

1.00
0.80
0.60
0.40
0.20
0.00
TBM
TB

RCR001
1.00
1.00

RCR002
0.24
0.19
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RCR003
0.24
0.21

RCR004
0.25
0.24

RCR003 (Figure 2.2A). A mutant containing substitution of the 6 nt pal with
HIV-1 pal sequence (5’ GCGCGC 3’) was constructed using S primer OTR 998
(5' GCG CGC GCG ATT AAA AGT GAA AGT AAA CTC 3') and AS primer
OTR 999 (5' CAC TTT TAA TCG CGC GCG CGC GAA CGC GTC GTC TTC
CTC 3') generating mutant RCR004 (Fig. 2.2A).
In addition two other mutants, RCR005 and RCR006 containing
heterologous trans-complementary sequence with a central “GC” dyad were also
created to determine if the palindromic nature of the sequence is necessary for in
vitro dimerization (Fig. 2.4A). The primers used for RCR005 and RCR006
construction included OTR 1000 (S primer; 5' ACG CAC GCG ATT AAA AGT
GAA AGT AAA CTC 3') and OTR 1001 (AS; 5' CAC TTT TAA TCG CGT
GCG TGC GAA CGC GTC GTC TTC CTC 3'), OTR 1002 (S primer; 5' GTG
CGT GCG ATT AAA AGT GAA AGT AAA CTC 3') and OTR 1003 (AS primer;
5' CAC TTT TAA TCG CAC GCA CGC GAA CGC GTC GTC TTC CTC 3'),
respectively. For all these mutants, the OTR 1004 (S) and OTR 1005 (AS) were
used as outer primers during the second round of amplification and the resulting
amplified product containing the T7 promoter and the desired mutation were
cleaved and cloned in pIC19R as described above for creating wild type clone
RCR001. Both the wild type clone, as well as all pal mutant clones were
confirmed by sequencing. PCRs were performed as described previously
(Jaballah et al., 2010; Rizvi et al., 2010). Briefly, approximately 3 μg of template
DNA was used for each reaction under the following amplification conditions:
denaturation at 94°C for 2 minutes followed by 30 cycles of 94°C for 1 minute,
annealing at 45-47°C depending on primers used for 90 seconds, extension at
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72°C for 90 seconds. Final extension was performed for 10 minutes at 72°C
followed by incubation at 4°C.
2.3.3. RNA preparation by in vitro transcription
DNA templates containing the T7 RNA promoter at the 5’ end of the
MPMV sequences were linearized by digesting with the SmaI restriction enzyme
at the site present at the 3’end of the MPMV sequence in the RCR clone series
(RCR001-RCR006). In vitro transcription was performed using bacteriophage T7
RNA polymerase for 2 hours at 37 ºC using conditions described previously
(Marquet et al., 1991). A small fraction of each sample was subjected to
electrophoresis on an 8% acrylamide/8M urea gel to analyze the in vitro
transcription reaction products. The rest of the sample was treated with DNase I
for 30 minutes at 37 ºC, then extracted with phenol-chloroform and finally ethanol
precipitated. The RNAs were purified by fast protein liquid chromatography
(FPLC; Pharmacia) on a TSK 250 column (Biorad) in a buffer containing 200 mM
sodium acetate (pH 6.5) and 1% (v/v) methanol. The desired fractions were
concentrated in Amicon Ultra-4 10K centrifugal filter device (Millipore) and the
RNA concentrations were determined following quantification through nanodrop
(ThermoScientific). Finally, the RNA homogeneity was checked by
electrophoresis on an 8% acrylamide gel.
2.3.4. SHAPE methodology
To validate the predicted secondary structure of MPMV packaging signal
RNA sequence (Jaballah et al., 2010) the purified in vitro transcribed RNAs were
subjected to selective 2’ hydroxyl acylation analyzed by primer extension
(SHAPE; Mortimer and Weeks, 2009) using benzoyl cyanide (BzCN). Briefly,
one picomole of RNA in 8 μL milli-Q water (Millipore) was denatured for 2
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minutes at 90 ºC and then chilled for 2 minutes on ice, following which 2 μL 5X
dimer buffer (250 mM sodium cacodylate, pH 7.5; 1.5 M KCl; 25 mM MgCl 2 )
was added to the samples which were then incubated at 37 ºC for 20 minutes.
Next, 2 μg of total yeast tRNA (Sigma Aldrich) was added to each sample and the
volume was adjusted to 15 μL by adding 1X dimer buffer and incubated for 10
minutes at room temperature. 3 μL of a 1 µM BzCN solution in anhydrous
dimethyl sulphoxide (DMSO) was used to modify the RNA samples for 1 minute
and the reaction was stopped by adding 82 μL water. The negative control
samples were treated in the same fashion but using only DMSO in the absence of
BzCN. All samples were then precipitated using 1 μL of 1 μg/μL glycogen
solution, 1/10 volume 3M sodium acetate (pH 6.5) and 3 volume ethanol for 30
minutes on dry ice and the precipitates were collected by centrifugation at 13,000
g for 20 minutes at 4 ºC. The RNA pellets were washed twice with 500 μL cold
80% ethanol to remove salts, dried in a vacuum dryer and dissolved in 7 μL milliQ water. Next, to identify the BzCN modification sites, reverse transcription (RT)
was performed on the samples. Towards this end, two types of primer sequence
were used to ensure RT of the entire 550 nt MPMV leader RNA. A set of four AS
primers labeled with different dyes corresponded to the 5’ AGT TAC TGG GAC
TTT CTC CG 3’ sequence (complementary to MPMV nt 483-502) and were
termed as OTRs 17, 18, 19 and 20. A second set of AS primers corresponded to
the 5’ CTT ACT TTC AGG TCC AAC GC 3’ sequence (complementary to
MPMV nt 235-254), and were named OTRs 21, 22, 23 and 24. These primers
were labeled with either 6-FAM, VIC, NED or PET. The purpose of using
different dyes was that each dye could be detected individually after capillary
electrophoresis in a DNA sequencer as described earlier (Merino et al., 2005;
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Mortimer & Weeks 2007, 2009). BzCN-modified RNAs were annealed to 1 μM
VIC-labeled primers OTR 18 or OTR 22 for 2 minutes at 90 ºC and 2 minutes in
ice. After the addition of 2 μL 5X RT buffer (Life Science, USA), the samples
were then incubated for 10 minutes at room temperature. Each sample was then
divided into two aliquots and elongation reaction was performed for 30 minutes at
42 ºC and for 15 minutes at 50 ºC in elongation buffer (1 μL 5X RT buffer, 3 μL
2.5 mM dNTPs mix, 1 μL 2U/μL RT AMV enzyme from Life Science, USA and
water to make the volume to 10.5 μL). For the unmodified RNA samples, 6-FAM
labeled primers OTR 17 or OTR 21 were used and RT reaction was performed in
the same manner as for the modified RNA samples. A ddA sequencing ladder
was prepared using 2 picomoles of untreated RNA and 1μL of 2 μM NED labeled
OTR 19 or OTR 23 in 8 µL milliQ water. Annealing was performed by heating at
90 ºC for 2 minutes and cooling on ice for 2 minutes. The volume was made to 10
μL by adding 2 μL 10X RT buffer and then the samples were incubated for 15
minutes at room temperature. The RNA sample was aliquoted into 2 tubes, and
the elongation reaction was performed with 1 μL 10X RT buffer, 3 μL A10
(0.25mM dATP, 1mM dGTP, 1mM dCTP, 1mM dTTP), 1 μL of 100 μM ddA and
1 μL of 1U/μL RT AMV enzyme. A ddG ladder was also prepared in the same
fashion by using PET labeled OTR 20 or OTR 24, G10 (0.25mM dGTP, 1mM
dATP, 1mM dCTP, 1mM dTTP) and 100 μM ddG. All the reactions were
stopped by adjusting the volume 45 μL with water and proteins were extracted
with 50 μL phenol-chloroform. For each experiment, the modified and
unmodified samples were pooled with the corresponding ddA and ddG sequencing
ladders (e.g., samples for which OTRs 17, 18, 19 and 20 were used were pooled
together) in a single tube containing 20 μL 3M sodium acetate and 600 μL ethanol
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for cDNA precipitation. The samples were incubated on dry ice for 30 minutes,
centrifuged at 13,000 g for 20 minutes at 4 ºC, and washed twice with 1 mL cold
80% ethanol. Pellets were spun for 5 minutes at each step to prevent material loss.
After drying the pellets in a vacuum dryer, they were resuspended in 10 μL HiDi
formamide (ABI) and heat denatured at 90 ºC and iced for 5 minutes each. The
samples were spun down before loading on the 96 well plates for sequencing on
an Applied Biosystems 3130xl genetic analyzer. The results were generated in the
form of electropherograms, which were analyzed with the SHAPEfinder program
(Vasa et al., 2008; Wilkinson et al., 2008) by following the steps prescribed by
program developers such as baseline adjustment, matrixing, cubic mobility shift,
signal decay correction, scale factor, alignment and integration to MPMV
sequence, and finally fitting. This software enables the calculation of the SHAPE
reactivity at each nucleotide. Prior to performing the SHAPE reactions, we
calibrated the fluorescent tagged primers for determining the mobility shift (Vasa
et al., 2008). The peaks in the electropherograms were normalized by subtracting
the peak area of the unmodified RNA sample from the peak area of the SHAPE
treated sample (Vasa et al., 2008). The data was then further normalized for
outliers by determining 10% of the highest values and excluding the highest 2% of
these values. The remaining 8% of the values were averaged and the average
value was used to divide the SHAPE data. The SHAPE reactivity data (provided
as supplemental data) obtained for each nucleotide were then applied as
constraints in the structure prediction program RNAstructure (version 5.3, Reuter
and Mathews 2010) in order to obtain the SHAPE-derived RNA structure of the
MPMV packaging signal RNA.
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2.3.5. In vitro dimerization assay
In vitro dimerization was performed as described previously (Marquet et
al., 1991). Briefly, 300 nM of the purified wild type or pal mutant RNAs were
incubated in dimer (250 mM sodium cacodylate, pH 7.5; 1.5 M KCl; 25 mM
MgCl 2 ) or monomer (250 mM sodium cacodylate, pH 7.5; 200 mM KCl; 0.5 mM
MgCl 2 ) buffer for 30 minutes at 37 ˚C. Following this incubation, loading dye
containing glycerol was added and samples were subjected to electrophoresis in
native 1% TBM (50 mM Tris base, 45 mM boric acid, 0.1mM MgCl 2 ) or semidenaturing TB (50 mM Tris base, 45 mM boric acid) agarose gel at 4 ˚C or 20 ˚C,
respectively, stained with ethidium bromide and visualized for band shift using
ultraviolet (UV) transillumination. Band intensities were measured using
Quantity One software and percentage (%) of dimerization was calculated for
each mutant employing the formula: (Intensity of dimer band - Intensity of
background)/ [(Intensity of monomer band - Intensity of background) + (Intensity
of dimer band - Intensity of background)]. Results for each pal mutant were
plotted as relative dimerization to the wild type values.
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2.4. Results and Discussion
To validate the predicted structure (Jaballah et al., 2010) and to generate a
more precise structural model of the MPMV gRNA packaging signals, we
employed selective 2’ hydroxyl acylation analyzed by primer extension (SHAPE),
which examines the flexibility of the RNA backbone at each nucleotide position
(Merino et al., 2005; Mortimer & Weeks, 2007, 2009). SHAPE reagents target
and modify the ribose moiety of all four nucleotides in single-stranded regions of
a folded RNA molecule, whereas the nucleotides that are base-paired or
architecturally constrained do not react or show reduced reactivity.
2.4.1. SHAPE data validated the major structural motifs predicted in the 5’
end of MPMV gRNA
Our SHAPE data validated the overall predicted structure (Jaballah et al.,
2010) of the MPMV packaging signal RNA. Figure 2.1A shows the
unconstrained predicted structure, whereas Figure 2.1B shows the SHAPEvalidated MPMV structure. An average of SHAPE reactivities numerical data for
each nucleotide that were drawn from 2-4 experiments were applied as pseudo
energy constraints in RNAstructure (Bellaousov et al., 2013; Reuter & Mathews,
2010) . As shown in Figure 2.1B, the SHAPE data robustly corroborated the freeenergy minimized predicted structure of the MPMV packaging signal RNA
presented in Figure 2.1A. Briefly, the SHAPE-validated model displayed major
structural components including pal SL, ssPurine-rich region, U5-Gag LRIs, SLs
1-3, and Gag SLs 1-2 in extensive conformity with the predicted structure.
Consistent with the predicted structure, all the loops and bulges containing
unpaired nucleotides showed SHAPE reactivity. A few base-paired nucleotides
located at the ends of a helix, near a bulge or a loop also showed reactivity (for
example nt 22, 25, and 26). Despite such a high conformity between the predicted
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and the SHAPE-validated structure models, some noticeable differences could be
observed. First, SHAPE data indicated that the actual apical loop of SL2 is larger
than predicted by Mfold (Fig. 2.1A and 2.1B). Second, this loop is shifted by two
nucleotides, inducing different base-pairing in the upper part of SL2, including the
primer binding site (PBS). Third, a small stem loop was observed in the SHAPEvalidated structure at the base of Gag SL2, which was not present in the predicted
structure model of the MPMV packaging signal RNA. Finally, even though the
same pal SL is present in the two structures, it is interesting to observe that the
nucleotides in the loop, which contains the “GC” dyad, displayed weak or no
reactivity, suggesting that these nucleotides are indeed base-paired. One
possibility is that these nucleotides may be base-paired with the same sequence on
the other gRNA which is consistent with the hypothesis that the pal SL might
function as the DIS of MPMV gRNA (Jaballah et al., 2010).
A very distinguishing feature of the predicted and the SHAPE-validated
structure is the two LRIs (LRI-I and LRI-II) involving sequences from U5 and
first 70 nt of gag (Fig. 2.1), which have been shown to be important in MPMV
RNA packaging (Jaballah et al., 2010; Schmidt et al., 2003). Except for canonical
base pairs at both ends of LRI-I, and wobble base pairs in both LRIs, all
nucleotides (except U62) in the complementary sequences of the LRIs were nonreactive to SHAPE reagent and, therefore, were base-paired as initially predicted
(Jaballah et al., 2010). U62 is highly reactive to the SHAPE reagent and forms a
bulge in LRI-II that was not predicted by Mfold.
2.4.2. Sequences in pal SL augments MPMV gRNA dimerization by
functioning as DIS
Earlier studies have shown that deletion of the 14 nt pal SL severely
compromised MPMV gRNA packaging (Jaballah et al., 2010; Schmidt et al.,
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2003). However, these studies did not study the impact of these mutations on
gRNA dimerization. The conservation of the pal sequence in different strains of
MPMV (Fig. 2.8) and the fact that it forms a hairpin with a “GC” dyad in the loop
(Fig. 2.1) makes it a credible candidate to function as MPMV gRNA DIS.
Therefore, we introduced a series of mutations in the pal sequence (Fig. 2.2A) and
performed in vitro dimerization assays using in vitro transcribed RNAs. The
mutant RCR002 contains the complete deletion of the pal sequence. In order to
ascertain whether preservation of the hairpin structure is sufficient to initiate
dimerization, mutant RCR003 was created in which the central 4 nt of the loop
were substituted with a stable tetra loop sequence. In order to determine if it is the
primary sequence or palindromic nature of the pal sequence that is required for
MPMV gRNA dimerization another mutant (RCR004) was constructed, which
contains the substitution of the central 6 nt of MPMV pal sequence with that of
HIV-1 pal sequence. Before introducing these mutations, Mfold was used to
predict the structure of the mutants in the monomer form to support the premise of
our experimental hypothesis.
The data obtained from three independent in vitro dimerization
experiments using wild type and pal mutant RNAs is summarized in Figure 2.2B
and 2.2C. In vitro transcribed wild type RNA showed around 87% and 65%
dimerization in TBM (50 mM Tris base, 45 mM boric acid, 0.1mM MgCl 2 ;
electrophoresis at 4 °C) and TB (50 mM Tris base, 45 mM boric acid;
electrophoresis at room temperature) gels, respectively (Fig. 2.2B). These wild
type (RCR001) values were considered as references for calculating the relative
dimerization efficiency (RDE) of the mutants (Fig. 2.2C). The pal deletion and
substitution mutants showed significant degrees of reduction in their abilities to
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dimerize (RDEs 0.19-0.25 in both semi-native and native conditions; 4-5.27 fold
reduction; P= 0.002-0.02; Fig. 2.2C) compared to the wild type. Mutants
RCR002 and RCR003 showed that not only the pal SL structure but also the
nature of the pal sequence is important for MPMV gRNA dimerization. The
results obtained with mutant RCR004 are more difficult to explain. The Mfold
structural model of RCR004 predicted the formation of a stem loop similar to
MPMV pal SL (data not shown) and therefore this mutant was expected to restore
dimerization to wild type levels, in contrast with our observation (Fig. 2.2B and
2.2C). In the case of HIV-1, the 5’ GCGCGC 3’ pal is flanked by three purines
residues that are crucial for the stability of the RNA dimer (Paillart et al., 1997).
Therefore, the inability of RCR004 to restore dimerization could in part be
attributed to the absence of flanking purines similar to HIV-1 pal in its native
genomic context.
Next we wanted to correlate the results of in vitro dimerization to the
SHAPE-validated structural model and establish the structure-function
relationships, if any, of MPMV pal SL during gRNA dimerization. Therefore, we
folded two molecules of the wild type 5’ end MPMV gRNA using RNAstructure
to predict the folding pattern of a dimer. Folding prediction of the wild type
homodimer showed an overall preservation of the RNA secondary structure of the
monomer, with a conformational change in the pal SL, which was predicted to
interact and base pair with the pal sequence on the second MPMV gRNA
sequence (Fig. 2.3). Thus, this structure prediction points towards the importance
of the pal SL sequence in MPMV gRNA dimerization, consistent with our RNA
dimerization assay and with our SHAPE data, which showed that the loop of the
pal hairpin is only moderately reactive. Furthermore in the homodimer structure,
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FIGURE 2.3. RNAstructure prediction of the MPMV wild type (RCR001)
RNA (nt +1-388) homodimer structure. The site of interaction between the
two gRNAs involving the pal sequence is enlarged for clarity. The central 6 nt
of the pal sequences are shown in red.
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the ssPurine-rich region was predicted to form a helix loop structural motif (Fig.
2.3) possibly making it more accessible for possible interaction with NC protein
as has earlier been suggested (Jaballah et al., 2010). In sharp contrast, the
homodimer structural predictions of mutants RCR002 and RCR003 suggested that
these mutants could dimerize using another 6 nt pal sequence (5’ GGCGCC 3’)
within the PBS (data not shown). This PBS-mediated homodimerization results in
the overall destabilization of the RNA secondary structure and is consistent with
our in vitro dimerization results. Taken together, our in vitro dimerization and
structure prediction results suggest that the 14 nt GC-rich MPMV pal SL is
important in mediating gRNA dimerization by functioning as a DIS.
2.4.3. In vitro heterodimerization can be mediated by trans-complementary
sequences on two RNAs
To confirm that the central 6 nt of the pal indeed constitute the point of
contact between two gRNAs to initiate the process of dimerization, we created
two trans-complementary mutants maintaining the central “GC” dyads (RCR005
and RCR006; Fig. 2.4A). When incubated separately, the RCR005 and RCR006
mutant RNAs formed significant amounts of dimer in TBM, even though
dimerization was reduced compared to wild type RNA (RDEs; 0.69-0.70; 1.431.45 fold reduction; P= 0.029-0.047; Fig. 2.4B, C). However, the ability of these
mutant RNAs to dimerize was severely compromised in semi-native condition
(RDEs; 0.14 and 0.09 for RCR005 and RCR006, respectively; 7.14-11.11 fold
reduction; P= 0.062-0.042; Fig. 2.4B lower panel; Fig. 2.4C). By contrast, when
incubated together, these trans complementary mutant RNAs dimerized to wild
type level, both in native and semi-native conditions (RDEs 0.88-1.09; Fig. 2.4B
last lane, and Fig. 2.4C).
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FIGURE 2.4. In vitro heterodimerization can be mediated by transcomplementary sequences on two RNAs. (A) Table showing the 6 nt wild type
pal sequence (in red) and the two complementary substitution mutations (in
blue). (B) In vitro dimerization assay of the MPMV WT and pal mutants. The
upper panel shows native 1% TBM gel run at 4 °C and the lower panel shows
semi-native 1% TB gel run at room temperature. M: monomer lane or
monomer conformer; D: dimer lane or dimer conformer for each sample. (C)
Relative dimerization of the complementary mutants to the wild type RNAs.
Dimerization abilities of the RNAs in each lane were calculated and the
dimerization data was represented as relative to the wild type dimerization.
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RCR005
+RCR006
0.88
1.09

These results prove that an intermolecular interaction mediated by the
central 6 nt of pal is required for the formation of a stable RNA dimer. In addition,
they reveal the existence of a second intermolecular interaction, which allows
formation of unstable dimers. Consistent with this interpretation, the unstable
homodimers formed by RCR005 and RCR006 RNAs migrated slightly more
slowly than the heterodimer or the wild type RNA homodimer (top panel of Fig.
2.4B), confirming that they formed different RNA dimers.
In an attempt to identify the residual intermolecular interaction in mutants
RNAs, we employed RNAstructure to predict the RCR005 and RCR006
homodimers and heterodimers structures. Structure predictions suggested that the
mutant RNAs RCR005 and RCR006 homodimerized via an alternate 6 nt pal
sequence within the PBS (Figs. 2.5A, B, 2.6B, C). As a consequence, SL2, which
is relatively long in the wild type homodimer and in the RCR005/RCR006
heterodimer, was predicted to be shortened due to PBS mediated intermolecular
interactions; however its apical loop was maintained (Figs. 2.5D, 2.6D). In the
predicted heterodimer structure of mutants RCR005 and RCR006, the two RNAs
interact via the substituted trans complementary sequences (Figs. 2.5D, 2.6D) as
expected, and as supported by our experimental data (Fig 2.4B and C). As a result,
the secondary structures of the wild type RNA homodimer and of the
RCR005/RCR006 heterodimer are identical (Fig. 2.6A and D). RNAstructure
predictions of the RCR005 and RCR006 homodimers and heterodimer illustrate
that not only the interaction between these trans complementary sequences result
in heterodimerization, but also that such interaction leads to conformational
changes in the structure allowing more extensive base pairing between
complementary sequences throughout the genome (2.5D).
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structures of the homodimers as well as heterodimers are shown in figure 2.6.

between RCR005 and RCR006 MPMV RNAs. (D) Predicted heterodimer structure of RCR005 and RCR006 RNAs. The complete predicted

mutant RNAs dimerize via a sequence in the primer binding site. (C) Schematic representation of the expected point of heterodimerization

FIGURE 2.5. Dimer predictions of the mutant RCR005 (A) and RCR006 (B) MPMV RNAs (nt +1-388) using RNAstructure showing that
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marked by blue arrows.

homodimer (A). The trans-complementary sequences in RCR005 and RCR006 homodimers and heterodimer are shown in blue color and are

heterodimer of RCR005 and RCR006 (D) is predicted to dimerize to exactly the same structural conformation as the WT (RCR001)

to dimerization are boxed. Mutants RCR005 (B) and RCR006 (C) are predicted to homodimerize via the primer binding site (PBS). The

(RCR005 and RCR006). The dimers were predicted using RNAstructure and the contact point of the sequences between two RNAs leading

FIGURE 2.6. Predicted homodimer (A-C) and heterodimer (D) structures of MPMV wild type (RCR001) and trans complementary mutants
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In summary, our systematic mutational analyses directed towards
ascertaining the functional significance of pal SL demonstrated that mutations
targeted towards disrupting the formation of the 6 nt pal loop diminished RNA
dimerization (Fig. 2.2 and 2.4). This could be attributed to the RNA folding
pattern rather than the primary sequence of the pal loop since mutants containing
trans complementary sequences in this loop were not only able to heterodimerize
at wild type levels, but were also able to re-establish the overall wild type RNA
secondary structure (Fig. 2.6). These results strongly suggest that the pal loop is
involved in “kissing loop” interactions between two MPMV gRNAs in order to
initiate gRNA dimerization, and thus functions as DIS. These observations
corroborate with an earlier genetic analysis that showed no effect on RNA
packaging when the MPMV native pal sequence was accidentally substituted with
a different palindromic sequence (Mustafa et al., 2004).
2.4.4. The SHAPE-validated secondary structural model is supported by
sequence conservation between different MPMV isolates
In order to examine the conservation of different structural motifs within
the MPMV packaging signal RNA, sequences from different strains of MPMV
were used to predict the RNA secondary structure of this region. Mfold
predictions of the sequences from different MPMV strains consistently revealed
the ability to form both LRIs involving sequences from U5 and Gag (Fig. 2.7A-E).
A sequence alignment of this region for these MPMV isolates was generated using
ClustalW and revealed a high degree of conservation of the sequences in the two
U5-Gag LRIs. The U5 and Gag sequences forming these LRIs slightly differ but
maintain a very high degree of complementarity (Fig. 2.7A-E and 2.8).
Based on the RNA free-energy minimized model predicted earlier and
validated by SHAPE (Fig. 2.1) in addition to phylogenetic, and in silico modeling
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(Takano et al., 2013), respectively.

(Sonigo et al., 1986), M11841.1 (Power et al., 1986), AF126467.1 (Marracci et al., 1995), FJ979638.1 (Zao et al., 2010) and AB611707.1

are highlighted by red and green boxes, respectively. The accession numbers for MPMV6/A, SRV1, SRV2, SRV4 and SRV5 are M12349.1

FIGURE 2.7. Mfold structural predictions of the 5’ end genomes of different MPMV strains (A-E). The U5/Gag LRIs and the pal sequence
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AB611707.1 (Takano et al., 2013), respectively.

M12349.1 (Sonigo et al., 1986), M11841.1 (Power et al., 1986), AF126467.1 (Marracci et al., 1995), FJ979638.1 (Zao et al., 2010) and

structural motifs are highlighted by different colors and boxed. The accession numbers for MPMV6/A, SRV1, SRV2, SRV4 and SRV5 are

FIGURE 2.8. ClustalW sequence alignment of the 5’ end genomes of different MPMV strains. The aligned sequences pertaining to major
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analyses presented here (Fig. 2.7 and 2.8), it is reasonable to hypothesize that such
LRIs between U5 and Gag sequences are likely to exist in vivo and have a
functional role in MPMV life cycle. Consistent with this, deletion of the gag
sequences involved in U5-Gag LRI-II while maintaining the gag sequences that
are involved in U5-Gag LRI-I severely diminished MPMV transfer vector RNA
packaging ability (Schmidt et al., 2003). On the other hand, inclusion of first 100
nt of gag sequences that would maintain both U5-Gag LRIs in the transfer vector
RNA restored packaging efficiency to the wild type level (Schmidt et al., 2003).
These results suggest that LRI-I and LRI-II play an important architectural role in
stabilizing the RNA secondary structure of the 5’ UTR sequences required for
MPMV gRNA packaging (Jaballah et al 2010; Schmidt et al., 2003). Such a
scenario could be comparable to that observed in other retroviruses (HIV-1, HIV2, and FIV) where interactions between the R/U5 regions and the start of gag
sequences have been proposed to stabilize the overall RNA secondary structure
essential for gRNA dimerization and packaging (Kenyon et al., 2008, 2011; Lu et
al., 2011b; Paillart et al., 2002; Rizvi et al., 2010; Song et al., 2008;).
Between SL2 and SL3 of our SHAPE-validated RNA structure is a very
distinctive pal SL, which has earlier been shown to be required for optimal
packaging of MPMV gRNA (Jaballah et al., 2010). The current study revealed
that the central 6 nt of this pal (5’ CGGCCG 3’) functions as DIS, thus probably
facilitating the encapsidation of the dimeric genome. Sequence alignment of five
different strains of MPMV revealed that the 6 nt central pal is conserved in all but
one strain (Fig. 2.8). In one strain (SRV1), the last G is substituted with a C
residue, but this strain still contains a 6 nt GC-rich pal (5’ GCCGGC 3’) shifted by
two nucleotides compared to the other strains (Fig. 2.8), supporting a functional
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role for this pal. Mfold analysis of these strains further revealed that in three
strains (MPMV 6/A, SRV1 and SRV2) the pal sequence fold into a stem loop (Fig.
2.7A-C). In the case of SRV4, the pal sequence is base-paired; whereas in the
case of SRV5, the pal sequence forms two small bulges (Fig. 2.7D-E). Similar
conservation of a DIS comprising a pal sequence has been reported in several
retroviruses including HIV-1, HIV-2, SIV, and FIV (Kenyon et al., 2008, 2011;
Lever 2007; Paillart et al., 2002; Russell et al., 2004). In a number of retroviruses,
sequences augmenting RNA dimerization and packaging have been shown to be
intermingled (Lanchy et al., 2003; Lanchy & Lodmell, 2007; Lever, 2007; Paillart
et al., 2004; Russell et al., 2004;), which is in agreement with the deletion of
MPMV pal SL resulting in ablation of RNA packaging (Jaballah et al., 2010).
Earlier studies have identified a prominent stretch of ssPurine-rich region
between pal SL and SL3 and a partial base-paired repeat sequence of the ssPurinerich region was observed in the adjacent region (“B”; Fig. 2.1A; Jaballah et al.,
2010). Sequence alignment revealed that out of the 16 nt within the ssPurine-rich
region, 10 nt are conserved among all the analyzed MPMV strains (Fig. 2.8). The
validation of the ssPurine-rich region and its based-paired repeat structural motifs
by SHAPE (Fig. 2.1B) in concurrence with sequence alignment (Fig. 2.8) and
earlier mutational and structure prediction analyses (Jaballah et al., 2010) further
emphasize the importance of the ssPurine-rich region in MPMV life cycle.
2.4.5. SL1, SL2, and SL3 are present in spliced as well as genomic RNAs
To establish the structure-function relationship of structural motifs
(especially of those present upstream of the major splice donor (mSD) site) and to
address how some of them may help the MPMV packaging machinery in
differentiating between genomic and spliced RNA, we predicted the structure of
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the 5’ region of the MPMV env spliced RNA (including 251 nt upstream of the
mSD and 138 nt downstream of env splice acceptor site). Mfold structural
predictions revealed that SL1, SL2, and SL3 are present in both MPMV 5’ end
genomic and env spliced RNAs (Fig. 2.9). SL1, SL2, and SL3 were also predicted
to be present in the shorter MPMV leader RNA that was truncated at the mSD
(+1-251; data not shown). The function of SL1 in the retroviral life cycle has not
yet been established, however, Mfold predictions (Fig. 2.7) and sequence
alignments (Fig. 2.8) of 5 different strains of MPMV showed that this motif is
conserved at the sequence and structural levels.
SL2 is a rather long and stable structure from which PBS protrudes (Fig.
2.1A, B). It is present in the SHAPE-validated structure of the genomic RNA
(Fig. 2.1B) and is predicted to exist in the env spliced RNA (Fig. 2.9). In silico
analysis revealed a high degree of conservation in the sequences forming SL2 (Fig.
2.8), which was predicted to fold in three out of the five MPMV strains (MPMV
6/A, SRV4 and SRV5) (Fig. 2.7A-E). In addition, SL2 has been shown to include
sequences that constitute part of a bipartite packaging signal (Jaballah et al., 2010).
All together these data point towards the importance of the overall RNA
secondary structure of SL2 in the MPMV life cycle (Jaballah et al., 2010; Schmidt
et al., 2003).
Immediately downstream of the ssPurine-rich region is SL3, which like
SL1 and SL2 was consistently predicted to fold in both genomic and spliced
RNAs (Fig. 2.9). Mfold predictions of different MPMV strains demonstrated that
SL3 is formed in all except for one strain (Fig. 2.7A-E) and its sequences are
fairly conserved among different strains (Fig. 2.8). However, deletion of the
majority of the sequences that are involved in base pairing of SL3 did not affect
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RNAs were folded.

genomic RNA. (B) Mfold structural predictions of MPMV envelope spliced RNA. In both cases, the first 388 nt (from the start of R) of the

FIGURE 2.9. SL1, SL2, and SL3 are present in genomic as well as spliced RNA. (A) Mfold structural predictions of MPMV 5’ end
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RNA packaging (Jaballah et al., 2010), suggesting that it might play a role in
MPMV life cycle that has not yet been established.
In conclusion, employing SHAPE, we validated the overall predicted
structure of the MPMV packaging signal RNA (Jaballah et al., 2010; Fig. 2.1).
Briefly, MPMV packaging signal RNA comprised five stem loops structures.
SL1-SL3 include sequences from R/U5 and UTR whereas Gag SL1 and Gag SL2
employ sequences exclusively from gag. SL2 involves sequences from region “A”
whereas SL3 in part comprises sequences from region “B”; both of these regions
have been shown earlier as major MPMV gRNA packaging determinants
(Schmidt et al., 2003; Jaballah et al., 2010). Between SL2 and SL3 is a very
distinctive pal SL followed by a stretch of ssPurine-rich region, both of which
have also been shown to be required for optimal packaging of MPMV gRNA
(Jaballah et al., 2010). The overall structure is anchored by two LRIs (Fig. 2.1A,
B) involving sequences from U5 and the first 70 nt of gag, which have been
shown to be important in MPMV RNA packaging (Schmidt et al., 2003; Jaballah
et al., 2010). Mfold predictions of different MPMV strains consistently revealed
the ability to form LRIs, suggesting a functional role for these LRIs (Fig. 2.7A-E).
Employing a systematic mutational approach, we showed that the central
6 nt of the pal, which are exposed in the pal SL loop play a crucial role in RNA
dimerization, by directly interacting with a second genomic RNA molecule (Fig.
2.2, 2.4 and 2.6). Thus, this sequence likely initiates genomic RNA dimerization
by forming a kissing loop complex. Despite some sequence variability, all MMPV
strains maintain a 6 nt GC pal at this position, reinforcing its functional role.
The SHAPE-validated structural model, in vitro dimerization analysis of
pal mutant and the homo- and heterodimer structural models presented here
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coupled with earlier published findings on MPMV RNA packaging signals, offer
an important functional correlation between gRNA dimerization and the
packaging processes. These observations while broadening the understanding of
functional regions of MPMV gRNA, further suggest that MPMV may select a
dimeric genome for packaging.

88

2.5. Acknowledgments
This research was funded primarily by a grant from the United Arab
Emirates University (UAEU-NRF 26) to TAR and, in part, by a grant from the
College of Medicine and Health Sciences (NP 09/18). RM is supported by the
Centre National de la Recherche Scientifique (C.N.R.S.). SJA is supported
through a scholarship from the Office of the Vice Provost for Research and
Graduate Studies of the UAEU. The authors wish to thank Ms. Reka
Raghunathan Chakravarthy for her assistance in cloning some of the mutant
clones.

89

CHAPTER 3
A palindromic stem loop functions as the dimerization initiation
site controlling packaging of the genomic RNA of
mouse mammary tumor virus (MMTV)

This chapter is a modified version of the manuscript submitted for publication in
Nuceic Acids Res. (Aktar, S. J., et al., submitted March 2014)
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3.1. Abstract
Dimerization of genomic RNA plays a key role in the retroviral life cycle,
as it is intimately linked to gRNA packaging. Earlier mutational analysis of the
MMTV genome indicated that MMTV gRNA packaging determinants comprise
sequences both within the 5’ untranslated region and the beginning of gag. To
establish structure-function relationships of various stem loops in the packaging
determinants, we elucidated RNA secondary structure of this region employing
selective 2’hydroxyl acylation analyzed by primer extension (SHAPE). SHAPE
analyses revealed presence of a U5-Gag long-range interaction (U5-Gag LRI), not
predicted by minimum free-energy structure predictions that potentially stabilizes
the global structure of this region. Structure conservation along with base-pair
covariations between different strains of MMTV further supported the SHAPEvalidated model. RNA dimerization, packaging, and propagation assays on a
series of mutants, coupled with SHAPE and structure predictions, revealed that a
palindromic sequence containing a canonical “GC” dyad (5’ CGGCCG 3’; pal II)
likely constitutes the MMTV RNA dimerization initiation site (DIS). A second
pal within the primer binding site (PBS) is also involved in RNA dimerization,
and the data presented here suggest that both pals are required for efficient RNA
dimerization, packaging and propagation.
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3.2. Introduction
An essential step in the retroviral life cycle is the efficient and specific
packaging of two copies of plus-strand full length genomic RNA (gRNA) into the
virus particle from a large pool of cellular and other viral RNAs in the cytoplasm
(reviewed in D’Souza & Summers, 2005; Johnson & Telenitsky, 2010; Lever,
2007; Lu et al., 2011; Paillart et al., 2004; Russell et al., 2004). Retroviral RNA
packaging process involves the recognition of packaging signal(s) by the zinc
finger(s) in the nucleocapsid (NC) domain of the Gag polyprotein (reviewed in
D’Souza & Summers, 2005; Johnson & Telenitsky, 2010; Lever, 2007; Lu et al.,
2011). Over the years, it has been shown that the packaging signals of different
retroviruses reside at the 5’ end of the gRNA and include continuous or
discontinuous sequences from the R, U5, and 5′ untranslated (UTR) regions and
extend into the 5’ end of the gag gene (reviewed in D’Souza & Summers, 2005;
Jaballah et al., 2010, Johnson & Telenitsky, 2010; Lever, 2007; Mustafa et al.,
2005, 2012).
The retroviral RNA genome is packaged as a non-covalent dimer, and the
processes of dimerization and packaging are closely interlinked (reviewed in
D’Souza & Summers, 2005; Johnson & Telenitsky, 2010; Lever, 2007; Lu et al.,
2011; Moore & Hu, 2009; Paillart et al., 2004; Russell et al., 2004). The
sequences responsible for retroviral gRNA packaging and dimerization of a
variety of retroviruses map to the same ~100-400 nucleotides (nt) at the 5’ end of
the gRNA, and in most cases are genetically indistinguishable (reviewed in
D’Souza & Summers, 2005; Johnson & Telenitsky, 2010; Lever, 2007).
Recent retroviral RNA cross-packaging studies have shown that the
specificity of retroviral gRNA packaging can be exchanged by substituting the
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packaging signal between genetically diverse retroviruses (Al Dhaheri et al., 2009;
Al Shamsi et al., 2011). This has further been substantiated by the fact that
heterodimers involving RNAs from two divergent retroviruses with no sequence
homology can also be packaged (Moore & Hu, 2009; Motomura et al., 2008;
reviewed in Johnson & Telenitsky, 2010). Therefore, the process of gRNA
dimerization and packaging is likely to involve recognition of structural motifs
rather than primary sequences (Al Dhaheri et al., 2009; Al Shamsi et al., 2011;
Moore et al., 2007; Parveen et al., 2004; Rizvi & Panganiban, 1993; White et al.,
1999; Yin & Hu, 1997). Consistent with this, the packaging and dimerization
sequences of almost all retroviruses have been shown to assume higher order
structures comprising various structural motifs that have been shown to mediate
RNA-RNA and RNA-protein interactions during retroviral RNA dimerization and
packaging (reviewed in D’Souza & Summers, 2005; Johnson & Telenitsky, 2010;
Lever, 2007; Lu et al., 2011; Miyazaki et al., 2011).
Retroviral RNA dimerization is usually mediated by a palindromic (pal)
sequence known as the dimerization initiation site (DIS) present in the 5’ region
of the gRNA. The DIS invariably assumes a hairpin structure containing a
canonical “GC” dyad which interacts with the DIS loop on the second gRNA copy,
resulting in a kissing loop interaction (Clever et al., 1996; Paillart et al., 1994,
1996a, 1997). Pal sequences involved in RNA dimerization have been identified
in HIV-1, HIV-2, SIV (Baig et al., 2007; Berkhout & van Wamel, 1996; Lanchy
et al., 2003; Lanchy & Lodmell, 2007; Laughrea et al., 1997; Paillart et al., 1996a;
Russell et al., 2004; reviewed in Paillart et al., 2004), feline immunodeficiency
virus (FIV; Kenyon et al., 2011; Rizvi et al., 2010) and Mason-Pfizer monkey
virus (MPMV) (Aktar et al., 2013; Jaballah et al., 2010). In addition to gRNA
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dimerization and packaging, mutations in the DIS have been shown to affect other
steps in retroviral life cycle such as reverse transcription (Berkhout & van Wamel,
1996; Houzet et al., 2007; Laughrea et al., 1997; Paillart et al., 1996a; Shen et al.,
2000) and recombination (Andersen et al., 2003; Balakrishnan et al., 2001; Chin et
al., 2005). Since DIS has been shown to regulate retroviral life cycle, it is
therefore an attractive target for antiretroviral drugs, such as aminoglycosides
(Ennifar et al., 2003, 2006).
Despite having been studied extensively, little is known about the
molecular mechanisms of gRNA dimerization and packaging during the MMTV
life cycle (Cardiff & Kenny, 2007; Ross, 2010). An earlier study by Salmons et
al., (1989) suggested that MMTV harbors sequences responsible for gRNA
packaging in the 5’ region of its genome. Recently, employing a biologically
relevant in vivo packaging and transduction assay (Rizvi et al., 2009), Mustafa et
al. (2012) identified a continuous region (spanning the beginning of R to 120 nt of
gag) critical for MMTV gRNA packaging and propagation. Folding algorithms
predicted that these sequences fold into a higher order structure comprising of a
number of stable structural motifs.
In this study we employed selective 2’hydroxyl acylation analyzed by
primer extension (SHAPE; Merino et al., 2005; Mortimer & Weeks, 2007, 2009)
to validate and further refine the predicted higher order features of the MMTV
packaging signal. The SHAPE-validated RNA secondary structure revealed three
prominent pal sequences (pal I, pal II and pal III) and one of them could
potentially function as a possible DIS for MMTV gRNA dimerization. In vitro
dimerization, in vivo packaging and transduction assays revealed that RNA
dimerization, packaging and propagation processes of pal II mutants were greatly
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compromised. Results obtained from these complementary approaches indicate
that pal II forms a hairpin structure that plays an important role in MMTV gRNA
dimerization and packaging by functioning as DIS.
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3.3. Materials and Methods
3.3.1. In silico analyses
The secondary structure of the 5’ region of the MMTV gRNA (nt 1-432,
i.e. including 120 nt of gag ) was predicted using the Mfold server (Mathews et al.,
1999; Zuker, 2003) and validated by applying SHAPE reactivity data in the
RNAstructure software (version 5.3; Reuter & Mathews, 2010). The Mfoldpredicted and SHAPE-validated structures were redrawn with the XRNA software
(http://rna.ucsc.edu/rnacenter/xrna/xrna.html).
Nucleotides 1-432 of the gRNA of different strains of MMTV were
aligned using Clustal Omega (Goujon et al., 2010; Sievers et al., 2011) and a
consensus or “conservation annotation” structure for these strains was predicted
using RNAalifold server (Bernhart et al., 2008). Accession numbers of MMTV
strains are the same as mentioned in figure 3.3A. The number/color scale on the
x-axis indicates six different types of base pairings (GC, CG, AU, UA, GU, UG)
with 1 (red color) representing completely conserved base pairs to 6 (violet color)
representing 6 different types of base pairings at that position among the various
strains. The y-axis represents the incompatible nature of the base pairing (nonWatson base pairing) observed for each viral strain. The number (0-2) or color
gradation (dark to very pale) represents increasing number of strains showing
incompatible (non-Wastson) base pairing within the structure of the various
strains. Thus, a dark red color denotes “highest” conservation of base pairings,
while a light violet color represents “least” conservation of base pairing among
different strains of MMTVs.
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3.3.2. Construction of plasmids
The 5’ end of MMTV gRNA corresponding to nt 1-712 was amplified by
polymerase chain reaction (PCR) using the MMTV sub-genomic transfer vector
DA024 (Rizvi et al., 2009) as the template and the sense (S) OTR 984 (5’
CCCAAGCTTAATACGACTCACTATAGGGCAACAGTCCTAATATTCACG
3') and the antisense (AS) OTR 985 (5’
AAACCCGGGTTCCCCTGGTCCCATAAG 3’) primers. These primers include
the T7 promoter sequence (underlined) at the 5’ end along with flanking
restriction sites (HindIII and XmaI/SmaI, shown in italics). The HindIII and XmaI
sites were utilized to introduce the MMTV sequence into a pUC-based cloning
vector (pIC19R; Marsh et al., 1984). The sequence of the resulting clone, SA035,
was confirmed by sequencing. SA035 was also used as the wild type clone for in
vitro gRNA dimerization assays.
A number of pal I (5’ GUCGGCCGAC 3’) and pal II (5’ CUGCAG 3’)
mutations, including deletions, substitutions and substitution containing
heterologous trans-complementary sequences, were introduced through splice
overlap extension (SOE) PCR as described previously (Aktar et al., 2013; Gibbs et
al., 1994; Jaballah et al., 2010; Rizvi et al., 2010). Briefly, in round one, the
MMTV sub-genomic vector DA024 was amplified in two separate PCRs using S
and AS primers generating products having overlapping complementary
sequences. In round two, the products from round one PCRs which anneal via
their overlapping complementary sequences were amplified using outer primers
OTR 984 (S) and OTR 985 (AS), generating a final product containing the desired
mutation(s). The S and AS primer sequences are provided in Table 3.1, along
with the clone names and the necessary description. Conventional PCR was
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clone created by Shackleford and Varmus (1988). Table is continued in the following page also.

Sequence in small letters: dummy sequence and restriction enzyme sequence. *S, sense; AS, antisense. **HYBMTV, MMTV molecular

TABLE 3.1. Description of primers used for cloning, sequencing, and conventional and real time PCR. Underlined sequence: T7 promoter.
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S
AS
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S
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S
AS
S
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S
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S
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S
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S
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S
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S
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S
S
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S
S
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S
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OTR 984

OTR 985
OTR 922
OTR 923
OTR 924
OTR 925
OTR 926
OTR 927
OTR 928
OTR 929
OTR 986
OTR 987
OTR 988
OTR 989
OTR 990
OTR 991
OTR 992
OTR 993
OTR 994
OTR 995
OTR 1075
OTR 1076
OTR 1077
OTR 1078
OTR 930
OTR 725
OTR 581
OTR 582
OTR 671
OTR 672
MTV-1LTR- SITEM1 FAM
MTV-1LTR-SITEF
MTV-1LTR-SITER

S/
AS

OTR 552

Oligo Name

-

-

SA031/
SA031P
SA032/
SA032P
SA033/
SA033P
SA034/
SA034P
SA041/
SA041P
SA042/
SA042P
SA043/
SA043P
SA044/
SA044P
SA045/
SA045P
SA046/
SA046P
SA047/
SA047P

SA035

-

Clone
Name

5’cccaagcttAATACGACTCACTATAGGGCAACAGTCCTAAT
ATTCACG 3’
5’aaacccgggTTCCCCTGGTCCCATAAG 3’
5’CCCCGCAGATGCGGCAGCTGGCGC 3’
5’ GCTGCCGCATCTGCGGGGGGACCC 3’
5’ TTCGTGCGGCAGCTGGCGCCCG 3’
5’ GCCGCACGAATCTGCGGGGGGACCCTCTGGA 3’
5’ CCCCCCGCAGCTGCGGCAGCTGGCGC 3’
5’ GCTGCCGCAGCTGCGGGGGGACCCTCTG 3’
5’ TTCGCTGCGGCAGCTGGCGCCCG 3’
5’ CCGCAGCGAACTGCGGGGGGACCCTCTGG 3’
5' GTAATCCCGCCTACGGAGAAGAGGTAG 3'
5' GCGGGATTACTCCCTATGGTGAGTCCGTTCC 3'
5' CACCATAGCCTACGGAGAAGAGGTAGG 3'
5' GTAGGCTATGGTGAGTCCGTTCCGCTC 3'
5' GGCGCGCTCCCGCCTACGGAGAAGAGG 3'
5' GCGGGAGCGCGCCTCCCTATGGTGAGTCCGTTCC 3'
5' GACGCACTCCCGCCTACGGAGAAGAGG 3'
5' GCGGGAGTGCGTCTCCCTATGGTGAGTCCGTTCC 3'
5' GGTGCGTTCCCGCCTACGGAGAAGAGG 3'
5' GCGGGAACGCACCTCCCTATGGTGAGTCCGTTCC 3'
5’ CGACTGCGGCGAACAGGGACCCTCGG 3’
5’ CCTGTTCGCCGCAGTCGGCCGACC 3’
5’ AAGCGCGCATCCCGCCTACGGAGAAGAGG 3’
5’ GCGGGATGCGCGCTTCTCCCTATGGTGAGTCCGTTC 3’
5’ GCTTGTGTGTTGGAGGTCGCTGAG 3'
5’ aaaaaagcggccgcCCCTCGGATAAGTGACCCTTGTC 3’
5’ GGCATGGGGGAGGGCATACC 3’
5’ CCAGTGGCTTCCCCAGTG 3’
5’ GTCCTAATATTCACGTCTCGTGTG 3’
5’ CTG TTCGGGCGCCAGCTGCCGCAG 3’
5’TCGCCATCCCGTCTCC 3’
5’CGTCTCGTGTGTTTGTGTTTGTGTCTGT 3’
5’CCTCTGGAAAGTGAAGGATAAGTGA 3’

5’ cgactagtgatatcGTTCCCCTGGTCCCATAAG 3’

Sequence

1179-1202
1321-1298
1214-1229
1192-1213
1259-1235

1867-1885
1264-1313
1258-1307
1299-1322
1304-1252
1260-1313
1307-1254
1298-1316
1303-1253
1442-1464
1434-1414
1446-1465
1430-1410
1442-1461
1434-1414
1442-1461
1434-1414
1442-1461
1434-1414
1315-1331
1303-1288
1442-1461
1435-1415
90-113
1325-1347

HYBMTV gag
HYBMTV U5 region
HYBMTV U5 region
HYBMTV U5 region
HYBMTV U5 region
HYBMTV U5 region
HYBMTV U5 region
HYBMTV U5 region
HYBMTV U5 region
HYBMTV UTR region
HYBMTV UTR region
HYBMTV UTR region
HYBMTV UTR region
HYBMTV UTR region
HYBMTV UTR region
HYBMTV UTR region
HYBMTV UTR region
HYBMTV UTR region
HYBMTV UTR region
HYBMTV UTR region
HYBMTV UTR region
HYBMTV UTR region
HYBMTV UTR region
pcDNA3
HYBMTV UTR region
Actin A. Spliced or unspliced mRNA
Actin S-1. Unspliced mRNA
HYBMTV R region
HYBMTV PBS region
HYBMTV U5 region
HYBMTV U5 region
HYBMTV U5 region

1173-1193 HYBMTV R (+1) start

Nucleotide
Position
Virus & Gene (or plasmid)
(nt)
1885-1867 HYBMTV** gag
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OTR 993
OTR 994
OTR 995
OTR 1075
OTR 1076
OTR 1077
OTR 1078
OTR 930
OTR 725
OTR 581
OTR 582
OTR 671
OTR 672
MTV-1LTR- SITEM1 FAM
MTV-1LTR-SITEF
MTV-1LTR-SITER

AS
S
AS
S
AS
S
AS
S
S
AS
S
S
AS
S
AS
-

-

SA044P
SA045/
SA045P
SA046/
SA046P
SA047/
SA047P

5' GCGGGAGTGCGTCTCCCTATGGTGAGTCCGTTCC 3'
5' GGTGCGTTCCCGCCTACGGAGAAGAGG 3'
5' GCGGGAACGCACCTCCCTATGGTGAGTCCGTTCC 3'
5’ CGACTGCGGCGAACAGGGACCCTCGG 3’
5’ CCTGTTCGCCGCAGTCGGCCGACC 3’
5’ AAGCGCGCATCCCGCCTACGGAGAAGAGG 3’
5’ GCGGGATGCGCGCTTCTCCCTATGGTGAGTCCGTTC 3’
5’ GCTTGTGTGTTGGAGGTCGCTGAG 3'
5’ aaaaaagcggccgcCCCTCGGATAAGTGACCCTTGTC 3’
5’ GGCATGGGGGAGGGCATACC 3’
5’ CCAGTGGCTTCCCCAGTG 3’
5’ GTCCTAATATTCACGTCTCGTGTG 3’
5’ CTG TTCGGGCGCCAGCTGCCGCAG 3’
5’TCGCCATCCCGTCTCC 3’
5’CGTCTCGTGTGTTTGTGTTTGTGTCTGT 3’
5’CCTCTGGAAAGTGAAGGATAAGTGA 3’
1179-1202
1321-1298
1214-1229
1192-1213
1259-1235

1434-1414
1442-1461
1434-1414
1315-1331
1303-1288
1442-1461
1435-1415
90-113
1325-1347

HYBMTV UTR region
HYBMTV UTR region
HYBMTV UTR region
HYBMTV UTR region
HYBMTV UTR region
HYBMTV UTR region
HYBMTV UTR region
pcDNA3
HYBMTV UTR region
Actin A. Spliced or unspliced mRNA
Actin S-1. Unspliced mRNA
HYBMTV R region
HYBMTV PBS region
HYBMTV U5 region
HYBMTV U5 region
HYBMTV U5 region

performed as described previously to amplify the cloning fragments (Jaballah et
al., 2010; Rizvi et al., 2010). All clones were confirmed by sequencing.
3.3.3. In vitro transcription assay
After linearization with the SmaI restriction enzyme, the wild type (SA035)
or mutant (SA031-SA034, SA041-SA045, SA046, SA047 and SA051) clones
were transcribed in vitro to generate the RNAs to be used in dimerization assays
as previously described (Marquet et al., 1991). Following DNase treatment, RNA
extraction, and RNA purification, the RNAs were concentrated using Amicon
Ultra-4 10K devices (Millipore) and their concentration was determined using
nanodrop (ThermoScientific) as described previously (Aktar et al., 2013). Finally,
the quality of the purified RNAs was checked by denaturing polyacrylamide gel
electrophoresis.
3.3.4. SHAPE methodology
SHAPE (Merino et al., 2005; Mortimer & Weeks, 2007, 2009) was
performed on in vitro transcribed RNAs using benzoyl cyanide (BzCN) following
the protocol described recently (Aktar et al., 2013). Briefly, RNAs were modified
in 50 mM sodium cacodylate, (pH 7.5), 300 mM KCl and 5 mM MgCl 2. in the
presence of 2 µg total yeast tRNA (Sigma Aldrich). The modified RNAs were
reverse transcribed using two sets of AS primers: OTRs 9, 10, 11 and 12 (5’
AACAGATTTGGCTTCTGCGG 3’; MMTV nt 614-633) and OTRs 13, 14, 15
and 16 (5’ AGTTTCTGCCCTTTTGAGCC 3’; MMTV nt 325-344), labelled with
VIC, FAM, NED, or PET, respectively. These two sets of primers enabled the
revere transcription of the entire RNA sequence except for a few nucleotides at
the 3’ end due to primer binding. The primer extension products were loaded onto
an Applied Biosystems 3130xl genetic analyzer and the electropherograms were
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analysed with the SHAPEfinder program (Vasa et al., 2008; Wilkinson et al.,
2008). The SHAPE reactivities were determined and normalized as described
earlier (Aktar et al., 2013; Vasa et al., 2008). These normalized SHAPE reactivity
data were used as constraints to validate the secondary structure of the MMTV
packaging signal with RNAstructure (version 5.3) (Reuter & Mathews, 2010) and
also to determine the effect of pal mutations on the overall structure.
3.3.5. In vitro dimerization assay
In vitro dimerization assays of wild type and mutant MMTV RNAs were
performed as described previously (Aktar et al., 2013; Marquet et al., 1991).
Briefly, RNAs (300nM) were heated at 90 ˚C and incubated in ice for 2 minutes,
incubated at 37 ˚C for 30 minutes in dimer (50 mM sodium cacodylate, pH 7.5;
300 mM KCl; 5 mM MgCl 2 ) or monomer (50 mM sodium cacodylate, pH 7.5; 40
mM KCl; 0.1 mM MgCl 2 ) buffer, and analysed by electrophoresis in TBM (50
mM Tris base, 45 mM boric acid, 0.1mM MgCl 2 ) or TB (50 mM Tris base, 45
mM boric acid, 1 mM EDTA) agarose gel at 4 ˚C or 20 ˚C, respectively. Results
for each pal mutant were expressed as dimerization relative to the wild type values.
3.3.6. In vivo genetic complementation assay
The in vivo genetic trans-complementation assay used two expression
plasmids, JA10 and MD.G, to provide the structural and enzymatic genes from
MMTV Gag/Pol and vesicular stomatitis virus (VSV-G) envelope regions,
respectively (Naldini et al., 1996; Rizvi et al., 2009). A third plasmid (MMTV
sub-genomic transfer vector- DA024) containing minimum cis-acting sequences
required for RNA packaging, reverse transcription, and integration, served as a
source of the packageable vector RNA (Fig. 3.1; Rizvi et al., 2009). The pal I and
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integrity of the nuclear membrane during RNA fractionation.

producer cells are harvested to isolate cytoplasmic and nuclear RNA fractions to ensure the export of the transfer vector RNA and the

hygromycin resistant colonies (colony forming unit/ml; CFU/ml) correlates with the amount of RNA being packaged. In parallel, transfected

Cells containing the integrated transfer vector (DA024) proviral DNA form hygromycin resistant colonies. The number of the resulting

real time PCR or to infect target cells to study RNA propagation. Infected target cells are selected with media containing hygromycin B.

particles produced following transfection contain the packaged transfer vector RNA (DA024) and are used to quantitate RNA packaging by

(DA024). A luciferase expressing control plasmid to monitor transfection efficiencies is also co-transfected into the producer cells. Virus

(MD.G) allows packaging of the transfer vector RNA by virtue of the presence of the packaging signal (ψ) on the MMTV transfer vector

human embryonic kidney (HEK) 293T cells with MMTV Gag/Pol expression plasmid (JA10) and VSV-G envelope expression plasmid

gRNA packaging and propagation developed earlier (Rizvi et al., 2009). The pseudotyped particles produced following transfection of

FIGURE 3.1. Design and rationale of three plasmid trans complementation assay for studying mouse mammary tumor virus (MMTV)
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pal II mutations introduced in the T7 promoter-based vectors were inserted in the
MMTV sub-genomic transfer vector DA024.
Human embryonic kidney (HEK) 293T producer cells were transfected
with 2 µg of each plasmid per well in 6-well plates using a calcium phosphate
transfection kit (Invitrogen, USA) to produce VSV-G-pseudotyped-MMTV virus
particles containing wild type or mutated RNAs. The luciferase expression vector,
pGL3 (Promega, USA), was used as an internal control to measure transfection
efficiency (Jaballah et al., 2010; Mustafa et al., 2005, 2012; Rizvi et al., 2010).
Supernatants containing viral particles were collected and spun down at 4000 rpm
on a table top centrifuge for 10 minutes. A portion of the supernatant was used to
infect the human cervical cancer cell line (HeLaT4) to determine the transduction
efficiency after selection with medium containing 200 µg/ml of hygromycin B
(Hyclone, USA). Cells transduced with virus particles containing the packageable
transfer vector RNA express the marker Hygr gene, resulting in colonies which are
measured as colony forming units (CFU/ml). The CFU/ml values were then
normalized to the transfection efficiency. The normalized propagation
efficiencies were then divided by the wild type values to represent the propagation
of the mutants relative to the wild type (Relative CFU/ml).
3.3.7. Nucleocytoplasmic fractionation and isolation of RNA, and cDNA
preparation
Cells from the transfected cultures were fractionated into nuclear and
cytoplasmic fractions as described previously (Ghazawi et al., 2006; Mustafa et al.,
2005). Cellular RNA from the cytoplasmic fractions and packaged viral RNA
were isolated from the pelleted viral particles using Trizol and Trizol LS regents,
respectively (Invitrogen), as described earlier (Ghazawi et al., 2006; Mustafa et al.,
2005). The extracted RNAs were amplified for 30 cycles by conventional PCR
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using vector-specific primers OTR 672 (AS) or OTR 562 (AS) and OTR 671 (S)
(Table 3.1) after DNase (Promega) treatment to ensure that there was no
contaminated DNA present in the RNA samples. The PCR conditions were as
follows: denaturation for 2 minutes at 94 ºC, followed by 30 cycles of 45 sec at 90
ºC, annealing for 45 sec at 60 ºC and extension for 45 sec at 72 ºC followed by
incubation at 4 ºC. The DNase-treated cytoplasmic and viral RNA samples were
reverse transcribed into cDNA and PCR amplified to determine the quality of the
cDNA samples. To determine the integrity of the nuclear membrane during
cytoplasmic RNA extraction, a multiplex PCR was performed on the cDNAs
prepared from the cytoplasmic RNA fractions using OTR 582 (S) and OTR 581
(AS) (Table 3.1) designed to amplify unspliced β-actin mRNA (Ghazawi et al.,
2006; Mustafa et al., 2005). Amplifications of the cDNAs using
primers/competimer for 18S ribosomal RNA (18S Quantum competimer control,
Ambion, USA) was also performed as an ancillary control for the presence of
amplifiable cDNA in the multiplex PCRs (Ghazawi et al., 2006; Mustafa et al.,
2005).
3.3.8. Real Time Quantitative PCR (qPCR) for transfer vector packaging
efficiency
To determine the packaging efficiency of the transfer vector RNA,
quantitative qPCR was performed on the cDNA prepared from the cytoplasmic
and viral RNAs as described earlier (Mustafa et al., 2012). The endogenous
control for qPCR was β-actin (Human β-actin Endogenous Control assay,
VIC⁄MGB probe, Applied Biosystems). The primers and probes for MMTV
transfer vector RNAs in the FAM-based Applied Biosystems custom expression
assay anneal at a 68 nt region in the MMTV U5 (nt 1192-1259) common to wild
type and mutant RNAs. The relative amplification efficiencies of the MMTV and
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β-actin custom expression assays was determined to be 0.0126 (Mustafa et al.,
2012), thus, validating the assays for quantitative PCR analysis using the ∆∆Ct
method. Equal amounts of viral and cytoplasmic cDNA were tested in triplicates.
The cycling conditions used were as follows: Uracil-N-glycosylase incubation 2
minutes at 50 ºC, denaturation for 10 minutes at 94 ºC, followed by 40 cycles of
denaturation and annealing/extension steps at 95 ºC for 15 sec and 60 ºC for 1
minutes. The relative packaging efficiencies were derived following a
modification of the method described earlier (Mustafa et al., 2012). Briefly, the
raw Ct (cycle threshold) values for the MMTV transfer vector were normalized by
the Ct values of the β-actin endogenous control. The normalized values were then
calculated relative to the mock sample (relative quantification, RQ) that was
transfected with all the plasmids, except the transfer vector plasmid forming the
empty virus particles without any packaged RNA. For final relative packaging
efficiency calculations, the relative viral RQ values were divided by the relative
cytoplasmic RQ values, and the resulting values were normalized to the
transfection efficiencies. The final values are presented relative to the wild type.
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3.4. Results
3.4.1. Predicted secondary structure of the MMTV 5’ gRNA
Earlier studies have shown that the sequences necessary for optimal
MMTV gRNA packaging start at R and extend into first 120 nt of gag (Mustafa et
al., 2012). Structural prediction analyses of this region using Mfold suggested
that this region comprises six stem loops 1-6 (SLs1-6, Fig. 3.2A). Two stable
stem loops, SL1 and SL2, were predicted in the R/U5/PBS/UTR region in addition
to SL5 and SL6 in the gag region (Fig. 3.2A). In between these stem loops, SL3
and a bifurcated SL4 were predicted in the UTR region. SL2 was found stably
maintained in all predicted structures (Fig. 3.2A). A closer look at the structure
revealed a presence of three palindromic sequences, a 10 nt pal I in SL2, a 6 nt pal
II in bifurcated SL4, and a 13 nt pal III in SL6 (Fig. 3.2A). Additionally, a 9 nt
stretch of single-stranded purines (ssPurines) was also observed in SL4. The first
apical loop of the bifurcated SL4 comprised pal II, while the second apical loop
contained the ssPurines (Fig. 3.2A).
3.4.2. Validation of the secondary structure by SHAPE
To experimentally validate the predicted structure of the MMTV
packaging signal RNA, SHAPE was employed (Merino et al., 2005; Mortimer &
Weeks, 2007, 2009). Briefly, RNA transcribed in vitro from our wild type
construct, SA035 (Fig. 3.2B), was purified and modified with BzCN as described
earlier (Aktar et al., 2013). BzCN selectively acylates the 2’hydroxy group of the
ribose of nucleotides in flexible (unpaired) regions. Reactivity at each nucleotide
was calculated by subtraction of the reverse transcription product of unmodified
RNA from that of BzCN-modified RNA (Aktar et al., 2013; Vasa et al., 2008).
The SHAPE reactivity data obtained for each nucleotide from 3-6 experiments
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BzCN. The data shown is an average of 3-6 independent experiments.

model of MMTV packaging signal. Nucleotides are color annotated as per the SHAPE reactivities key depending on their modification by

MMTV genome, showing the region used to create the wild type T7 expression plasmid, SA035. (C) SHAPE-constrained RNA structure

secondary structure predicted using Mfold. mSD, major splice donor, PBS, primer binding site. (B) Schematic representation of full length

FIGURE 3.2. Predicted and SHAPE-validated structural models of the MMTV packaging signal RNA. (A) MMTV packaging signal RNA
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were then applied as pseudo-energy constraints in the structure prediction program
RNAstructure in order to develop a refined RNA structural model of the
sequences required for MMTV gRNA dimerization and packaging.
Consistent with the predicted structure, all the loops and bulges containing
unpaired nucleotides in the MMTV packaging signal RNA showed SHAPE
reactivity (Fig. 3.2C). High reactivities were observed for nucleotides forming
G-U base pairs, especially at the end of helices (G120, U320, G193, U294, G324,
U356, U357, U358, U415, Fig. 3.2C). Some base paired nucleotides (G21, C25,
G84) located on either side of a bulge or loop also showed certain amount of
reactivity, as expected. The refined structural model corroborated well with the
predicted structure, supporting the existence of major structural motifs (SL1-SL6;
Fig. 3.2C). Even though a high conformity was observed between the predicted
and the SHAPE-validated structural models, some conspicuous dissimilarity could
be noted. In the SHAPE validated structure, SL1 and SL6 were shorter, resulting
in the formation of SL7 which was not observed in the predicted structure (Fig.
3.2C). In addition, the sequences 5’ to the shortened SL6 form a new SL, which is
different from SL5 (Fig. 3.2B) and therefore was labeled as SL5’ (Fig. 3.2C).
Furthermore, the SHAPE-validated structure harbored a long-range interaction
(LRI) involving complementary sequences from U5 and Gag (U5-Gag LRI; Fig.
3.2C) which was not predicted by Mfold. This U5-Gag LRI is made up of three
short helices separated by a bulge and an internal loop (Fig. 3.2C).
3.4.3. The SHAPE-validated RNA structural model is supported by
phylogeny
Sequence alignment of eight strains of MMTV (sequence from +1R-120 nt
gag) revealed a high degree of conservation relative to the wild type mtv-1
(AF228550.1) strain, especially of sequences of the major structural motifs such
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as U5-Gag LRI, ssPurines, pal II, and PBS (Fig. 3.3A) once superimposed on the
SHAPE-validated structure (Fig. 3.3B). Only a few nucleotides showed
conservation in less than 6 strains (Fig. 3.3B). A phylogenetic tree of MMTV
packaging signal RNA, drawn using CLC Sequence Viewer software (Version
6.8.2; http://www.clcbio.com), further substantiated the high level of sequence
conservation and revealed that these strains share a close evolutionary history (Fig.
3.3C). Finally, a consensus structure of this region using RNAalifold was
generated (Fig. 3.4). Consistent with the SHAPE-validated structure (Fig. 3.2C),
consensus RNA secondary structure predictions (Fig. 3.4) revealed that the major
structural motifs were consistently maintained. In addition, the consensus
structures predicted by RNAalifold also supported the existence of SHAPEvalidated short SL6 and SL5’ over the Mfold predicted long SL6 and SL5 motifs
(compare Figs. 3.2A, 3.2C, and 3.4). The consensus structures also revealed the
existence of LRI which is very similar to the one observed in the SHAPEvalidated structure (Figs. 3.2C, 3.4).
3.4.4. Identification of the pal sequence mediating MMTV gRNA
dimerization
The sequence of the MMTV RNA packaging signal revealed three pal sequences:
pal I, a 10 nt base paired sequence in the SL2 stem, pal II, a 6 nt sequence present
in a loop of the bifurcated SL4, pal III, forming the apical part of SL6 (13 nt) one
of these could possibly function as a DIS (Fig. 3.2A, 3.2C). To ascertain which
pal sequence may function as the DIS for MMTV gRNA dimerization,
dimerization of three RNAs with different truncated 3’ ends containing different
number of pals was compared (Fig. 3.5). The longest RNA (712 nt) encompassed
all the three pals, the intermediate 371 nt RNA contained only the first two pals,
while the shortest RNA included only pal I (Fig. 3.5A).
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FIGURE 3.3. Phylogenetic conservation of the sequences of major structural
motifs of MMTV packaging signal RNA in different strains. (A) Clustal
Omega sequence alignment of eight different strains of MMTV packaging
signal RNA. Sequences of the major structural motifs are highlighted in
different colors, whereas the 11 nt pal sequence within PBS is boxed. The
accession numbers for the MMTV strains are AF228550.1 (mtv-1; Hook et al.,
2000), L37517.1 (mtv-6; Cho et al., 1995), AF033807.1 (Petropoulos, 1997),
M15122.1 (BR6; Moore et al., 1987), D16249.1 (JYG; Moore et al., 1987),
AF228551.1 (C3H/HeJ; Hook et al., 2000), X00018.1 (GR; Fasel et al., 1983)
and AF228552.1 (C3H; Hook et al., 2000). (B) Sequence conservation is
superimposed on the SHAPE validated structure. The nucleotides are colorcoded based on their conservation level ranging from <75 to 100%. (C)
Phylogenetic tree of the eight different strains of MMTV packaging signal
RNA. Neighbor joining method was used for creating the phylogenetic tree.
The horizontal lines are branches and represent evolutionary lineages changing
over time. The units of branch length are nucleotide substitutions given as
fractional change (the number of changes or 'substitutions' divided by the
length of the sequence). Figure continues on the following page.
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A

CLUSUAL 2.1 mulUiple sequence alignmenU

A

U5 LRI

AF228550.1
L37517.1
AF033807.1
M15122.1
D16249.1
AF228551.1
X00018.1
AF228552.1

GCAACAGUCCUAAUAUUCACGUCUCGUGUGUUUGUGUCUGUUCGCCAUCCCGUCUCCGCU
------GUCCUAACAUACACGUCUCGUGUGUUUGUGUCUGUUCGCCAUCCCGUCUCCGCU
GCAACAGUCCUAACAUUCACCUCUCGUGUGUUUGUGUCUGUUCGCCAUCCCGUCUCCGCU
GCAACAGUCCUAACAUUCACCUCUCGUGUGUUUGUGUCUGUUCGCCAUCCCGUCUCCGCU
GCAACAGUCCUAACAUCCGUCUCUCGUGUGUUUGUGUCUGUUCGCCAUCCCGUCUCCGCU
GCAACAGUCCUAAUAUUCACGUCUCGUGUGUUUGUGUCUGUUCGCCAUCCCGUCUCCGCU
GCAACAGUCCUAACAUUCUUCUCUCGUGUGUUUGUGUCUGUUCGCCAUCCCGUCUCCGCU
GCAACAGUCCUAACAUUCACCUCUUGUGUGUUUGUGUCUGUUCGCCAUCCCGUCUCCGCU
******* ** *
*** ***********************************

60
54
60
60
60
60
60
60

AF228550.1
L37517.1
AF033807.1
M15122.1
D16249.1
AF228551.1
X00018.1
AF228552.1

CGUCACUUAUCCUUCACUUUCCAGAGGGUCCCCCCGCAGACCCCGGUGACCCUCAGGUCG
CGUCACUUAUCCUUCACUUUCCAGAGGGUCCCCCCGCAGACCCCGGUGACCCUCAGGUCG
CGUCACUUAUCCUUCACUUUCCAGAGGGUCCCCCCGCAGACCCCGGUGACCCUCAGGUCG
CGUCACUUAUCCUUCACUUUCCAGAGGGUCCCCCCGCAGACCCCGGUGACCCUCAGGUCG
CGUCACUUAUCCUUCACUUUCCAGAGGGUCCCCCCGCAGACCCCGGUGGCCCUCGGGUUC
CGUCACUUAUCCUUCACUUUCCAGAGGGUCCCCCCGCAGACCCCGGUGACCCUCAGGUCG
CGUCACUUAUCCUUCACUUUUCAGAGGGUCCCCCCGCAGAUCCCGGUCACCCUCAGGUCG
CGUCACUUAUCCUUCACUUUCCAGAGGGUCCCCCCGCAGACCCCGGCGACCCUCAGGUCG
******************** ******************* ***** .*****.***

120
114
120
120
120
120
120
120

AF228550.1
L37517.1
AF033807.1
M15122.1
D16249.1
AF228551.1
X00018.1
AF228552.1

GCCGACUGCGGCAGCUGGCGCCCGAACAGGGACCCUCGGAUAAGUGACCCUUGUCUCUAU
GCCGACUGCGGCAGCUGGCGCCCGAACAGGGACCCUCGGAUAAGUGACCCUUGUCUCUAU
GCCGACUGCGGCAGCUGGCGCCCGAACAGGGACCCUCGGAUAAGUGACCCUUGUCUCUAU
GCCGACUGCGGCAGCUGGCGCCCGAACAGGGACCCUCGGAUAAGUGACCCUUGUCUCUAU
GCCGACUGCGGCAGCUGGCGCCCGAACAGGGACCCUCGGAUAAGUGACCCUUGUCUCUAU
GCCGACUGCGGCAGCUGGCGCCCGAACAGGGACCCUCGGAUAAGUGACCCUUGUCUUUAU
GCCGACUGCGGCAGCUGGCGCCCGAACAGGGACCCUCGGAUAAGUGACCCUUGUCUUUAU
GCCGACUGCGGCAGCUGGCGCCCGAACAGGGACCCUCGGAUAAGUGACCCUUGUCUCUAU
******************************************************** ***

180
174
180
180
180
180
180
180

AF228550.1
L37517.1
AF033807.1
M15122.1
D16249.1
AF228551.1
X00018.1
AF228552.1

UUCUACUAUUUGGUGUUUGUCUUGUAUUGUCUCUUUCUUGUCUGGCUAUCAUCACAAGAG
UUCUACUAUUUGGUGUUCGUCUUGUAUUGUCUCUUUCUUGUCUGGCUAUCAUCACAAGAG
UUCUACUAUUUUGUGUUCGUCUUGUUUUGUCUCUAUCUUAUCUGGCUAUUAUCACAAGAG
UUCUACUAUUUUGUGUUCGUCUUGUUUUGUCUCUAUCUUAUCUGGCUAUUAUCACAAGAG
UUCUACUAUUUGGUGUUCGUCUUGUAUUGUCUCUUUCUUGUCUGGCUAUCAUCACAAGAG
UUCUACUAUUUUGUGUUCGUCUUGUUUUGUCUCUAUCUUGUCUGGCUAUCAUCACAAGAG
UUCUACUAUUUUGUGUUCGUCUUGUUUUGUCUCUAUCUUGUCUGGCUAUCAUCACAAGAG
UUCUACUAUUUGGUGUUUGUCUUGUAUUGUCUCUUUCUUGUCUGGCUAUCAUCACAAGAG
*********** ***** *******:********:****.********* **********

AF228550.1
L37517.1
AF033807.1
M15122.1
D16249.1
AF228551.1
X00018.1
AF228552.1

CGGAACGGACUCACCAUAGGGAGCUGCAGUCCCGCCUACGGAGAAGAGGUAGGUUACGGU
CGGAACGGACUCACCACAGGGAGCUGCAGUCCCGCCUACGGAGGAGAGGUAGGUUACGGU
CGGAACGGACUCACCACAGGGAACUGCAGUCUCGCCUACAGAGAAGAGGUAGGUUACGGU
CGGAACGGACUCACCACAGGGAACUGCAGUCUCGCCUACAGAGAAGAGGUAGGUUACGGU
CGGAACGGACUCACCACAGGGAACUGCAGUCCCGCCUACGGAGGAGAGGUAGGUUACGGU
CGGAACGGACUCACCACAGGGAACUGCAGUCUCGCCUACGGAGAAGAGGUAGGUUACGGU
CGGAACGGACUCACCACAGGGAACUGCAGUCUCGCCUACGGAGAAGAGGUAGGUUACGGU
CGGAACGGACUCACCAUAGGGAGCUGCAGUCCCGCCUACGGAGAAGAGGUAGGUUACGGU
**************** *****.******** *******.***.****************

300
294
300
300
300
300
300
300

AF228550.1
L37517.1
AF033807.1
M15122.1
D16249.1
AF228551.1
X00018.1
AF228552.1

GAGCCAUUGGAAAUGGGGGUCUCGGGCUCAAAAGGGCAGAAACUCUUUGUUUCUGUUUUA
GAGCCAUUGGAUAUGGGGGUCUCGGGCUCAAAAGGGCAGAAACUCUUCGUUUCUGUACUA
GAGCCAUUGGAAAUGGGGGUCUCGGGAUCAAAAGGGCAGAAACUCUUUGUUUCUGUUCUA
GAGCCAUUGGAAAUGGGGGUCUCGGGAUCAAAAGGGCAGAAACUCUUUGUUUCUGUUCUA
GAGCCAUUGGAAAUGGGGGUCUCGGGCUCAAAAGGGCAGAAACUCUUCGUUUCUGUUUUA
GAGCCAUUGGAAAUGGGGGUCUCGGGCUCAAAAGGGCAGAAACUCUUUGUUUCUGUUUUA
GUGCCAUUGGAUAUGGGGGUCUCGGGCUCAAAAGGGCAGAAACUCUUUGUUUCUGUUUUA
GAGCCAUUGGAAAUGGGGGUCUCGGGCUCAAAAGGGCAGAAACUCUUUGUUUCUGUUUUA
*:*********:**************.******************** ********: **

360
354
360
360
360
360
360
360

AF228550.1
L37517.1
AF033807.1
M15122.1
D16249.1
AF228551.1
X00018.1
AF228552.1

CAAAGGCUCCUCUCAGAGAGGGGUCUUCAUGUGAAAGAGAGUAGUGCAAUAGAAUUUUAU
CAAAGGCUCCUCUCAGAGAGGGGUCUUCAUGUGAAAGAGAGUAGUGCAAUAGAAUUUUAU
CAAAGACUCCUCUCAGAGAGGGGUCUUCAUGUGAAAGAGAGCAGUGCAAUAGAGUUUUAU
CAAAGACUCCUCUCAGAGAGGGGUCUUCAUGUGAAAGAGAGCAGUGCAAUAGAGUUUUAU
CAAAGGCUUCUCUCAGAGAGGGGUCUUCAUGUGAAAGAGAGCAGUGCAAUAGAAUUCUAU
CAAAGGCUCCUCUCAGAGAGGGGUCUUCAUGUGAAAGAGAGCAGCGCAAUAGAGUUUUAU
CAAAGGCUCCUCUCAGAGAGGGGUCUUCAUGUGAAGGAGAGCAGCACAAUAGAGUUUUAU
CAAAGGCUCCUCUCAGAGAGGGGUCUUCAUGUGAAAGAGAGUAGUGCAAUAGAAUUUUAU
*****.** **************************.***** ** .*******.** ***
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420
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420
420
420
420

AF228550.1
L37517.1
AF033807.1
M15122.1
D16249.1
AF228551.1
X00018.1
AF228552.1

CAGUUUCUAAUA
CAGUUUCUGAUA
CAGUUCCUAAUA
CAGUUCCUAAUA
CAGUUCCUAAUA
CAGUUUCUUAUA
CAGUUUCUGAUA
CAGUUUCUUAUA
***** ** ***

pal I

pal sequence within PBS

PBS

pal II

ssPurines

Gag LRI

240
234
240
240
240
240
240
240

pal III

432
426
432
432
432
432
432
432

114

B

U5 LRI

UGUCUGUUCGCCAUCCCGUCUCCGCU
UGUCUGUUCGCCAUCCCGUCUCCGCU
UGUCUGUUCGCCAUCCCGUCUCCGCU
UGUCUGUUCGCCAUCCCGUCUCCGCU
UGUCUGUUCGCCAUCCCGUCUCCGCU
UGUCUGUUCGCCAUCCCGUCUCCGCU
UGUCUGUUCGCCAUCCCGUCUCCGCU
UGUCUGUUCGCCAUCCCGUCUCCGCU
**************************

60
54
60
60
60
60
60
60

CGCAGACCCCGGUGACCCUCAGGUCG
CGCAGACCCCGGUGACCCUCAGGUCG
CGCAGACCCCGGUGACCCUCAGGUCG
CGCAGACCCCGGUGACCCUCAGGUCG
CGCAGACCCCGGUGGCCCUCGGGUUC
CGCAGACCCCGGUGACCCUCAGGUCG
CGCAGAUCCCGGUCACCCUCAGGUCG
CGCAGACCCCGGCGACCCUCAGGUCG
****** ***** .*****.***

120
114
120
120
120
120
120
120

CUCGGAUAAGUGACCCUUGUCUCUAU
CUCGGAUAAGUGACCCUUGUCUCUAU
CUCGGAUAAGUGACCCUUGUCUCUAU
CUCGGAUAAGUGACCCUUGUCUCUAU
CUCGGAUAAGUGACCCUUGUCUCUAU
CUCGGAUAAGUGACCCUUGUCUUUAU
CUCGGAUAAGUGACCCUUGUCUUUAU
CUCGGAUAAGUGACCCUUGUCUCUAU
********************** ***

180
174
180
180
180
180
180
180

UUCUUGUCUGGCUAUCAUCACAAGAG
UUCUUGUCUGGCUAUCAUCACAAGAG
AUCUUAUCUGGCUAUUAUCACAAGAG
AUCUUAUCUGGCUAUUAUCACAAGAG
UUCUUGUCUGGCUAUCAUCACAAGAG
AUCUUGUCUGGCUAUCAUCACAAGAG
AUCUUGUCUGGCUAUCAUCACAAGAG
UUCUUGUCUGGCUAUCAUCACAAGAG
:****.********* **********

240
234
240
240
240
240
240
240

pal I

ssPurines

CCUACGGAGAAGAGGUAGGUUACGGU
CCUACGGAGGAGAGGUAGGUUACGGU
CCUACAGAGAAGAGGUAGGUUACGGU
CCUACAGAGAAGAGGUAGGUUACGGU
CCUACGGAGGAGAGGUAGGUUACGGU
CCUACGGAGAAGAGGUAGGUUACGGU
CCUACGGAGAAGAGGUAGGUUACGGU
CCUACGGAGAAGAGGUAGGUUACGGU
*****.***.****************

300
294
300
300
300
300
300
300

GGCAGAAACUCUUUGUUUCUGUUUUA
GGCAGAAACUCUUCGUUUCUGUACUA
GGCAGAAACUCUUUGUUUCUGUUCUA
GGCAGAAACUCUUUGUUUCUGUUCUA
GGCAGAAACUCUUCGUUUCUGUUUUA
GGCAGAAACUCUUUGUUUCUGUUUUA
GGCAGAAACUCUUUGUUUCUGUUUUA
GGCAGAAACUCUUUGUUUCUGUUUUA
************* ********: **

360
354
360
360
360
360
360
360

AAGAGAGUAGUGCAAUAGAAUUUUAU
AAGAGAGUAGUGCAAUAGAAUUUUAU
AAGAGAGCAGUGCAAUAGAGUUUUAU
AAGAGAGCAGUGCAAUAGAGUUUUAU
AAGAGAGCAGUGCAAUAGAAUUCUAU
AAGAGAGCAGCGCAAUAGAGUUUUAU
AGGAGAGCAGCACAAUAGAGUUUUAU
AAGAGAGUAGUGCAAUAGAAUUUUAU
*.***** ** .*******.** ***
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414
420
420
420
420
420
420

B
pal I
(5’ GUCGGCCGAC 3’)

B

100%

75-100%
<75%

U5/Gag LRI

pal III
(5’ CCUCUCAGAGAGG 3’)

pal II
(5’
CUGCAG
3’)
ssPurines

C

115

116

color represents “least” conservation of base pairing among different strains of MMTVs.

pairing within the structure of the various strains. Thus, a dark red color denotes “highest” conservation of base pairings, while a light violet

The number (0-2) or color gradation (dark to very pale) represents increasing number of strains showing incompatible (non-Wastson) base

(see Materials and Methods for details). The y-axis represents the incompatibility score based on non-Watson base pairing within each strain.

completely conserved base pairing to 6 (violet color) representing 6 different types of base pairings at that position among the various strains

“conservation annotation” structure. The number/color scale on the x-axis indicates base pairing conservation with 1 (red color) representing

Clustal Omega and the aligned sequences were used as input in the RNAalifold server (Hofacker et al., 2002) to predict the consensus or

Accession numbers of MMTV strains are the same as mentioned in figure 2A. The sequences of the 8 MMTV strains were aligned using

FIGURE 3.4. Consensus RNA secondary structure prediction of MMTV packaging signal RNA using sequences from eight different strains.
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SL2

SL3

U5/Gag LRI

SL4

SL5’

SL6

118

loss of dimerization of the 265 nt RNA in TB gels. Wild type HIV-1 RNA (615 nt) was used as a positive control for dimerization.

RNAs. (C) Representative RNA dimerization gels. M: incubation in monomer buffer; D: incubation in dimer buffer. The circles show the

TBM or TB gels electrophoresed at 4 °C and at room temperature, respectively, showing the percentage of dimerization of the truncated

secondary structures of the three truncated RNAs (712 nt, 321 nt, and 265 nt). (B) Summary of the in vitro dimerization data analyzed on

FIGURE 3.5. Contribution of the pal sequences to MMTV gRNA dimerization. (A) Schematic representations of the predicted RNA
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RNA samples were incubated in dimer or monomer buffer and analyzed on 1%
TBM or TB agarose gels at 4 ºC or 20 ºC, respectively. The TBM gels stabilized
weak dimer conformers, while only stable dimers survive electrophoresis through
TB gels. Our results revealed that the longest RNA as well as the intermediate
RNA dimerized efficiently, whereas the shortest RNA barely dimerized (Fig. 3.5B,
C). These results suggest that pal II may play a crucial role in MMTV gRNA
dimerization. Consistently, pal II is the only pal that is observed to adopt a
hairpin conformation with a canonical “GC” dyad (Fig. 3.2A, C).
3.4.5. Mutational analysis of pal I
To further test the role of pal I (if any) in dimerization and packaging, a
series of mutations were introduced and tested employing a combination of
genetic and biochemical approaches (Fig. 3.6A). These mutations included
complete deletion of 26 nt of the apical stem loop of SL2 containing pal I, as well
as simultaneous substitution of the deleted sequences with a UUCG stable
tetraloop in order to maintain a stem loop structure without pal I. It is important
to mention that the attachment (att) sites needed for integration of the provirus
were not affected in pal I mutants, thus allowing us to test the same mutations in
both the in vitro dimerization as well as in vivo packaging and propagation assays
(Rizvi et al., 2009). None of the deletion and/or deletion/substitution mutants
showed any effects on dimerization when compared to the wild type clone SA035
(Fig. 3.6B). The percentage dimerization of the wild type, SA035 clone and
mutant clones (SA031-SA034) was observed to be 81-96% in TBM gels and 3969% in TB gels (data not shown). Thus, these experiments indicated that pal I is
not the DIS, which is in agreement with the analysis of the truncated RNAs in the
in vitro dimerization assay (Fig. 3.5).
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continues on the following page.

propagation efficiencies. In (C), (E), and (F), the histograms represent data from at least three independent experiments (±SD). Figure

(F) Relative hygromycin resistance (Hygr) colony forming unit per ml (CFU/ml) for mutant transfer vectors reflecting the relative RNA

of cytoplasmic cDNA using primers that amplify spliced β-actin mRNA. (E) Relative packaging efficiency (RPE) of transfer vector RNAs.

Multiplex amplifications were conducted in the presence of primers/competimer for 18S ribosomal RNA. The fourth panel (iv) shows PCR

(iii), amplification was conducted on the cDNAs obtained from cytoplasmic RNAs using primers that amplify unspliced β-actin mRNA.

(D) PCR amplifications of the DNase treated cytoplasmic (panel i) and viral (panel ii) RNAs using virus specific primers. In the third panel

efficiencies of the mutants and wild type transfer vectors that were used to normalize the packaging efficiency. LUC: Luciferase activity.

mutant MMTV RNAs. M: monomer lane or monomer conformer; D: dimer lane or dimer conformer for each sample. (C) Transfection

pal I sequence is shown in blue and the mutations are depicted in red. (B) Typical RNA dimerization TBM and TB gels of wild type and

FIGURE 3.6. Role of pal I in MMTV gRNA dimerization, packaging, and propagation. (A) Description of the pal I mutants. The wild type
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To evaluate the functional impact of mutations in pal I, we tested these
mutants in an in vivo packaging and propagation assay. Wild type and mutant
viral particles were produced in HEK 293T cells that were used to: 1) measure the
packaged viral RNA using qPCR, and 2) assess the propagation of the packaged
RNA in the target cells which was monitored by the appearance of Hygromycin
resistant colonies. First, the transfection efficiency of the cultures containing
mutant transfer vectors was checked. The transfection efficiencies from at least
three independent experiments were observed to be within 2 folds of each other,
suggesting that all cultures were efficiently transfected (Fig. 3.6C). These
transfection efficiencies were taken into account to normalize and calculate the
packaging efficiency and propagation for each mutant relative to the wild type.
To determine the RNA packaging efficiency, cDNAs were prepared from
cytoplasmic and pelleted virion RNAs. Before making the cDNAs these RNAs
were subjected to DNase treatment to ensure that there was no contaminating
plasmid DNA, followed by PCR using virus-specific primers. The lack of a
positive signal indicated that the DNA contamination in our RNA preparations
was below the detection levels (Fig. 3.6D, panels i and ii). After having
confirmed this, RNA preparations were reverse transcribed and cDNAs were
prepared. Since the relative packaging efficiency data is expressed in relation to
the efficiently and stably expressed viral RNAs that are exported from the nucleus
to the cytoplasm, the integrity of the cytoplasmic RNA fraction was monitored by
checking for the absence of unspliced β-actin mRNA by RT-PCR (Fig. 3.6D,
panel iii). To ensure that each cytoplasmic RNA fraction contained amplifiable
cDNAs, the unspliced β-actin PCRs were conducted in the presence of
primers/competimer for 18S ribosomal RNAs as an internal control (Jaballah et
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al., 2010; Mustafa et al., 2012; Rizvi et al., 2010). In a separate amplification
reaction, the same cytoplasmic cDNA samples were amplified using spliced βactin primers (Fig. 3.6D, panel iv). Figure 3.6D (panels iii, and iv) shows that
while 18S ribosomal RNA and spliced β-actin mRNA were amplifiable, unspliced
β-actin mRNA was not. These results indicated that the fractionation technique
employed was robust and that the nuclear membrane integrity was maintained
during the fractionation process.
Following normalization of the RNA packaged into the virus particles with
the cytoplasmic transfer vector RNA expression and to transfection efficiencies,
the in vivo gRNA packaging data revealed that none of the pal I mutations
significantly affected gRNA packaging (Fig. 3.6E). This corroborated well with
the dimerization data for the same mutants which showed no significant
dimerization defect (Fig. 3.6B). Interestingly, when viral particles containing
RNAs from these mutants were used to transduce target cells with a hygromycin
resistance gene, a drastic reduction of RNA propagation (3-20 fold reduction of
the relative CFU/ml, P < 0.05) was observed for all mutants (Fig. 3.6F). Lack of
RNA propagation of the packaged mutant transfer vector RNAs suggests that the
mutations impaired reverse transcription or/and integration since our readout
assay is dependent on successful completion of these steps in retroviral life cycle.
Consistent with this hypothesis, mutations in close vicinity of the PBS (as has
been the case for these pal I mutants) have been shown to greatly impinge reverse
transcription (Mikkelsen et al., 1996; Oh et al., 2008; Paillart et al., 1996a).
3.4.6. Pal II functions as the dimerization initiation site (DIS)
To test if pal II modulates MMTV gRNA dimerization and packaging, a
series of similar mutations was introduced including a complete deletion of pal II
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as well as substitution with a stable tetraloop sequence, in order to maintain the
overall RNA secondary structure of this region (Fig. 3.7A). Complete deletion of
pal II revealed a significant ~two-fold decrease in RNA dimerization, both in
TBM and TB gels (Fig. 3.7B, C, compare mutant SA042 with SA035, P<0.001).
Deletion of pal II with simultaneous substitution with a stable tetraloop had the
same effect on RNA dimerization (Fig. 3.7B, C, mutant SA41; 1.85-2.40-fold
reduction in relative RNA dimerization; P<0.001).
These results indicated that although pal II deletion mutants could reduce
RNA dimerization, they could not completely abrogate it. This suggested the
presence of another sequence that is able to facilitate dimerization in the absence
of pal II, though not to the wild type level. Therefore, the pal II deletion mutant
(SA042) sequence was folded using the RNAstructure software, which revealed
that in the absence of pal II, the MMTV RNA packaging signal could potentially
dimerize via the PBS (Fig. 3.8B), which contains two adjacent pals (5’
CAGCUGGCGCC 3’; the first pal is in italics and the second pal is underlined.
To determine if this was the case, a mutant (SA051) was generated containing
deletion of the 11 nt pal sequence within the PBS. Along the same lines, a double
mutant (SA046) was created containing the deletion of pal II sequence as well as
the 11 nt pal within the PBS ((Fig. 3.7A). Deletion of the 11 nt pal in the PBS
alone resulted in 3 to 6-fold decreased RNA dimerization (SA051; (Fig. 3.7B, C).
Deletion of both sequences (SA046) resulted in almost complete abrogation of
dimerization in TBM conditions and to a five-fold decrease in TB (Fig. 3.7B, C).
These results revealed an additive and/or synergistic role of pal II and the pal
sequence within PBS in mediating MMTV gRNA dimerization.
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Relative packaging efficiency of transfer vector RNAs. (G) RNA propagation efficiency expressed as

experiments (±SD). Figure continues on the following page.

Hygr colony forming unit per ml (CFU/ml). In (C), (D), (F), and (G) the histograms represent data from at least three independent

amplify spliced β-actin mRNA. (F)

in the presence of primers/competimer for 18S ribosomal RNA. The fourth panel (iv) shows PCR of cytoplasmic cDNA using primers that

the cDNAs obtained from cytoplasmic RNAs using primers that amplify unspliced β-actin mRNA. Multiplex amplifications were conducted

treated cytoplasmic (panel i) and viral (panel ii) RNAs using virus specific primers. In the third panel (iii), amplification was conducted on

type transfer vectors that were used to normalize the packaging efficiency. LUC: Luciferase activity. (E) PCR amplifications of the DNase

dimer lane or dimer conformer. (C) Quantification of the relative RNA dimerization. (D) Transfection efficiencies of the mutants and wild

(B) Typical RNA dimerization in TBM and TB gels of wild type and mutant MMTV RNAs. M: monomer lane or monomer conformer; D:

FIGURE 3.7. Role of pal II in MMTV gRNA dimerization, RNA packaging and viral propagation. (A) Description of the pal II mutants.
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PBS, primer binding site; ssPurines, single stranded purines.

using RNAstructure and the contact point (point of dimerization) of the sequences between two RNAs leading to dimerization are boxed.

sequence within PBS (SA051) and (D) double deletion of both pal II and pal sequence within PBS (SA046). The dimers were predicted

FIGURE 3.8. Predicted homodimer structures of (A) MMTV wild type (SA035), (B) pal II deletion (SA042), (C) deletion of the pal
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To ascertain whether the primary sequence or the palindromic nature of
pal II was important for MMTV gRNA dimerization, a few additional mutants
were generated. The wild type pal II was substituted with the HIV-1 6 nt pal or
with the HIV-1 pal flanked by additional purines on either side (Fig. 3.9A,
mutants SA043 and SA047; respectively). Two additional mutants were also
created in which the pal II sequence was substituted by non-palindromic transcomplementary sequences (Fig. 3.9A, mutants SA044 and SA045). In all these
mutants, the pal sequence within the PBS was maintained. Consistent with the
effect of the purines flanking the pal sequence on HIV-1 RNA dimerization
(Paillart et al., 1997), replacing pal II by the HIV-1 pal (SA043) reduced MMTV
RNA dimerization by ~two-fold, while replacing it by the HIV-1 pal containing
flanking purines (SA047) preserved MMTV RNA dimerization to wild type levels
(Fig. 3.9B, C). The trans-complementary mutants SA044 and SA045 were
incubated either separately or together, allowing them to interact to initiate
dimerization due to the trans-complementary nature of the sequences. When
incubated separately, the mutants displayed a ~two-fold decrease in dimerization
(Fig. 3.9B, C), as expected similar to other pal II substitution and deletion mutants
(Figs. 3.7B, C, 3.9B, C). Surprisingly, RNA dimerization was not restored when
these mutants were co-incubated (Fig. 3.9B, C), in sharp contrast with other
retroviral systems in which dimerization has been restored to wild type levels in
the mutants containing trans-complementary sequences (Aktar et al., 2013; Chen J.
et al., 2009; Jossinet et al., 2001; Paillart et al., 1996b).
3.4.7. Pal II regulates MMTV gRNA packaging and propagation
Next, the RNA packaging and propagation efficiencies of sub-genomic
transfer vectors containing pal II mutations was analyzed by transfecting the HEK
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independent experiments (±SD). Figure continues on the following page.

expressed as Hygr colony forming unit per ml (CFU/ml). In (C), (E), (F), and (G) the histograms represent data from at least three

packaging efficiency. LUC: Luciferase activity. (F) Relative packaging efficiency of transfer vector RNAs. (G) RNA propagation efficiency

amplify spliced β-actin mRNA. (E) Transfection efficiencies of the mutants and wild type transfer vectors that were used to normalize the

in the presence of primers/competimer for 18S ribosomal RNA. The fourth panel (iv) shows PCR of cytoplasmic cDNA using primers that

the cDNAs obtained from cytoplasmic RNAs using primers that amplify unspliced β-actin mRNA. Multiplex amplifications were conducted

treated cytoplasmic (panel i) and viral (panel ii) RNAs using virus specific primers. In the third panel (iii), amplification was conducted on

conformer; D: dimer lane or dimer conformer. (C) Quantification of the relative RNA dimerization. (D) PCR amplifications of the DNase

The last two lanes correspond to the co-incubation of trans-complementary mutants SA044 and SA045. M: monomer lane or monomer

Description of the pal II substitution mutants. (B) Typical RNA dimerization in TBM and TB gels of wild type and mutant MMTV RNAs.

FIGURE 3.9. Effects of pal II substitution mutations on MMTV gRNA dimerization, RNA packaging and viral propagation. (A)
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293T cells along with the packaging and VSV-G envelope expression constructs.
As described previously for pal I mutants, data from several experiments showed
that pal II mutants’ transfection efficiencies were within two folds and that the
transfer vector RNAs were expressed efficiently (Figs. 3.7D, E, 3.9D, E). When
similar amounts of virions were used to isolate packaged RNA, all of the mutants
tested except for SA051P and SA043P, were found to be severely impaired for
gRNA packaging (27-150 fold reduction, P<0.001, Figs. 3.7F, 3.9F). Although
packaged, the relative packaging efficiency of SA051P and SA043P mutants were
reduced by 9- and 2-fold, respectively, when compared to the wild type (Figs.
3.7F, 3.9F). Propagation of these mutants, as measured by counting the number of
hygromycin resistant colonies (CFU/ml) in the infected cultures (Figs. 3.7G,
3.9G), corroborated well with the RNA packaging data, except for mutant
SA051P. Lack of propagation of this mutant can be explained by the deletion in
the PBS since our assay requires the packaged RNA to be successfully reverse
transcribed (initiated by an intact PBS) before integration to allow expression of
the hygromycin resistant gene. Altogether, the dimerization, packaging, and
propagation results suggest that the pal II hairpin plays an important role in both
MMTV gRNA dimerization and packaging; however, RNA dimerization is not
sufficient to ensure efficient packaging and propagation. The case of mutant
SA047P, containing substitution of pal II with HIV-1 pal along with flanking
purines, is particularly intriguing as its RNA packaging and propagation are
abolished (Fig. 3.9F, G), despite displaying wild type RNA dimerization levels.
These results could indicate that the pal II hairpin is also involved in RNA-protein
interactions during genome encapsidation.
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3.4.8. SHAPE analyses of pal II and PBS pal mutants support their role in
MMTV gRNA dimerization
In order to test whether the dimerization, packaging and propagation data
could be explained by effects of the mutations in pal II on the MMTV RNA
secondary structure, we performed SHAPE analyses on all the pal II mutants in
dimer buffer. Figures 3.10 and 3.11 focus on the SL4 region (~ nt 250-303,
encompassing pal II) and the PBS region, respectively. In the wild type RNA
(SA035) and in the substitution mutant with the HIV-1 pal containing flanking
purines (SA047), the two pals displayed limited or no SHAPE reactivity,
consistent with their normal role in RNA dimerization (Fig. 3.10A). Accordingly,
pal II substitution mutants with decreased RNA dimerization displayed high
reactivity of at least one nucleotide in the mutated region (SA041, SA044, SA045,
SA043, Fig. 3.10A). The ssPurines sequence was highly reactive in all RNAs
(Fig. 3.10A). Several mutants (SA041, SA044, SA043, and SA047) preserved the
bifurcated stem loop structure of SL4 (Fig. 3.10B). Surprisingly, SA045 adopted
a totally different structure in which the mutated sequence is mostly base-paired.
Misfolding of this RNA likely explains why the trans-complementary mutants
SA044 and SA045 were unable to form heterodimers (Fig. 3.9B, C). In these two
pal II deletion mutants (SA042 and SA046), SL4 adopted a single hairpin
conformation in which most of the nucleotides that formed the bifurcating loop in
the wild type structure were base-paired.
Since we observed that the PBS pal played some role in MMTV gRNA
dimerization (Fig. 3.7B, C), the structure of the SL2 domain which contains the
PBS was analysed in the wild type and mutant RNAs (Fig. 3.11A). Although the
PBS is predicted to be unpaired in monomeric RNA, the pal PBS was only weakly
reactive, especially the second pal (5’ GGCGCC 3’), consistent with a role in
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page.

blue. The complete predicted structures of the wild type SA035 homodimer is shown in figure 3.8A. Figure continues on the following

RNAstructure predicted site of interaction (point of dimerization) between two wild type gRNAs. The central 6 nt of pal II are shown in

experiments. (B) Structure of the wild type and mutant SL4 domain in the SHAPE-constrained RNA model by RNAstructure (C) The

mutant RNAs. Blue boxes indicate pal II, ssPurines, and deletion/substitutions in pal II. Data are an average of at least three independent

FIGURE 3.10. Structural analysis of the SL4 domain of the pal II and PBS pal mutants. (A) SHAPE reactivity profile of the wild type and
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motif is shown after being constrained by SHAPE data.

SA035 SL2 domain structure and the nucleotides are color-coded according to SHAPE reactivity. (C) The mutant SA046 SL2 structural

on the x-axis of SA046 SHAPE reactivity profile indicate the site of deletion of the PBS pal sequence. (B) The SHAPE-validated wild type

mutant RNAs are presented as color-coded histograms. The blue boxes highlight the SL2 loop sequences and the 11 nt PBS pal. The dashes

FIGURE 3.11. Structural analysis of the SL2 domain of the pal II and PBS pal mutants. (A) The SHAPE reactivity of the wild type and
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RNA dimerization. The reactivity of this region was not affected by deletion or
substitutions in pal II (Fig. 3.11A, mutants SA042, SA043 and SA047),
suggesting the second pal within the PBS could perhaps mediate the residual RNA
dimerization observed with these mutants (Figs. 3.7, 3.9). In addition, deletion of
the 11 nt PBS pal (SA046) did not perturb the global folding of the SL2 domain
when compared to the wild type SA035 (compare Fig. 3.11B, C), as the SL2
apical loop is reactive in all RNAs. Thus, the diminished dimerization of mutant
SA051 (Fig. 3.7C) could not be attributed to RNA misfolding, but due to the
direct deletion of the PBS pal.
3.4.9. Structural prediction of pal II mutant dimers support dimerization
data
To establish a structural basis of the in vitro dimerization results, minimal
free energy models of the wild type and mutant MMTV RNA dimers were
predicted using RNAstructure. This software predicted that wild type RNA
dimerizes via the pal II sequence (Figs. 3.8A, 3.10C), while deletion of pal II
(SA042) induces dimerization via the PBS pal (Fig, 3.8B), in agreement with our
RNA dimerization and SHAPE data (Figs. 3.7, 3.9, 3.10, and 3.11). The predicted
structure of SA051 (deletion of 11 nt pal sequence within PBS), revealed that the
native structure (like wild type homodimer) was restored except for the loss of the
PBS loop (Fig. 3.8C) which could in part explain its ability to dimerize though
much less efficiently when compared to the wild type (Fig. 3.7B, C). The mutant
with simultaneous deletions of pal II and the PBS pal (SA046) was predicted to
dimerize via pal III (Fig. 3.8D), but according to our experimental data, this
mutant RNA dimerized weakly (Fig. 3.7B, C). Substitution mutants with nonpalindromic sequences in place of pal II (SA044 and SA045) were predicted to
dimerize via the PBS pal (Fig. 3.12A, B). Surprisingly and in good agreement
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leading to dimerization are boxed. PBS, primer binding site; ssPurines, single stranded purines.

SA045). The dimers were predicted using RNAstructure and the contact point of the sequences (point of dimerization) between two RNAs

FIGURE 3.12. Predicted homodimer (A-B) and heterodimer (C) structures of MMTV pal II trans-complementary mutants (SA044 and
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5’ ACGCAC 3’

ssPurines

SA044-SA045
heterodimer
ΔG = -313.9 kcal/mol

C

5’ GUGCGU 3’

ssPurines

PBS pal
5’ GGCGCC 3’

with our experimental data, these two mutant RNAs were predicted to form
heterodimers via the PBS pal rather than via their trans-complementary mutated
sequences (Fig. 3.12C).
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3.5. Discussion
In an attempt to enhance our understanding of the gRNA dimerization and
packaging processes during MMTV life cycle, we first validated the predicted
structure of MMTV packaging signal RNA employing SHAPE. The SHAPEvalidated structure was similar, but not identical to the Mfold-predicted structure.
An important feature revealed by SHAPE was a U5-Gag LRI, which was also
supported by phylogeny and in silico RNA structure predictions (Figs. 3.2, 3.3,
and 3.4). The U5-Gag LRI anchors the overall structure of MMTV packaging
signal RNA and is consistent with an earlier report showing that the MMTV
packaging sequence extends into gag (Mustafa et al., 2012). Similar LRIs exist in
the packaging signal RNAs of a number of retroviruses (Aktar et al., 2013;
Kenyon et al., 2008, 2011; Paillart et al., 2002; Song et al., 2008; Spriggs et al.,
2008) and in several cases, disruption of LRIs have been shown to affect RNA
dimerization and packaging (Paillart et al., 2002; Rizvi et al., 2010; Song et al.,
2008). In addition to LRI, SHAPE validated the existence of the SL2 and SL4
domains. The SL2 domain contains the PBS and the pal I sequence, and a similar
large SL2 domain is found in a number of other retroviral packaging signal RNAs
(Aktar et al., 2013; Baudin et al., 1993; Jaballah et al., 2010; Kenyon et al., 2008,
2011). The bifurcated SL4 hairpin contains a pal helix loop (pal II) and an
ssPurines loop (Fig. 3.2). Both SL2 and SL4 structures are conserved in all the 8
MMTV strains studied (Figs. 3.3, 3.4).
Retroviral gRNA dimerization has been suggested as a prerequisite for
packaging into the budding virions (reviewed in D’Souza & Summers, 2005;
Johnson & Telenitsky, 2010; Lever, 2007; Lu et al., 2011; Nikolaitchik et al.,
2013; Paillart et al., 2004; Russell et al., 2004). This process is usually initiated
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by conserved palindromic sequences that initiate kissing loop interactions (Aktar
et al., 2013; Berkhout & van Wamel, 1996; Kenyon et al., 2008, 2011; Lanchy et
al., 2003; Lanchy & Lodmell, 2007; Laughrea et al., 1997; Leitner et al.,
2005; Lever, 2007; Paillart et al., 1996a, 1996b, 2002; Rizvi et al., 2010; Russell
et al., 2004; Skripkin et al., 1994). The MMTV packaging signal RNA initially
revealed 3 pal sequences (pal I, pal II and pal III, Fig. 3.2). Our mutational
analysis clearly indicated that pal I is not involved in RNA dimerization and
packaging (Fig. 3.6). Nevertheless, pal I mutants had significant propagation
defects (Fig. 3.6), suggesting it is possible that mutations close to the PBS affect
annealing of the primer tRNA or initiation of reverse transcription itself. On the
other hand, mutational analysis revealed a key role of pal II in MMTV RNA
dimerization (Figs. 3.7, 3.9). However, mutations in pal II only reduced RNA
dimerization by twofold, rather than abrogating it. This observation led us to
identify an 11 nt sequence in the PBS consisting of two adjacent pals (PBS pal) as
also playing an important role in RNA dimerization (Fig. 3.7). Similarly, a pal
sequence within the PBS has also been shown to participate in HIV-2 RNA
dimerization (Jossinet et al., 2001; Lanchy & Lodmell, 2002). In the case of
MMTV, of these two pals, pal II exposed in an apical hairpin and harboring the
canonical “GC” dyad, likely functions as the DIS. Interestingly, deletion of either
pal II or the PBS pal has a pronounced effect on RNA packaging (even though
deletion of pal II is more dramatic), suggesting that the MMTV Gag precursor
initially recognizes an RNA dimer with two points of contacts (Fig. 3.7). The
overall 3D structure of the packaging domain would thus probably be important
for Gag binding. This could explain why deletion of 5’ UTR sequences predicted
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to form the basal part of SL2 abrogated MMTV gRNA packaging (Mustafa et al.,
2012).
A classical way of demonstrating the existence of any intermolecular
interaction between viral RNAs is by using trans-complementary mutants (Aktar
et al., 2013; Chen et al., 2009; Gavazzi et al., 2013; Jossinet et al., 2001; Paillart et
al., 1996b). In the present study, trans-complementary pal II mutants did not
restore either RNA dimerization or packaging (Fig. 3.9). This unexpected result
could be explained by misfolding of one of the mutants (SA045; Figs. 3.10B,
3.12B). These two mutants were predicted to form heterodimer via the PBS pal
rather than via their complementary mutated sequences (Fig. 3.12C). The results
obtained with these mutants stress the importance of performing structural
analyses on key RNA mutants; they also demonstrate that while the wild type
structure is very stable (Figs. 3.2C, 3.8A), alternative folds with potentially altered
biological functions are only marginally less stable. This could provide MMTV
the possibility to control key functions by RNA switches, as observed for other
retroviruses (Badorrek et al., 2006; Lu et al., 2011; Ooms et al., 2004; Paillart et
al., 2004). SHAPE analysis was also important for understanding the results
obtained with mutants SA043 and SA047 (in which pal II is replaced by the HIV1 pal without or with the flaking purines, respectively). Even though these two
mutants have a palindromic sequence in place of pal II, SHAPE indicated that the
intermolecular interactions are not mediated by the mutated sequences in the
absence of the flaking purines (Fig. 3.10), thus corroborating the RNA
dimerization data (Fig. 3.9). Although mutant SA047 displayed wild type RNA
dimerization levels, its RNA packaging and propagation were abolished (Fig. 3.9),
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suggesting that the pal II hairpin could also be involved in RNA-protein
interactions during genome encapsidation.
The presence of a stretch of purines in the packaging sequences on
retroviral gRNA has been proposed to facilitate RNA packaging by functioning as
a potential NC binding site (Lever, 2009; Moore & Hu, 2009; Paillart et al., 1997;
Zeffman et al., 2000). Thus, it is interesting to note that the bifurcated SL4
domain contains a purine loop (5’ GGAGAAGAG 3’) adjacent to the pal II helix
loop (Fig. 3.2), reminiscent to the situation found in MPMV (Aktar et al., 2013;
Jaballah et al., 2010). In the case of MPMV, genetic and structure-prediction
analyses have suggested that either ssPurines or its partial repeat base-paired
sequence in an adjacent region play a crucial role in gRNA packaging, possibly by
functioning as a NC binding site (Jaballah et al., 2010). Therefore, it will be
interesting to investigate the role of ssPurines in MMTV gRNA packaging. The
result presented in this study enhances our understanding of MMTV gRNA
dimerization and packaging processes and the role of structural motifs with
respect to RNA-RNA and possibly RNA-protein interactions that might be taking
place during MMTV life cycle.
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CHAPTER 4
Conclusions
and
Future Directions
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4.1. Conclusions
The main intent of the research presented in this dissertation was to
validate the predicted structures of MPMV and MMTV packaging signal RNAs
and to identify their DIS that plays an important role in augmenting the gRNA
dimerization and packaging processes.
Employing a combination of genetic and structural prediction analyses, our
laboratory has earlier shown that MPMV core packaging determinants (5’ UTR
and beginning of Gag) are discontinuous (50 bp long region “A” and 23 bp long
region “B”; Jaballah et al., 2010) and the intervening sequences are dispensable.
Jaballah et al., (2010) also predicted that the 5’ end of the MPMV RNA genome
folds into a RNA secondary structure. In the first part of this thesis (Chapter 2),
the predicted structure of the MPMV packaging signal RNA was validated using a
novel chemo-enzymatic approach known as SHAPE. SHAPE data of this region
validated the overall predicted structure comprising of five stem loop structures
(SL1-5). A very distinguishing feature of the SHAPE-validated structure of
MPMV packaging signal RNA is the two LRIs (LRI-I and LRI-II) involving
sequences from the U5 and first 70 nt of gag, which have been shown to be
important in MPMV RNA packaging (Jaballah et al., 2010; Schmidt et al., 2003).
Therefore, it is reasonable to propose that these two LRIs between U5 and gag
sequences could potentially play a role in MPMV RNA packaging by maintaining
the overall RNA secondary structure, as has recently been shown in the case of
FIV (Kenyon et al., 2008, 2011; Rizvi et al., 2010). Between SL2 and SL3, the
SHAPE-validated structure also confirmed the presence of a pal SL followed by a
stretch of ssPurine-rich region and these sequences have been shown to be
required for optimal MPMV gRNA packaging (Jaballah et al., 2010). The
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importance of the pal SL and ssPurine-rich sequences was further supported by
their conservation in different MPMV strains (Aktar et al., 2013). Since the pal
SL forms a helix loop containing a canonical “GC” dyad, it was hypothesized that
it may act as a RNA DIS and initiate the forming of a kissing loop complex, thus
facilitating MPMV to encapsidate two copies of its gRNAs. To prove the
hypothesis, a series of mutations were introduced into the pal SL and their
analyses revealed that any interruption of pal sequences affected RNA
dimerization severely, suggesting the crucial role of pal SL in MPMV gRNA
dimerization. To further validate these observations, the in vitro transcribed
RNAs from trans complementary pal mutants were incubated together to study
their effects on RNA dimerization. Results from these tran-complementary
approaches revealed that RNA dimerization was restored to wild type levels,
further authenticating that the pal loop (5’ CGGCCG 3’) functions as DIS
controlling MPMV gRNA dimerization.
In the second part of this thesis, presented in Chapter 3, SHAPE, structure
prediction and in silico analyses were employed to validate the higher-order
structure of MMTV packaging signal RNA which seems to be architecturally
anchored by complementary sequences in U5 and gag. Of these complementary
sequences gag sequences have earlier been shown to be crucial for MMTV gRNA
packaging (Mustafa et al., 2012), further validating the existence and potential
biological role of such LRI. We have also identified a 6 nt palindromic sequence
(pal II; 5’ CUGCAG 3’) that folds into a helix loop structural motif that is needed
for efficient MMTV gRNA dimerization and packaging. Employing a systematic
deletion and/or substitution, and trans-complementary mutational approaches
combined with structure predictions, our data convincingly reveal that pal II
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functions as DIS, which is capable of initiating and mediating loop-loop
intermolecular interaction to augment gRNA dimerization and packaging.
Sequence alignment and a consensus structure prediction of 8 MMTV strains
revealed that pal II primary sequence and its helix loop nature at the same location
is phylogenetically preserved, further authenticating its pivotal role as DIS both at
the primary sequence as well as at the structure level. In addition, another pal
sequence within the PBS was also identified and its mutational analysis revealed
its involvement in gRNA dimerization, suggesting that both pals are required for
efficient MMTV gRNA dimerization, packaging, and propagation.
Therefore, results presented in this thesis should enhance our
understanding of MPMV and MMTV gRNA dimerization and packaging
processes and the role of structural motifs with respect to RNA-RNA and possibly
RNA-protein interactions that might be taking place during MMTV life cycle.
4.2. Future Directions
Findings presented in this thesis on pal helix loop in the packaging signal
RNA of MPMV and MMTV suggest that these pal helix loops play important
roles in regulating MPMV and MMTV gRNA dimerization and packaging, yet the
intricacies underlying these mechanisms are not yet fully resolved. Thus, these
studies have opened new avenues for research which can be the subject of future
research projects. Some of these potential topics that could be addressed are as
follows:
1. It has been proposed that during retroviral gRNA dimerization, pal
loop-loop intermolecular interactions initiates a kissing loop dimer which leads to
further conformational changes in RNA secondary structure, exposing NC binding
sites making them accessible for interaction with gRNA to facilitate its packaging
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(D’Souza & Summers, 2004; Johnson & Telenitsky, 2010; Lu et al., 2011). The
presence of a stretch of purines in the packaging sequences on retroviral gRNA
has been proposed to facilitate RNA packaging by functioning as a potential NC
binding site (Lever, 2009; Moore et al., 2009; Paillart et al., 1997; Zeffman et al.,
2002). Consistent with these observations, a distinguishing feature of the
SHAPE-validated structures of MPMV and MMTV packaging signal RNAs is the
prominent stretch of ssPurines in the close vicinity of pal helix loops that have
been identified as DIS. In the case of MPMV, a partial base-paired repeat
sequence of the ssPurines was observed in the adjacent region that had earlier
been shown to be important in MPMV gRNA packaging (Jaballah et al., 2010).
Deletion mutants containing the region encompassing ssPurines showed an
interesting structure folding prediction in which the stretch of duplicated basepaired purines became single stranded, restoring gRNA packaging significantly as
well as the RNA secondary structure to that of the wild type (Jaballah et al.,
2010). Since the overall predicted secondary structure and packaging was
restored only in mutants in which duplicated base-paired purines became single
stranded (the stretch of duplicated purines compensated for the conformational
structure that would have been lost with the deletion of the ssPurines), it is
reasonable to hypothesize that a stretch of native ssPurines or alternate purines in
MPMV function either at the primary sequence, structural or both levels in
mediating gRNA packaging, possibly by functioning as a potential NC binding
site. Therefore, it would be interesting to substitute the single stranded purines
with an alternate sequence, with and without altering the purine content, and
observe their effects on MPMV and MMTV gRNA packaging both at the primary
sequence as well as at the structural levels.
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2. In a number of retroviruses such as HIV-1 and FIV, LRIs between
complementary U5 and Gag sequences have been identified in their packaging
signal RNAs (Aktar et al., 2013; Kenyon et al., 2008, 2011; Paillart et al., 2002;
Song et al., 2008; Spriggs et al., 2008). Such an LRI, in the case of FIV, has
recently been shown to have biological relevance during FIV gRNA packaging by
providing the stability to the overall RNA secondary structure (Rizvi et al., 2010).
The SHAPE-validated structures of MPMV and MMTV packaging signal RNAs
also predict LRIs between U5 and Gag complementary sequences. Existence of
such LRIs in these retroviruses was further supported by in silico analyses of
different strains. In light of the results presented in this thesis, it is reasonable to
propose that the U5 and gag complementary sequences involved in LRI could
either function at the primary sequence level or at a structure level during MPMV
and MMTV RNA packaging processes. Therefore, it will be important to ascertain
the existence as well as biological significance of the LRIs during MPMV and
MMTV gRNA packaging.
3. The SHAPE-validated structural models of MPMV and MMTV
packaging signal RNAs revealed the presence of a large SL2 which has been
shown to be conserved in a number of other retroviral packaging signal RNAs
(Baudin et al., 1993; Kenyon et al., 2008, 2011). Consistent with this observation,
Mfold structural predictions of different MPMV and MMTV strains have revealed
the conservation of SL2 suggesting that such a structural motif could be of vital
importance during MPMV and MMTV replication. Therefore, it will be
interesting to mutate SL2 using different using different types of mutations
(deletion, substitution, compensatory, etc.) to determine the importance of the
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sequences involved in base pairing of SL2 in MPMV and MMTV gRNA
packaging.

158

References

159

1.

Abbink, T.E., & Berkhout, B. (2003). A novel long distance base-pairing
interaction in human immunodeficiency virus type 1RNA occludes the
Gag start codon. J. Biol. Chem., 278, 11601–11611.

2.

Aktar, S.J., Jabeen, A., Ali, L.M., Vivet-Boudou, V., Marquet, R., & Rizvi,
T.A. (2013). SHAPE analysis of the 5' end of the Mason-Pfizer monkey
virus (MPMV) genomic RNA reveals structural elements required for
genome dimerization. RNA, 19, 1648-1658.

3.

Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., & Walter, P.(ed).
(2002). Control of gene expression, Molecular Biology of the Cell. 4th
Edition. Garland Science Publishing. N. Y. and London.

4.

Allan, J. S., Coligan, J. E., Barin, F., McLane, M. F., Sodroski, J. G.,
Rosen, C. A., Haseltine, W. A., Lee, T. H., & Essex, M. (1985). Major
glycoprotein antigens that induce antibodies in AIDS patients are encoded
by HTLV-III. Science, 228, 1091-1094.

5.

Al Dhaheri, N.S., Phillip, P.S., Ghazawi, A., Ali,J., Beebi, E., Jaballah,
S.A., & Rizvi,T.A. (2009). Cross-packaging of genetically distinct mouse
& primate retroviral RNAs. Retrovirology, 6, 66.

6.

Al Shamsi, I.R., Al Dhaheri, N.S., Phillip, P.S., Mustafa, F., & Rizvi, T.A.
(2011). Reciprocal cross-packaging of primate lentiviral (HIV-1 & SIV)
RNAs by heterologous non-lentiviral MPMV proteins. Virus Res., 155,
352-357.

7.

Andersen, E.S., Jeeninga, R. E., Damgaard, C.K., Berkhout, B., & Kjems,
J. (2003). Dimerization and template switching in the 5′ untranslated
region between various subtypes of human immunodeficiency virus type 1.
J. Virol., 77, 3020-3030.

8.

Anderson, E. C., & Lever, A. M. (2006). Human immunodeficiency virus
type 1 Gag polyprotein modulates its own translation. J. Virol., 80, 1047810486.

9.

Badorrek, C. S., Gherghe, C. M., & Weeks, K. M. (2006). Structure of an
RNA switch that enforces stringent retroviral genomic RNA dimerization.
Proc. Natl. Acad. Sci. USA., 103, 13640-13645.

10.

Baig, T. T., Lanchy, J. M., & Lodmell, J. S. (2007). HIV-2 RNA
dimerization is regulated by intramolecular interactions in vitro. RNA, 8,
1341-1354.

11.

Balakrishnan, M., Fay, P.J., & Bambara, R.A. (2001). The kissing hairpin
sequence promotes recombination within the HIV-I 5′ leader region. J.
Biol. Chem., 276, 36482-36492.

12.

Balakrishnan, M., Roques, B.P., Fay, P.J., & Bambara, R.A. (2003).
Template dimerization promotes an acceptor invasion-induced transfer
160

mechanism during human immunodeficiency virus type 1 minus-strand
synthesis. J. Virol., 77, 4710-4721.
13.

Baltimore, D. (1970). RNA-dependent DNA polymerase in virions of
RNA tumor viruses. Nature, 226, 1209–1211.

14.

Balvay, L., Lopez Lastra, M., Sargueil, B., Darlix, J. L., & Ohlmann, T.
(2007). Translational control of retroviruses. Nat Rev Microbiol., 5, 128-40.

15.

Baudin, F., Marquet, R., Isel, C., Darlix, J. L., Ehresmann, B., &
Ehresmann, C. (1993). Functional sites in the 5' region of human
immunodeficiency virus type 1 RNA form defined structural domains. J.
Mol. Biol., 229, 382-397.

16.

Bellaousov, S., Reuter, J.S., Seetin, M.G., & Mathews, D.H. (2013).
RNAstructure: web servers for RNA secondary structure prediction and
analysis. Nucleic Acids Res. 41, W471-W474.

17.

Bender, W., Chien, Y. H., Chattopadhyay, S., Vogt, P. K., Gardner, M. B.,
& Davidson, N. (1978). High-molecular-weight RNAs of AKR, NZB and
wild mouse viruses and avian reticuloendotheliosis virus all have similar
dimer structures. J. Virol., 25, 888-896.

18.

Berkhout, B., & van Wamel, J.L. (1996). Role of the DIS hairpin in
replication of human immunodeficiency virus type 1. J. Virol., 70, 67236732.

19.

Berkowitz, R. D., Ohagen, A., Höglund, S., & Goff, S. P. (1995).
Retroviral nucleocapsid domains mediate the specific recognition of
genomic viral RNAs by chimeric Gag polyproteins during RNA packaging
in vivo. J. Virol., 69, 6445-6456.

20.

Bernhart, S.H., Hofacker, I.L., Will, S., Gruber, A.R., & Stadler, P.F.
(2008). RNAalifold: improved consensus structure prediction for RNA
alignments. BMC Bioinformatics, 9, 1471-2105.

21.

Bray, M., Prasad, S., Dubay, J.W., Hunter, E., Jeang, K. T., Rekosh, D., &
Hammarskjöld, M. L. (1994). A small element from the Mason-Pfizer monkey
virus genome makes human immunodeficiency virus type 1 expression and
replication Rev-independent. Proc Natl Acad Sci USA 91, 1256-1260.

22.

Brierley, I., & Dos Ramos, F.J. (2006). Programmed ribosomal
frameshifting in HIV-1 and the SARS-CoV. Virus Res., 119, 29-42.

23.

Browning, M. T., Mustafa, F., Schmidt, R. D., Lew, K. A., Rizvi, T.A.
(2003a) Delineation of sequences important for efficient FIV RNA
packaging. J. Gen. Virol. 84, 621–627.

24.

Browning, M. T., Mustafa, F., Schmidt, R. D., Lew, K. A., Rizvi, T. A.
(2003b) Sequences within the gag gene of feline immunodeficiency virus
161

(FIV) are important for efficient RNA encapsidation. Virus. Res. 93, 199–
209.
25.

Butsch, M., & Boris-Lawrie, K.. (2000). Translation is not required To
generate virion precursor RNA in human immunodeficiency virus type 1infected T cells. J. Virol., 74, 11531-11537.

26.

Cardiff, R.D., & Kenney,N. (2007). Mouse Mammary Tumor Biology: A
Short History. Adv. Cancer Res., 98, 53-116.

27.

Chamanian, M., Purzycka, K.J., Wille, P.T., Ha, J.S., McDonald, D., Gao,
Yong., Le Grice, S.F.J., & Arts, E.J. (2013). A cis-acting element in
retroviral genomic RNA links Gag-Pol ribosomal frameshifting to
selective viral RNA encapsidation. Cell host microbe, 13, 181-192.

28.

Chen, J., Nikolaitchik, O., Singh, J., Wright, A., Bencsics, C. E., Coffin, J.
M., Ni, N., Lockett, S., Pathak, V. K., & Hu, W. S. (2009). High efficiency
of HIV-1 genomic RNA packaging and heterozygote formation revealed
by single virion analysis. Proc. Natl. Acad. Sci.USA., 106, 13535-13540.

29.

Chin, M. P., Rhodes, T. D., Chen, J., Fu, W., & Hu, W. S. (2005).
Identification of a major restriction in HIV-1 intersubtype recombination.
Proc. Natl Acad. Sci., 102, 9002-9007.

30.

Cho, K., Ferrick, D. A., & Morris, D.W. (1995). Structure and biological
activity of the subgenomic Mtv-6 endogenous provirus. Virology, 206,
395-402.

31.

Choi, Y., Kappler, J.W., & Marrack, P. A. (1991). superantigen encoded in
the open reading frame of the 3' long terminal repeat of mouse mammary
tumour virus. Nature, 350, 203 207.

32.

Clever,J. L., Wong,M. L., & Parslow,T. G. (1996) Requirements for
kissing-loop-mediated dimerization of human immunodeficiency virus
RNA. J. Virol., 70, 5902-5908.

33.

Coffin, J. M. (1992). Structure and classification of retroviruses, p. 19-49.
In J. A. Levy (ed.), The Retroviridae, Plenum Press, New York, NY.

34.

Coffin, J. M. (1996). Retroviridae: the viruses and their replication, pp
1767-1846. In B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J.
L. Melnick, T. P. Monath, B. Roizman, and S. E. Straus (ed.), Fields
Virology, 3rd edition. Lippincott-Raven Publishers, Philadelphia, PA.

35.

Cullen, B. R., & Greene, W. C. (1990). Functions of the auxiliary gene
products of the human immunodeficiency virus type 1.Virology, 178, 1-5

36.

Darlix, J. L., Gabus, C., Nugeyre, M. T., Clavel, F., & Barre-Sinoussi, F.
(1990). Cis elements and trans-acting factors involved in the RNA
162

dimerization of the human immunodeficiency virus HIV-1. J. Mol. Biol,
216, 689-699.
37.

Darlix, J. L., Lapadat-Tapolsky, M., de Rocquigny, H., & Roques, B. P.
(1995). First glimpses at structure-function relationships of the
nucleocapsid protein of retroviruses. J. Mol. Biol., 254, 523-537.

38.

Dayton, A. I., Sodroski, J. G., Rosen, C. A., Goh, W. C., Haseltine, W. A.
(1986). The trans-activator gene of the human T cell lymphotropic virus
type III is required for replication. Cell, 44, 941-947

39.

Dey, A., York, D., Smalls-Mantey, A., & Summers, M. F. (2005).
Composition and sequence-dependent binding of RNA to the nucleocapsid
protein of Moloney murine leukemia virus. Biochemistry, 44, 3735-3744.

40.

Dorman, N., & Lever, A. (2000). Comparison of viral genomic RNA
sorting mechanisms in human immunodeficiency virus type 1 (HIV-1),
HIV-2, and Moloney murine leukemia virus. J. Virol., 74, 11413-7.

41.

D’Souza, V., & Summers, M. F. (2004). Structural basis for packaging the
dimeric genome of Moloney murine leukemia virus. Nature, 431, 586–590.

42.

D’Souza, V., & Summers, M. F. (2005). How retroviruses select their
genomes. Nat. Rev. Microbiol., 8, 643-655.

43.

Ennifar, E., Paillart, J.C., Marquet, R., Ehresmann, B., Ehresmann, C.,
Dumas, P., & Walter, P. (2003). “HIV-1 RNA dimerization initiation site
is structurally similar to the ribosomal A site and binds aminoglycoside
antibiotics.” J. Biol. Chem., 278, 2723-2730.

44.

Ennifar, E., Paillart, J. C., Bodlenner, A., Walter, P., Weibel, J. M.,
Aubertin, A. M., Pale, P., Dumas, P., & Marquet, R. (2006). “Targeting
the dimerization initiation site of HIV-1 RNA with aminoglycosides: from
crystal to cell.” Nucleic Acids Res., 34, 2328-2339.

45.

Fasel, N., Buetti, E., Firzlaff, J., Pearson, K., & Diggelmann, H. (1983)
Nucleotide sequence of the 5' noncoding region and part of the gag gene of
mouse mammary tumor virus; identification of the 5' splicing site for
subgenomic mRNAs. Nucleic Acids Res., 11, 6943-6955.

46.

Fisher, A. G., Feinberg, M. B., Josephs, S. F., Harper, M. E., Marselle, L.
M., Reyes, G., Gonda, M. A., Aldovini, A., Debouk, C., Gallo, R. C., et al.
(1986) The trans-activator gene of HTLV-III is essential for virus
replication. Nature, 320, 367-371.

47.

Frankel, A. D., Young, J. A. (1998). HIV-1: fifteen proteins and an RNA.
Annu Rev Biochem, 67, 1-25

163

48.

Frankel, W. N., Rudy, C., Coffin, J. M., & Huber, B. T. (1991). Linkage of
Mls genes to endogenous mammary tumour viruses of inbred mice. Nature
349, 526-528.

49.

Frecha, C., Lévy, C., Cosset, F. L., & Verhoeyen, E. (2010) Advances in the
field of lentivector-based transduction of T and B lymphocytes for gene
therapy. Mol Ther, 18, 1748-1757.

50.

Fu, W., & Rein, A. (1993). Maturation of dimeric viral RNA of Moloney
murine leukemia virus. J Virol, 67, 5443-5449.

51.

Gao, G., X. Guo, & S. P. Goff. (2002). Inhibition of retroviral RNA
production by ZAP, a CCCH-type zinc finger protein. Science, 297, 1703–
1706.

52.

Garcia, J. A., Harrich, D., Soultanakis, E., Wu, F., Mitsuyasu, R., Gaynor, R.
B. (1989). Human immunodeficiency virus type 1 LTR TATA and TAR
region sequences required for transcriptional regulation. EMBO. J., 8, 765778.

53.

Gavazzi, C., Yver, M., Isel, C., Smyth, R. P., Rosa-Calatrava, M., Lina, B.,
Moulès, V., & Marquet, R. (2013). A functional sequence-specific
interaction between influenza A virus genomic RNA segments. Proc. Natl
Acad.Sci.USA, 110, 16604-16609.

54.

Ghazawi, A., Mustafa, F., Phillip, P. S., Jayanth, P., Ali, J., & Rizvi, T. A.
(2006) Both the 5' and 3' LTRs of FIV contain minor RNA encapsidation
determinants compared to the two core packaging determinants within the
5' untranslated region and gag. Microbes Infect., 8, 767-78.

55.

Gibbs, J. S., Regier, D. A., & Desrosiers, R. C. (1994) Construction and in
vitro properties of SIV mac mutants with deletions in "nonessential" genes.
AIDS Res. Hum. Retrovirus, 10, 607-616.

56.

Goff, S. P. (2001). Retroviridae: The viruses and their replication, p. 843913. In D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb, M.A. Martin,
B. Roizman, and S.E. Straus (ed.), Fundamental Virology. 4th ed.
Lippincott Williams & Williams, Philadelphia, PA.

57.

Goff, S. P., (2004). Retrovirus restriction factors. Mol. Cell, 16, 849-859.

58.

Gong, Y. S., Zhang, K. L., Jiang, X. G, Wang, Z. W., Sun, Z. Q., & Cai, J.
(2007). Retroviral gene transfer of tissue-type plasminogen activator targets
thrombolysis in vitro and in vivo. Gene Ther., 14, 1537-42.

59.

Goujon, M., McWilliam, H., Li, W., Valentin, F., Squizzato, S., Paern, J.,
& Lopez, R. (2010). A new bioinformatics analysis tools framework at
EMBL-EBI. Nucleic Acids Res., 38, (Web Server issue):W695-9. doi:
10.1093/nar/gkq313.
164

60.

Greatorex, J. (2004). The retroviral RNA dimer linkage: different
structures may reflect different roles. Retrovirology, 18, 1–22.

61.

Green, L. M., & Berg, J. M. (1989). A retroviral Cys-Xaa2-Cys-Xaa4-HisXaa4-Cys peptide binds metal ions: spectroscopic studies and a proposed
three-dimensional structure. Proc Natl Acad Sci USA., 86, 4047-4051.

62.

Griffin, S. D. C., Allen, J. F., & Lever, A. M. L. (2001). The major human
immunodeficiency virus type 2 (HIV-2) packaging signal is present on all
HIV-2 RNA species: cotranslational RNA encapsidation and limitation of
gag protein confer specificity. J. Virol., 75, 12058-12069.

63.

Guan, Y., Whitney, J. B., Diallo, K., & Wainberg, M. A. (2000). Leader
sequences downstream of the primer binding site are important for
efficient replication of simian immunodeficiency virus. J.Virol, 74, 8854–
8860.

64.

Guan, Y., Whiteny, J. B., Liang, C., & Wainberg, M. A. (2001). Novel,
live attenuated simian immunodeficiency virus constructs containing
major deletions in leader RNA sequences. J. Virol., 75, 2776–2785.

65.

Guesdon, F. M. J., Greatorex, J., Rhee, S. R., Fisher, R., Hunter, E., &
Lever, A. M. L. (2001). Sequences in the 5’ leader of Mason-Pfizer
monkey virus which affect viral particle production and genomic RNA
packaging: development of MPMV packaging cell lines. Virology, 288,
81-88.

66.

Haddrick, M., Lear, A. L., Cann,A. J., & Heaphy, S. (1996). Evidence that
a kissing loop structure facilitates genomic RNA dimerization in HIV-1. J.
Mol. Biol., 259, 58-68.

67.

Ham, J., Thomson, A., Needham, M., Webb, P., & Parker, M. (1988).
Characterization of response elements for androgens, glucocorticoids and
progestins in mouse mammary tumour virus. Nucleic Acids Res, 16, 52635276.

68.

Harrison, G. P., Hunter, E., & Lever, A. M. L. (1995). Secondary structure
model of the Mason-Pfizer monkey virus 5’ leader sequence: identification
of a structural motif common to a variety of retroviruses. J. Virol., 69,
2175-2186.

69.

Heilbronn, R., & Weger, S. (2010). Viral vectors for gene transfer: current
status of gene therapeutics. Handb Exp Pharmacol, 197, 143-170.

70.

Heistad, D. D. (2001). Gene transfer to blood vessels: a research tool and
potential therapy. Am J Hypertens, 14, 28S-32S.

71.

Henderson, L. E., Copeland, T. D., Sowder, R. C., Smythers, G. W., &
Oroszlan, S. (1981). Primary structure of the low molecular weight nucleic
165

acid-binding proteins of murine leukemia viruses. J. Biol. Chem., 256, 84008406.
72.

Herzog, R. W., Cao, O., & Srivastava, A. (2010). Two decades of clinical gene
therapy-success is finally mounting. Discov Med, 9,105-111.

73.

Heng, X., Kharytonchyk, S., Garcia, E. L., Lu, K., & Divakaruni, S. S. (2012)
Identification of a minimal region of the HIV-1 59 leader required for RNA
dimerization, NC binding, and packaging. J. Mol. Biol., 417, 224–239.

74.

Hibbert, C. S., Mirro, J., & Rein, A. (2004). mRNA molecules containing
murine leukemia virus packaging signals are encapsidated as dimers. J.
Virol., 78, 10927-10938.

75.

Hofacker, I. L., Fekete, M., & Stadler, P. F. (2002). Secondary Structure
Prediction for Aligned RNA Sequences. J. Mol. Biol., 319, 1059-1066.

76.

Hook, L. M., Agafonova, Y., Ross, S. R., Turner, S. J., & Golovkina, T. V.
(2000). Genetics of mouse mammary tumor virus-induced mammary
tumors: linkage of tumor induction to the gag gene. J. Virol., 74, 88768883.

77.

Houzet, L., Paillart, J. C., Smagulova, F., Maurel, S., Morichaud, Z.,
Marquet, R. & Mougel, M. (2007). HIV controls the selective packaging
of genomic, spliced viral and cellular RNAs into virions through different
mechanisms. Nucleic Acids Res., 35, 2695-2704.

78.

Hussein, I. T. M., Ni, N., Galli, A., Chen, J., Moore, M. D., & Hu, W. S.
(2010). Delineation of the preferences and requirements of the human
immunodeficiency virus type 1 dimerization initiation signal by using an
in vivo cell-based selection approach. J. Virol., 84, 6866-6875.

79.

Hu, B., Tai, A., & Wang, P. (2011). Immunization Delivered by Lentiviral
Vectors for Cancer and Infectious Diseases. Immunol Rev., 239, 45-61.

80.

Indik, S., Gunzburg, W. H., Salmons, B., & Rouault, F. (2005). A novel,
mouse mammary tumor virus encoded protein with Rev-like properties.
Virology, 337, 1-6.

81.

Jaballah, S. A., Aktar, S. J., Ali, J., Phillip, P. S., Al Dhaheri, N. S., Jabeen,
A., & Rizvi, T. A. (2010). A G-C rich palindromic structural motif and a
stretch of single stranded purines are required for optimal packaging of
Mason-Pfizer monkey virus (MPMV) genomic RNA. J. Mol. Biol., 401,
996-1014.

82.

Jakobovits, A., Smith, D. H., Jakobovits, E. B., Capon, D. J. (1988). A
discrete element 3' of human immunodeficiency virus 1 (HIV-1) and HIV2 mRNA initiation sites mediates transcriptional activation by an HIV
trans activator. Mol Cell Biol, 8, 2555-2561.

166

83.

Johnson, S. F., & Telesnitsky, A. (2010). Retroviral RNA dimerization and
packaging: the what, how, when, where, and why. PLoS Pathog., 6,
e1001007.

84.

Jossinet, F., Lodmell, J. S., Ehresmann, C., Ehresmann, B., & Marquet, R.
(2001). Identification of the in vitro HIV-2/SIV RNA dimerization site
reveals striking differences with HIV-1. J. Biol. Chem. 276, 5598-5604.

85.

Jouvenet, N., Lainé, S., Pessel-Vivares, L., & Mougel, M. (2011). Cell biology
of retroviral RNA packaging. RNA Biol., 8, 572–580.

86.

Kawase, Y., Ladage, D., & Hajjar, R. J. (2011). Method of gene delivery in
large animal models of cardiovascular diseases. Methods Mol. Biol., 709, 35567.

87.

Kaye, J. F., & Lever, A. M. (1999) Human immunodeficiency virus types 1
and 2 differ in the predominant mechanism used for selection of genomic
RNA for encapsidation. J Virol., 73, 3023-3031.

88.

Kenyon, J. C., Ghazawi, A., Cheung, W. K., Phillip, P. S., Rizvi, T. A., &
Lever, A. M. (2008). The secondary structure of the 5’ end of the FIV
genome reveals a long-range interaction between R/U5 and gag sequence,
and a large, stable stem loop. RNA, 14, 2597.

89.

Kenyon, J. C., Tanner, S., Legiewicz, M., Phillip, P. S., Rizvi, T. A.,
LeGrice, S., & Lever, A. M. (2011). SHAPE analysis of the FIV leader
RNA reveals a structural switch potentially controlling viral packaging and
genome dimerization. Nucleic Acids Res., 39, 6692-6704.

90.

Klein, R., Ruttkowski, B., Schwab, S., Peterbauer, T., Salmons, B., Günzburg,
W. H., & Hohenadl, C. (2008). Mouse mammary tumor virus promotercontaining retroviral promoter conversion vectors for gene-directed enzyme
prodrug therapy are functional in vitro and in vivo. J. Biomed. Biotechnol.,
2008:683505.

91.

Kowalski, M., Potz, J., Basiripour, L., Dorfman, T., Goh, W. C., Terwilliger,
E., Dayton, A., Rosen, C., Haseltine, W., Sodroski, J. (1987). Functional
regions of the envelope glycoprotein of human immunodeficiency virus type 1.
Science, 237, 1351-1355

92.

Kuzembayeva, M., Dilley, K., Sardo, L., & Hu, W. S. (2014). Life of psi:
How full-length HIV-1 RNAs become packaged genomes in the viral
particles. Virology, doi: 10.1016/j.virol.2014.01.019. (Epub ahead of print).

93.

Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., &
Hendrickson, W. A. (1998). Structure of an HIV gp120 envelope
glycoprotein in complex with the CD4 receptor and a neutralizing human
antibody. Nature, 393, 648-59.

167

94.

Lanchy, J. M., & Lodmell, J. S. (2002). Alternate usage of two
dimerization initiation sites in HIV-2 viral RNA in vitro. J. Mol. Biol., 319,
637-648.

95.

Lanchy, J. M., Ivanovitch, J. D., & Lodmell, J. S. (2003). A structural
linkage between the dimerization and encapsidation signals in HIV-2
leader RNA. RNA, 9, 1007-1018.

96.

Lanchy, J. M., & Lodmell, J. S. (2007). An extended stem-loop 1 is
necessary for human immunodeficiency virus type 2 replication and
affects genomic RNA encapsidation. J. Virol., 7, 3285-3292.

97.

Laughrea, M., Jetté, L., Mak, J., Kleiman, L., Liang, C., & Wainberg, M.
A. (1997). Mutations in the kissing-loop hairpin of human
immunodeficiency virus type 1 reduce viral infectivity as well as genomic
RNA packaging and dimerization. J. Virol., 71, 3397-3406.

98.

Lever, A. M. L. (2007). HIV RNA packaging. Adv. Pharmacol., 55, 1-32.

99.

Lever, A. M. L. (2009). RNA packaging in lentiviruses. Retrovirology, 6,
113.

100.

Lecellier, C. H., Dunoyer, P., Arar, K., Lehmann-Che, J., Eyquem, S.,
Himber, C., Saïb, A., & Voinnet, O. (2005). A cellular microRNA
mediates antiviral defense in human cells. Science, 308, 557-560.

101.

Leitner, T., Foley, B., Hahn, B., Marx, P., McCutchan, F., Mellors, J.,
Wolinsky, S., & Korber, B. (2005). HIV sequence compendium.
Theoretical Biology and Biophysics Group, Los Alamos National
Laboratory, NM, LA-UR 06-0680.

102.

Lodmell, J. S., Ehresmann, C., Ehresmann, B., & Marquet, R. (2000).
“Convergence of natural and artificial evolution on an RNA loop-loop
interaction: The HIV-1 dimerization initiation site.” RNA, 6, 1267-1276.

103.

Lodmell, J. S., Ehresmann, C., Ehresmann, B., & Marquet, R. (2001).
“Structure and dimerization of HIV-1 kissing loop aptamers.” J. Mol. Biol.,
311, 475-490.

104.

Lu, K., Heng, X., & Summers, M. F. (2011a). Structural determinants and
mechanism of HIV-1 genome packaging. J. Mol. Biol., 410, 609-633.

105.

Lu, K., Heng, X., Garyu, L., Monti, S., Garcia, E. L., Kharytonchyk, S.,
Dorjsuren, B., Kulandaivel, G., Jones, S., Hiremath, A., Divakaruni, S. S.,
LaCotti, C., Barton, S., Tummillo, D., Hosic, A., Edme, K., Albrecht, S.,
Telesnitsky, A., & Summers, M. F. (2011b). NMR detection of structures
in the HIV-1 5'-leader RNA that regulate genome packaging. Science, 334,
242-245.

168

106.

Ly, H. Q., Kawase, Y., & Hajjar, R. J.(2008). Advances in gene-based therapy
for heart failure. J. Cardiovasc. Transl. Res., 1, 127-136.

107.

Ly, H., Kawase, Y., Yoneyama, R., & Hajjar, R. J. (2007). Gene therapy in the
treatment of heart failure. Physiology, 22, 81-96.

108.

Lyon, A. R., Sato, M., Hajjar, R. J., Samulski, R. J., & Harding, S. E. (2008).
Gene therapy: targeting the myocardium. Heart, 94, 89-99.

109.

Mangasarian, A., & Trono, D. (1997) The multifaceted role of HIV Nef. Res.
Virol., 148, 30-33.

110.

Marquet, R., Baudin, F., Gabus, C., Darlix, J. L., Mougel, M., Ehresmann,
C., & Ehresmann, B. (1991). Dimerization of human immunodeficiency
virus (type 1) RNA: stimulation by cations and possible mechanism.
Nucleic Acids Res., 9, 2349-2357.

111.

Marracci, G. H., Kelley, R. D., Pilcher, K. Y., Crabtree, L., Shiigi, S. M.,
Avery, N., Leo, G., Webb, M. C., Hallick, L. M., Axthelm, M. K., &
Machida, C.A. (1995). Simian AIDS type D serogroup 2 retrovirus:
isolation of an infectious molecular clone and sequence analyses of its
envelope glycoprotein gene and 3' long terminal repeat. J. Virol., 69, 26212628.

112.

Marsh, J. L., Erfle, M., & Wykes, E. J. (1984). The pIC plasmid and phage
vectors with versatile cloning sites for recombinant selection by insertional
inactivation. Gene, 32, 481-485.

113.

Mathews, D. H., Sabina, J., Zuker, M., & Turner, D. H. (1999). Expanded
sequence dependence of thermodynamic parameters improves prediction
of RNA secondary structure. J. Mol. Biol., 288, 911-940.

114.

McBride, M. S., & Panganiban, A. T. (1997). Position dependence of
functional hairpins important for human immunodeficiency virus type 1
encapsidation in vivo. J. Virol., 71, 2050-2058.

115.

McDougal, J. S., Kennedy, M. S., Sligh, J. M., Cort, S. P., Mawle, A.,
Nicholson, J. K. (1986). Binding of HTLV-III/LAV to T4+ T cells by a
complex of the 110K viral protein and the T4 molecule. Science, 231, 382385.

116.

Medina, D. (2010). Of mice and women: A short history of mouse
mammary cancer research with an emphasis on the paradigms inspired by
the transplantation method. Cold Spring Harb. Perspect. Biol., 2, a004523.

117.

Mehle, A., Strack, B., Ancuta, P., Zhang, C., McPike, M., & Gabuzda, D.
(2004). Vif overcomes the innate antiviral activity of APOBEC3G by
promoting its degradation in the ubiquitinproteasome pathway. J. Biol.
Chem., 279, 7792-7798.
169

118.

Merino, E. J., Wilkinson, K. A., Coughlan, J. L., & Weeks, K. M. (2005).
RNA structure analysis at single nucleotide resolution by selective 2’hydroxyl acylation and primer extension (SHAPE). J. Am. Chem. Soc., 127,
4223-4231.

119.

Mertz, J. A., Simper, M. S., Lozano, M. M., Payne, S. M., & Dudley, J. P.
(2005). Mouse mammary tumor virus encodes a self-regulatory RNA
export protein and is a complex retrovirus. J. Virol., 79, 14737-14747.

120.

Mertz, J. A., Lozano, M. M., & Dudley, J. P. (2009a). Rev and Rex
proteins of human complex retroviruses function with the MMTV Remresponsive element. Retrovirology, 6, 10.

121.

Mertz, J. A., Chadee A. B., Byun, H., Russell, R., Dudley, J. P.(2009b).
Mapping of the functional boundaries and secondary structure of the
mouse mammary tumor virus Rem-responsive element. J. Biol. Chem.,
284, 25642-25652.

122.

Meyer, B. E., Malim, M. H. (1994). The HIV-1 Rev trans-activator
shuttles between the nucleus and the cytoplasm. Genes Dev., 8, 15381547.

123.

Mikkelsen, J. G., Lund, A. H., Kristensen, K. D., Duch, M., Sørensen, M.
S., Jørgensen, P., & Pedersen, F. S. (1996). A preferred region for
recombinational patch repair in the 5' untranslated region of primer
binding site-impaired murine leukemia virus vectors. J. Virol., 70, 1439-47.

124.

Miyazaki, Y., Miyake, A., Nomaguchi, M., & Adachi, A. (2011).
Structural dynamics of retroviral genome and the packaging. Frontiers in
Microbiology, 2, 1-9.

125.

Moore, M. D., Fu, W., Nikolaitchik, O., Chen, J., Ptak, R. G., & Hu, W. S.
(2007). Dimer initiation signal of human immunodeficiency virus type 1:
its role in partner selection during RNA copackaging and its effects on
recombination. J. Virol. 81, 4002-4011.

126.

Moore, M. D., Nikolaitchik, O. A., Chen, J., Hammarskjöld, M. L.,
Rekosh, D., & Hu, W.S. (2009). Probing the HIV-1 genomic RNA
trafficking pathway and dimerization by genetic recombination and single
virion analyses. PLoS Pathog., 5, e1000627.

127.

Moore, M. D., & Hu, W. S. (2009). HIV-1 RNA dimerization: It takes two
to tango. AIDS Rev., 11, 91-102.

128.

Moore, R., Dixon, M., Smith, R., Peters, G., & Dickson, C. (1987).
Complete nucleotide sequence of a milk-transmitted mouse mammary
tumor virus: two frameshift suppression events are required for translation
of gag and pol. J. Virol.,61, 480-490.

170

129.

Mortimer, S. A., & Weeks, K. M. (2007). A fast-acting reagent for
accurate analysis of RNA secondary and tertiary structure by SHAPE
chemistry. J. Am. Chem. Soc., 129, 4144-4145.

130.

Mortimer, S. A., & Weeks, K. M. (2009). Time-resolved RNA SHAPE
chemistry: quantitative RNA structure analysis in one-second snapshots
and at single-nucleotide resolution. Nat. Protoc., 4, 1413-21.

131.

Motomura, K., Chen, J., & Hu, W. S. (2008). Genetic recombination
between human immunodeficiency virus type 1 (HIV-1) and HIV-2, two
distinct human lentiviruses. J. Virol., 82, 1923-1933.

132.

Müllner, M., Salmons, B., Günzburg, W. H., & Indik, S. (2008).
Identification of the Rem-responsive element of mouse mammary tumor
virus. Nucleic Acids Res., 36, 6284-6294.

133.

Murphy, F. A., Fauquet, C. M., Bishop, D. H. L., Ghabrial, S. A., Jarvis, A.
W., Martelli, G. P., Mayo, M. A., & Summers, M. D. (ed). (1994). Virus
taxonomy: the classification and nomenclature of viruses, Retroviridae.
Springer-Verlag, Vienna.

134.

Murti, K. G., Bondurant, M., & Tereba, A. (1981). Secondary structural
features in the 70S RNAs of Moloney murine leukemia and Rous sarcoma
viruses as observed by electron microscopy. J. Virol. 37, 411-419.

135.

Mustafa, F., Lozano, M., & Dudley, J. P. (2000). C3H mouse mammary tumor
virus superantigen function requires a splice donor site in the envelope gene. J.
Virol., 74, 9431-40.

136.

Mustafa, F., Lew, K. A., Schmidt, R. D., Browning, M. T., & Rizvi, T. A.
(2004). Mutational analysis of the predicted secondary RNA structure of
the Mason-Pfizer monkey virus packaging signal. Virus Res., 99, 35-46.

137.

Mustafa, F., Ghazawi, A., Jayanth, P., Phillip, P. S., Ali, J., & Rizvi, T.A.
(2005). Sequences intervening between the core packaging determinants
are dispensable for maintaining the packaging potential and propagation of
feline immunodeficiency virus transfer vector RNAs. J. Virol., 79, 1381713821.

138.

Mustafa, F., Al Amri, D., Al Ali, F., Al Sari, N., Al Suwaidi, S., Jayanth,
P., Philips, P.S., & Rizvi, T.A. (2012). Sequences within both the 5' UTR
and Gag are required for optimal in vivo packaging and propagation of
mouse mammary tumor virus (MMTV) genomic RNA. PLoS One, 7,
e47088.

139.

Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H.,
Verma, I. M., & Trono, D. (1996). In vivo gene delivery and stable
transduction of nondividing cells by a lentiviral vector. Science, 272, 263267.
171

140.

Nikolaitchik, O. A., Dilley, K. A., Fu, W., Gorelick, R. J., Tai, S. H.,
Soheilian, F., Ptak, R. G., Nagashima, K., Pathak, V. K., & Hu, W. S.
(2013). Dimeric RNA recognition regulates HIV-1 genome packaging.
PLoS Pathog., 9,e1003249.

141.

Nikolaitchik, O. A., & Hu,W. S. (2014). Deciphering the role of the GagPol ribosomal frameshift signal in HIV-1 RNA genome packaging. J. Virol.
(Epub ahead of print).

142.

Oh, J., McWilliams, M. J., Julias, J. G., & Stephen Hughes, H. (2008).
Mutations in the U5 region adjacent to the primer binding site affect tRNA
cleavage by human immunodeficiency virus type 1 reverse transcriptase in
vivo. J. Virol., 82, 719-727.

143.

Ooms, M., Huthoff, H., Russell, R., Liang, C., & Berkhout, B. (2004). A
riboswitch regulates RNA dimerization and packaging in human
immunodeficiency virus type 1 virions. J. Virol. 78, 10814-10819.

144.

Pachori, A. S., Huentelman, M. J., Francis, S. C., Gelband, C. H., Katovich, M.
J., & Raizada, M. K. (2001).The future of hypertension therapy: sense,
antisense, or nonsense? Hypertension, 37,357-364.

145.

Parveen, Z., Mukhtar, M., Goodrich, A., Acheampong, E., Dornburg, R.,
& Pomerantz,R.J. (2004). Cross-packaging of human immunodeficiency
virus type 1 vector RNA by spleen necrosis virus proteins: construction of
a new generation of spleen necrosis virus-derived retroviral vectors. J.
Virol., 78, 6480-6488.

146.

Paillart, J. C., Marquet, R., Skripkin, E., Ehresmann, B., & Ehresmann, C.
(1994). Mutational analysis of the bipartite dimer linkage structure of
human immunodeficiency virus type 1 genomic RNA. J. Biol. Chem., 269,
27486-27493.

147.

Paillart, J. C., Berthoux, L., Ottmann, M., Darlix, J. L., Marquet, R.,
Ehresmann, B., & Ehresmann, C. (1996a). A dual role of the putative RNA
dimerization initiation site of human immunodeficiency virus type 1 in
genomic RNA packaging and proviral DNA synthesis. J. Virol., 70, 83488354.

148.

Paillart, J. C., Skripkin, E., Ehresmann, B., Ehresmann, C., & Marquet, R.
(1996b). A loop-loop "kissing" complex is the essential part of the dimer
linkage of genomic HIV-1 RNA. Proc. Natl Acad. Sci. USA, 93, 55725577.

149.

Paillart, J. C., Westhof, E., Ehresmann, C., Ehresmann, B., & Marquet, R.
(1997). Non-canonical interactions in a kissing loop complex: the
dimerization initiation site of HIV-1 genomic RNA. J. Mol. Biol., 270, 3649.

172

150.

Paillart, J. C., Skripkin, E., Ehresmann, B., Ehresmann, C., Marquet, R.
(2002). In vitro evidence for a long range pseudoknot in the 5′-untranslated
and matrix coding regions of HIV-1 genomic RNA. J. Biol. Chem., 277,
5995–6004.

151.

Paillart, J. C., Xhilag, M. S., Marquet, R., & Mak, J. (2004). Dimerization
of retroviral RNA genomes: An inseparable pair. Nat. Rev. Microbiol., 2,
461-472.

152.

Patel, J., Wang, S. W., Izmailova, E., Aldovini, A. (2003). The simian
immunodeficiency virus 59 untranslated leader sequence plays a role in
intracellular viral protein accumulation and in RNA packaging. J. Virol.,
77, 6284–6292.

153.

Pavlakis, G. N., Felber, B. K. (1990). Regulation of expression of human
immunodeficiency virus. New Biol., 2, 20-31.

154.

Pedersen, F.S., & Duch, M. (2006). Retroviral replication. Encyclopedia of
life sciences, John Wiley & Sons, Ltd. doi: 10.1038/npg.els.0004239.

155.

Petropoulos, C. J. (1997). Retroviral taxonomy, protein structure,
sequences, and genetic maps. In Coffin, J.M. (ed.), Retroviruses. Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 757.

156.

Power, M. D., Marx, P. A., Bryant, M. L., Gardner, M. B., Barr, P. J., &
Luciw, P. A. (1986). Nucleotide sequence of SRV-1, a type D simian
acquired immune deficiency syndrome retrovirus. Science, 231, 15671572.

157.

Reuter, J. S., & Mathews, D. H. (2010). RNA structure: software for RNA
secondary structure prediction and analysis. BMC Bioinformatics, 11, 129.

158.

Rizvi, T. A., & Panganiban, A. T. (1993). Simian immunodeficiency virus
RNA is efficiently encapsidated by human immunodeficiency virus type 1
particles.
J. Virol., 67, 2681-2688.

159.

Rizvi, T. A., Ali, J., Phillip, P. S., Ghazawi, A., Jayanth, P., & Mustafa, F.
(2009). Role of a heterologous retroviral transport element in the
development of genetic complementation assay for mouse mammary
tumor virus (MMTV) replication.
Virology, 385, 464-472.

160.

Rizvi, T. A., Kenyon, J. C., Ali, J., Aktar, S. J., Phillip, P. S., Ghazawi, A.,
Mustafa, F., & Lever, A. M. L. (2010). Optimal packaging of FIV genomic
RNA depends upon a conserved long-range interaction and a palindromic
sequence within gag. J. Mol. Biol., 403, 103-119.

161.

Ross, S. R.(2010). Mouse mammary tumor virus molecular biology and
oncogenesis. Viruses, 2, 2000-12.
173

162.

Russell, R. S., Liang, C. and Wainberg, M. A. (2004). Is HIV-1 RNA
dimerization a prerequisite for packaging? Yes, no, probably?
Retrovirology, 1, 23.

163.

Sakuragi J., Shioda, T., & Panganiban, A. T. (2001). Duplication of the
primary encapsidation and dimer linkage region of human
immunodeficiency virus type 1 RNA results in the appearance of
monomeric RNA in virions. J. Virol., 75, 2557-2565.

164.

Sakuragi J., Iwamoto, A., & Shioda, T. (2002). Dissociation of genome
dimerization from packaging functions and virion maturation of human
immunodeficiency virus type 1. J. Virol., 76, 959-967.

165.

Salmons, B., Moritz-Legrand, S., Garcha, I., & Günzburg, W. H. (1989).
Construction and characterization of a packaging cell line for MMTVbased conditional retroviral vectors. Biochem. Biophys. Res. Commun.,
159, 1191-1198.

166.

Santa-Marta, M., de Brito, P. M., Godinho-Santos, A., Goncalves, J.
(2013). Host Factors and HIV-1 Replication: Clinical Evidence and
Potential Therapeutic Approaches. Front Immunol., 4, 343.

167.

Schmidt, R. D., Mustafa, F., Lew, K. A., Browning, M. T., & Rizvi, T. A.
(2003). Sequences within both the 5’ untranslated region and the gag gene
are important for efficient encapsidation of Mason-Pfizer monkey virus
RNA. Virology, 309, 166-178.

168.

Seif, E., Niu, M., & Kleiman, L. (2013). Annealing to sequences within
the primer binding site loop promotes an HIV-1 RNA conformation
favoring RNA dimerization and packaging. RNA, 19, 1384-1393.

169.

Shackleford, G. M., & Varmus, H. E. (1988). Construction of a clonable,
infectious, and tumorigenic mouse mammary tumor virus provirus and a
derivative genetic vector. Proc. Natl Acad. Sci., 85, 9655-9659.

170.

Shen, N., Jette, L., Liang, C., Wainberg, M. A., & Laughrea, M. (2000).
Impact of human immunodeficiency virus type 1 RNA dimerization on
viral infectivity and of stem-loop B on RNA dimerization and reverse
transcription and dissociation of dimerization from packaging. J. Virol., 74,
5729-5735.

171.

Sievers, F., Wilm, A., Dineen, D., Gibson, T. J., Karplus, K., Li, W.,
Lopez, R.,
McWilliam, H., Remmert, M., Söding, J., Thompson, J. D., & Higgins, D.
G. (2011). Fast, scalable generation of high-quality protein multiple
sequence alignments using Clustal Omega. Mol. Syst. Biol. 7, 539.

172.

Skripkin, E., Paillart, J. C., Marquet, R., Ehresmann, B., & Ehresmann,C.
(1994). Identification of the primary site of the human immunodeficiency
174

virus type 1 RNA dimerization in vitro. Proc. Natl Acad. Sci. USA, 91,
4945-4949.
173.

Song, L., Wang, J., Wang, R., Yu, M., Sun, Y., Han, G., Li, Y., Qian, J., Scott,
D. W., Kang, Y., Soukhareva, N., & Shen, B. (2004). Retroviral delivery of
GAD-IgG fusion construct induces tolerance and modulates diabetes: a role
for CD4+ regulatory T cells and TGF-? Gene Therapy, 11, 1487-1496.

174.

Song, R., Kafaie, J., & Laughrea, M. (2008). Role of the 5′ TAR stem-loop
and the U5-AUG duplex in dimerization of HIV-1 genomic RNA.
Biochemistry, 47, 3283–3293.

175.

Sonigo, P., Barker, C., Hunter, E., & Wain-Hobson, S. (1986). Nucleotide
sequence of Mason-Pfizer monkey virus: an immunosuppressive D-type
retrovirus. Cell, 45, 375-385.

176.

Spriggs, S., Garyu, L., Connor, R., & Summers, M. F. (2008). Potential
intra- and intermolecular interactions involving the unique 5′ region of the
HIV-1 5′ UTR. Biochemistry, 47, 13064–13073.

177.

Stoye, J. P. (2012). Studies of endogenous retroviruses reveal a continuing
evolutionary saga. Nat. Rev. Microbio.10, 395-406.

178.

Strebel, K., Daugherty, D., Clouse, K., Cohen, D., Folks, T., Martin, M. A.
(1987). The HIV 'A' (sor) gene product is essential for virus infectivity.
Nature, 328, 728-730.

179.

Strappe, P. M., Greatorex, J., Thomas, J., Biswas, P., & McCann, E.
(2003). The packaging signal of simian immunodeficiency virus is
upstream of the major splice donor at a distance from the RNA cap site
similar to that of human immunodeficiency virus types 1 and 2. J. Gen.
Virol., 84, 2423–2430.

180.

Summers, M. F., Henderson, L. E., Chance, M. R., Bess, J. W. Jr., South,
T. L., Blake, P. R., Sagi, I., Perez-Alvarado, G., 3rd Sowder, R. C., & Hare,
D. R. (1992). Nucleocapsid zinc fingers detected in retroviruses: EXAFS
studies of intact viruses and the solution-state structure of the nucleocapsid
protein from HIV-1. Protein Sci., 1, 563-574.

181.

Sztuba-Solinska, J., & Le Grice, S. F. (2012). Probing Retroviral and
Retrotransposon Genome Structures: The "SHAPE" of Things to Come.
Mol. Biol. Int., 530754.

182.

Takano, J., Leon, A., Kato, M., Abe, Y., & Fujimoto, K. (2013). Isolation
and DNA Characterization of a Simian retrovirus 5 from a Japanese
monkey (Macaca fuscata). J. Gen. Virol. 94, 955-9599.

183.

Telesnitsky, A., & Goff, S. P. (1997). Reverse transcriptase and the generation
of retroviral DNA. In Coffin, J. M., Hughes, S. H., Varmus, H. E. (Eds.),
Retroviruses, Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press.
175

184.

Temin, H. M., & Mitzutani, S. (1970). RNA-directed DNA polymerase in
virions of Rous sarcoma virus. Nature, 226, 1211-1213.

185.

Tian, C., Bagley, J., Cretin, N., Seth, N., Wucherpfennig, K. W., & Lacomini,
J. (2004). Prevention of type 1 diabetes by gene therapy. J Clin. Invest, 114,
969-978.

186.

Tiganos E, Yao, X. J., Friborg, J., Daniel, N., Cohen, E. A. (1997). Putative
alpha-helical structures in the human immunodeficiency virus type 1 Vpu
protein and CD4 are involved in binding and degradation of the CD4 molecule.
J. Virol., 71, 4452-4460.

187.

Vasa, S. M., Guex, N., Wilkinson, K. A., Weeks, K. M., & Giddings, M. C.
(2008). ShapeFinder: a software system for high-throughput quantitative
analysis of nucleic acid reactivity information resolved by capillary
electrophoresis. RNA, 14, 1979-1990.

188.

Verma, I. M., & Weitzman, M. D. (2005). Gene therapy: twenty-first century
medicine. Annu Rev Biochem, 74, 711-38.

189.

Veronese, F. D., DeVico, A. L., Copeland, T. D., Oroszlan, S., Gallo, R. C.,
Sarngadharan, M. G.(1985). Characterization of gp41as the transmembrane
protein coded by the HTLV-III/LAV envelope gene. Science, 229, 1402-1405.

190.

Vile, R.G., Ali, M., Hunter, E., & McClure, M. O. (1992). Identification of
a generalized packaging sequence for D-type retroviruses and generation
of a D-type retroviral vector. Virology, 189, 786-791.

191.

Weeks, K. M. (2010). Advances in RNA secondary and tertiary structure
analysis by chemical probing. Curr. Opin. Struct. Biol., 20, 295-304.

192.

Wei, M. Q., Ren, R., Good, D., & Anné, J. (2008). Clostridial spores as live
'Trojan Horse' vectors for cancer gene therapy: comparison with viral delivery
systems. Genet Vaccines Ther., 6, 8.

193.

White, S. M., Renda, M., Nam, N. Y., Klimatcheva, E., Zhu, Y., Fisk, J.,
Halterman, M., Rimel, B.J., Federoff, H., Pandya, S., Rosenblatt, J. D. &
Planelles,V. (1999). Lentivirus vectors using human and simian
immunodeficiency virus elements. J. Virol., 73, 2832-2840.

194.

Whitney, J. B., & Wainberg, M. A. (2006). Impaired RNA incorporation
and dimerization in live attenuated leader variants of SIVmac239.
Retrovirology, 3, 96.

195.

Wiley, J., & Sons Ltd. (2012). www.wiley.co.uk/genmed/clinical. Journal of
Gene Medicine.

196.

Wilkinson, K. A., Gorelick, R. J., Vasa, S. M., Guex, N., Rein, A.,
Mathews, D. H., Giddings, M. C., & Weeks, K. M. (2008). Highthroughput SHAPE analysis reveals structures in HIV-1 genomic RNA
176

strongly conserved across distinct biological states. PLoS Biol., 6, e96. doi:
10.1371/journal.pbio.0060096.
197.

Willey, R. L., Bonifacino, J. S., Potts, B. J., Martin, M. A., Klausner, R. D.
(1988). Biosynthesis, cleavage, and degradation of the human
immunodeficiency virus 1 envelope glycoprotein gp160. Proc. Natl. Acad
Sci. U.S.A., 85, 9580-9584.

198.

Willey, R.L., Maldarelli, F., Martin, M. A., Strebel, K. (1992). Human
immunodeficiency virus type 1 Vpu protein induces rapid degradation of
CD4. J. Virol., 66, 7193-7200.

199.

Woo, C. Y., Osada, T., Clay, T. M., Lyerly, H. K., & Morse, M. A. (2006).
Recent clinical progress in virus-based therapies for cancer. Expert Opin. Biol.
Ther., 11, 1123-34.

200.

Woodland, D. L., Lund, F. E., Happ, M. P., Blackman, M. A., Palmer, E., &
Corley, R. B. (1991). Endogenous superantigen expression is controlled by
mouse mammary tumor proviral loci. J. Exp. Med., 174, 1255-1258.

201.

Yang, J., Jiang, H., Chen, S. S., Chen, J., Li, W. Q., Xu, S. K., & Wang, J. C.
(2010). Lentivirus-mediated RNAi targeting CREB binding protein attenuates
neointimal formation and promotes re-endothelialization in balloon injured rat
carotid artery. Cell Physiol. Biochem., 26, 441-8.

202.

Yap, M. W., Nisole, S., Lynch, C., & Stoye, J. P. (2004). Trim5alpha protein
restricts both HIV-1 and murine leukemia virus. Proc. Natl. Acad. Sci. U.S.A.,
101, 10786-10791.

203.

Yin, P. D. & Hu, W. S. (1997). RNAs from genetically distinct
retroviruses can copackage and exchange genetic information in vivo. J.
Virol., 71, 6237-6242.

204.

Ylinen, L. M., Keckesova, Z., Wilson, S. J., Ranasinghe, S., & Towers,
G.J. (2005). Differential restriction of human immunodeficiency virus type
2 and simian immunodeficiency virus SIVmac by TRIM5alpha alleles. J.
Virol., 79, 11580-11587.

205.

Yu, X., Yu, Y., Liu, B., Luo, K., Kong, W., Mao, P., & Yu, X. (2003).
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 VifCul5-SCF complex. Science, 302, 1056-1060.

206.

Zao, C. L., Armstrong, K., Tomanek, L., Cooke, A., Berger, R., Estep, J.
S., Marx, P. A., Trask, J. S., Smith, D. G., Yee, J. L. and Lerche, N.W.
(2010). The complete genome and genetic characteristics of SRV-4
isolated from cynomolgus monkeys (Macaca fascicularis). Virology, 405,
390-396.

177

207.

Zeffman, A., Hassard, S., Varani, G., Lever, A. (2000). The major HIV-1
packaging signal is an extended bulged stem loop whose structure is
altered on interaction with the Gag polyprotein. J. Mol. Biol., 297, 877-893.

208.

Zhang, H., Yang, B., Pomerantz, R. J., Zhang, C., Arunachalam, S. C., &
Gao, L. (2003). The cytidine deaminase CEM15 induces hypermutation in
newly synthesized HIV-1 DNA. Nature, 424, 94-98.

209.

Zhang, Y. Q., & Barklis, E. (1995). Nucleocapsid protein effects on the
specificity of retrovirus RNA encapsidation. J. Virol., 69, 5716-5722.

210.

Zuker, M. (2003). Mfold web server for nucleic acid folding and
hybridization prediction. Nucleic Acids Res., 31, 3406-3415.

178

